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I 
Summary 
The transcription factor nuclear factor-kappaB (NF-B) plays a key role in the immune 
system by controlling lymphocyte survival and activation. Conversely, aberrant NF-B 
activity has been implicated in several lymphoid malignancies and contributes to a variety 
of autoimmune disorders. 
While multiple kinases and phosphorylated target proteins that induce NF-B activity have 
been identified, the molecular machinery involved in the termination of antigen receptor-
mediated NF-B activation is only partially understood. Since signal transduction from 
activated receptors to NF-B largely relies on phosphorylation events, phosphatases are 
expected to play a major role in the modulation and termination of NF-B activity. 
Therefore, the current study aimed at systematically defining phosphatases that are 
involved in T cell receptor (TCR)-induced NF-B signaling. To this end, an RNA 
interference (RNAi) genetic screen has been adopted based on a novel NF-B-dependent 
reporter system. Using this approach, several NF-B-modulating phosphatases were 
identified among which the protein phosphatase 4 regulatory subunit 1 (PP4R1) was 
confirmed as a central negative regulator of NF-B activity in T lymphocytes. PP4R1 
expression is strongly upregulated in primary human T lymphocytes upon activation. 
PP4R1 specifically binds to the inhibitor of NF-B kinase  (IKK) and the catalytic 
subunit PP4c, thereby directing PP4c phosphatase activity to dephosphorylate and 
inactivate the IKK complex. Accordingly, PP4R1 silencing causes sustained and 
increased IKK activity and T cell hyperactivation as reflected by enhanced induction of 
NF-B target genes and secretion of cytokines. Conversely, PP4R1 overexpression 
significantly impairs NF-B activation upon TCR stimulation, but does not affect AP-1 
signaling. Furthermore, PP4R1 was found to be downregulated in a subset of malignant T 
lymphocytes derived from patients with Sézary syndrome, a severe form of cutaneous T 
cell lymphoma (CTCL). PP4R1 deficiency causes constitutive IKK/NF-B signaling and is 
required for survival of NF-B-addicted CTCL cells. 
In summary, the present work identified PP4R1 as a central gatekeeper of IKK activity and 
as a suppressor of T cell activation and lymphoma survival. These findings expand our 
current knowledge of NF-B signal transduction and contribute to a more precise 
molecular understanding of NF-B regulation in health and disease. 
 
II 
Zusammenfassung 
Der Transkriptionsfaktor nuclear factor-kappaB (NF-B) nimmt eine zentrale Stellung im 
Immunsystem ein. Physiologische NF-B Aktivität ist essentiell für das Überleben und die 
Aktivierung von Lymphozyten. Hingegen ist aberrante NF-B Signalgebung mit 
verschiedenen hämatologischen Neoplasien und Autoimmunerkrankungen assoziiert. 
Die T Zell-Rezeptor (TZR)-induzierte NF-B Signalkaskade involviert eine Vielzahl von 
Kinasen und phosphorylierter Effektormoleküle. Im Gegensatz hierzu sind die 
molekularen Mechanismen, die der negativen Regulation des NF-B Signalweges 
zugrunde liegen, nur zum Teil verstanden. Da Phosphorylierungsreaktionen ein zentrales 
Merkmal der Rezeptor-induzierten NF-B Aktivierung darstellen, werden Phosphatasen 
als wichtige Modulatoren von NF-B Aktivität vermutet. 
Ziel der vorliegenden Studie war es daher, die Funktion einzelner Phosphatasen im TZR-
induzierten NF-B Signalweg systematisch zu adressieren. Hierfür wurde ein RNA 
Interferenz (RNAi) Screen durchgeführt auf Grundlage eines neu entwickelten NF-B-
spezifischen Reporter-Systems. Unter verschiedenen NF-B-modulierenden Phospha-
tasen wurde die protein phosphatase 4 regulatory subunit 1 (PP4R1) als ein zentraler 
negativer Regulator der NF-B Aktivierung in T Lymphozyten identifiziert. Die PP4R1 
Expression wird in aktivierten humanen T Lymphozyten stark induziert. PP4R1 fungiert als 
ein Adapter zwischen der inhibitor of NF-B kinase  (IKK) und der katalytischen PP4 
Untereinheit PP4c und reguliert somit PP4 Phosphatase Aktivität zur spezifischen 
Dephosphorylierung und Inaktivierung des IKK Komplexes. Die RNAi-vermittelte 
Suppression der PP4R1 Expression verursacht eine erhöhte und prolongierte IKK Aktivität 
und eine verstärkte Induktion und Sekretion NF-B-abhängiger Gene bzw. Zytokine. 
Umgekehrt führt die Überexpression von PP4R1 zu einer spezifischen Blockade des    
NF-B Signalweges nach TZR Stimulation. In malignen T Lymphozyten von Patienten mit 
dem Sézary Syndrom, einer aggressiven und leukemischen Variante des Kutanen T Zell 
Lymphoms (engl.: cutaneous T cell lymphoma, CTCL) ist die PP4R1 Expression deutlich 
erniedrigt. Die Defizienz von PP4R1 resultiert in konstitutiver IKK/NF-B Signalgebung 
und ist verantwortlich für das Überleben NF-B-abhängiger CTCL-Zellen. 
In dieser Arbeit konnte PP4R1 als ein neuer zentraler Regulator des NF-B Signalweges 
und als ein Suppressor von T Zell-Aktivierung und T Zell-Lymphomen identifiziert werden. 
Dies erweitert unser molekulares Verständnis des NF-B Signalweges und seiner 
Regulation unter physiologischen und pathophysiologischen Bedingungen. 
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1 
1 Introduction 
 
1.1 The immune system 
Metazoan organisms are exposed throughout their whole life span to a wide variety of 
infectious microbial pathogens. In order to counteract this permanent menace the immune 
system has evolved as a highly efficient humoral and cellular network capable of microbial 
recognition and elimination. In vertebrates two general branches of immunity can be 
distinguished: innate and adaptive (acquired) immunity. The main distinction between 
these two immunological components lies in the receptor systems and signaling pathways 
used for antigen sensing and subsequent induction of effector responses. Both systems 
do not act independently of each other, but are functionally interconnected. Although still 
being partially enigmatic, the capability to discriminate between “self” and “nonself” has 
emerged as a fundamental paradigm of immunity (Janeway, Jr., 1992; Matzinger, 2002). 
 
1.1.1 Innate immunity 
The innate immune system is an evolutionarily ancient form of the host defence present in 
most multicellular organisms. The innate immune response is rapidly initiated in the early 
phase of an infection, provides the first line of host defence, and controls and precedes 
the initiation of the primary adaptive response. Cellular constituents of this type of 
immunity are dendritic cells (DCs), granulocytes, mast cells, neutrophils, monocytes, 
macrophages and natural killer cells (NK cells). In addition, humoral components of innate 
immunity comprise the complement system, acute phase proteins, as well as different 
enzymes, cytokines (e.g. interferons), and lysozymes. 
A hallmark of innate immunity is the use of a restricted number of germline-encoded 
receptors – so-called pattern recognition receptors (PRRs) – that act as sensors of 
conserved and constitutive microbial structures, known as pathogen-associated molecular 
patterns (PAMPs). Since these molecular signatures are unique to microorganisms of a 
given class the innate immune recognition system is able to efficiently detect both the 
presence and the nature of infectious agents (Fearon and Locksley, 1996; Medzhitov, 
2001; Medzhitov and Janeway, Jr., 2002). Multiple and distinct PRRs have been identified 
that can be broadly categorized into secreted, transmembrane, and cytosolic receptor 
families. The major effector functions of PRRs comprise opsonization, activation of 
complement and coagulation cascades, phagocytosis, and triggering of proinflammatory 
signaling pathways (Iwasaki and Medzhitov, 2010). 
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1.1.2 Adaptive immunity 
The adaptive immune response is organized around two classes of specialized cells: B 
lymphocytes (B referring to the avian bursa of Fabricius) and T lymphocytes (T referring to 
thymus). Both types of lymphocytes originate from haematopoietic stem cells within the 
bone marrow. A small fraction of these cells further develops into lymphoid precursor cells 
that finally give rise to mature B and T lymphocytes. Whereas B lymphocytes mature in 
the bone marrow and spleen, T cell progenitors migrate into the thymus to ultimately 
differentiate into mature T lymphocytes (Shortman et al., 1990). 
The clonal selection of antigen-specific lymphocytes is the basis of adaptive immunity 
(Burnet, 1959; Litman et al., 1993). Since each lymphocyte is endowed with a single kind 
of receptor of potentially unique specificity – the B and T cell antigen receptor, 
respectively (BCR and TCR) – the repertoire of antigen receptors in the entire population 
of lymphocytes is extremely large and diverse, capable of recognizing virtually any antigen 
(Medzhitov and Janeway, 2000). In contrast to the relatively small number of PRRs of 
innate immunity, the high diversity of antigen-specific receptors is generated randomly by 
somatic receptor gene rearrangements during lymphopoesis (Tonegawa, 1993; Jung and 
Alt, 2004). Early in ontogenesis encountering of (auto-)antigens induces negative 
selection by programmed cell death (apoptosis), thus ensuring self-tolerance (Rathmell 
and Thompson, 2002; Starr et al., 2003). By contrast, binding of specific antigen by 
clonotypic receptors on mature lymphocytes triggers clonal expansion and differentiation 
into effector cells. B lymphocytes either differentiate into plasma cells or germinal center 
(GC) B cells to secrete antigen-specific antibodies and thereby constitute the humoral 
branch of adaptive immunity (Rajewsky, 1996). Similarly, T lymphocytes are able to 
differentiate into various T cell effector subsets such as CD8+ cytotoxic T cells or CD4+ T 
helper cells, including Th1, Th2 and Th17 T cells (Locksley, 2009). Subsets of B and T 
cells that have encountered antigen persist within the organism over a long time and 
provide rapid and specific protection against reinfection, a process referred to as 
immunological memory (Ahmed and Gray, 1996). The plasticity of the adaptive antigen 
receptor repertoire and the ability to establish a long lasting antigen-specific memory 
represent major distinctions from the rather static immune recognition systems employed 
by innate immunity. 
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1.1.3 Cross talk between innate and adaptive immunity: initiation of an acquired 
immune response 
Since antigen receptors are generated de novo during lymphocyte ontogenesis they lack 
the intrinsic capability to discriminate between antigens derived from “infectious-nonself” 
and “noninfectious-self”. Therefore, the immune system has evolved as multi-layered 
control system in order to mount a specific immune response against microbial invaders 
while exercising tolerance to auto-antigens. At a first level in T development self-reactive 
thymocytes are clonally deleted (central tolerance). A second level of control in the 
periphery (peripheral tolerance) involves the requirement of proper (co-)stimulation of 
antigen-specific T lymphocytes by specialized antigen presenting cells (APCs) to undergo 
full activation, proliferation and differentiation (Janeway, Jr., 1989; Medzhitov and 
Janeway, Jr., 1999; Medzhitov and Janeway, Jr., 1999). APCs include B cells, 
macrophages and in particular DCs (Inaba et al., 1990). Foreign antigens that are 
physically associated with PAMPs are recognized and internalized by APCs, 
enzymatically processed and the resulting microbial peptide fragments are bound to major 
histocompatibility complex (MHC) molecules and presented on the cell surface (Inaba et 
al., 1990; Trombetta and Mellman, 2005). Activation of an antigen-specific T cell occurs 
via specific binding of the clonal TCR to the complex composed of “nonself” peptide (p) 
and “self” MHC (pMHC) (Hennecke and Wiley, 2001). Whereas CD8+ T cells bind to MHC 
class I molecules loaded with peptides of cytosolic origin, CD4+ T cells bind to complexes 
of MHC class II molecules and peptides of extracellular origin that have been internalized 
by phagocytosis or macropinocytosis (Rudolph et al., 2006). However, there is cross talk 
between the cell-intrinsic MHC class I and the cell-extrinsic MHC class II pathways via 
mechanisms including autophagy and cross-presentation (Iwasaki and Medzhitov, 2010). 
Importantly, binding of the TCR to pMHC alone is not sufficient to induce T cell activation, 
but has to be complemented by two auxiliary signals. (i) For a naïve T lymphocyte to get 
programmed into a differentiated effector cell a co-stimulating signal is required that has to 
be delivered by the same pMHC-presenting APC. Among the co-stimulating receptors on 
T cells that mediate this signal CD28 is the most important member. Its natural ligands are 
B7 family members (CD80 and CD86) expressed on mature APCs (Greenwald et al., 
2005). (ii) T cell activation depends on the presence of interleukin 2 (IL-2), a T cell growth 
factor that binds to IL-2 receptors on the T cell surface (Mak, 2007). In contrast, TCR 
triggering in the absence of co-stimulation results in a long-lived state of functional 
unresponsiveness, termed anergy (Ohashi, 2002; Fathman and Lineberry, 2007). 
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The interactions between T cells and DCs take place within the secondary lymphoid 
organs. Activated DCs that have encountered foreign antigen express high levels of MHC 
and co-stimulatory molecules and start migrating into the draining lymph nodes. Here, 
naïve antigen specifc T cells are primed by mature DCs and subsequently undergo clonal 
expansion. The upregulated expression of co-stimulating molecules requires the 
maturation of DCs which is in turn dependent on the activation of PRRs. The physical 
association between antigenic peptides presented by MHC molecules and PAMPs 
provides a functional link between innate and adaptive immunity and ensures that the 
adaptive immune response is selectively directed against infectious pathogens, but not 
against self-antigens (Medzhitov and Janeway, Jr., 2002). 
 
 
1.2 Signal transduction from the T cell antigen receptor (TCR) 
The adaptive immune response is based on an intricate network of cellular interactions. 
Accordingly, the outcome of an individual cellular response is determined by the reception 
and transduction of extracellular signals through antigen receptors and regulatory co-
receptors followed by signal amplification, integration and processing involving a series of 
complex intracellular signaling circuits. In the following sections the molecular 
mechanisms underlying initiation, propagation and regulation of TCR-mediated signal 
transduction will be discussed in detail. 
 
1.2.1 Structure and composition of the TCR 
The TCR, together with the BCR and certain types of Fc receptors, belongs to the family 
of multichain immune recognition receptors. In contrast to receptor protein tyrosine 
kinases (e.g. epidermal growth factor receptor, EGFR) ligand binding and signaling 
subunits are located on different polypeptide chains, and immunoreceptors lack intrinsic 
catalytic activity. The TCR consists of clonotypic  and  subunits mediating ligand 
recognition and binding, and a number of non-polymorphic signal transducing units 
including the the , ,  and  chains of the CD3 complex (Samelson, 2002). A minority of 
T cells of about 5% express a TCR composed of a TCR and a TCR chain. 
The exact stoichiometry of the TCR/CD3 complex has been a long-standing controversy 
in immunology. It is now assumed that the CD3 complex is composed of a CD3-
CD3heterodimer, a CD3-CD3 heterodimer and a -homodimer that are non-covalently 
associated with the TCR. However, it is still elusive whether one or two single  TCR 
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heterodimers form part of one TCR/CD3 complex (Exley et al., 1995; Fernandez-Miguel et 
al., 1999; Davis, 2002; Smith-Garvin et al., 2009). 
The CD3 complex forms the invariant signal transducing subunit of the TCR complex. 
Unlike the TCR polypeptides CD3 proteins have long cytosolic tails containing conserved 
peptide motifs, designated immunoreceptor tyrosine-based activation motifs (ITAMs), that 
are also found in the signaling components of the BCR and some types of Fc receptors. 
The ITAM is characterized by the consensus amino acid sequence 
D/Ex7D/ExxYxxI/Lx7YxxI/L (in single-letter code for amino acids, x may be any residue) 
(Reth, 1989; Cambier, 1995). Whereas each  chain contains three copies of one ITAM, 
the CD3 ,  and  proteins each harbour on ITAM sequence in their intracytoplasmic 
domains resulting in ten ITAM sequences per CD3 complex (Pitcher and van Oers, 2003). 
Using transmembrane chimeras it could be demonstrated that the ITAM is the minimally 
functional motif required for coupling of the TCR and other immunoreceptors to the 
intracellular signaling apparatus (Irving and Weiss, 1991; Letourneur and Klausner, 1992; 
Romeo et al., 1992; Flaswinkel and Reth, 1994). Whether multiple ITAM motifs of the CD3 
complex serve redundant or specific functions remains elusive, though (Pitcher and van 
Oers, 2003). The functional and physical association of the TCR with the CD3 complex is 
further demonstrated by the fact that there is an obligatory co-expression of both entities 
on the T cell surface (Weiss and Stobo, 1984). 
 
1.2.2 Assembly and activation of the TCR proximal signalosome 
Engagement of TCR by cognate pMHC or agonistic antibodies is thought to induce 
conformational changes within the TCR as well as receptor oligomerization (Smith-Garvin 
et al., 2009), which is accompanied and/or followed by the transient translocation of 
activated TCR/CD3 complexes into particular compartments of the plasma membrane, 
known as glycosphingolipid-enriched microdomains (GEMs) or lipid-rafts (Xavier and 
Seed, 1999; Janes et al., 1999). One of the earliest events detectable upon triggering of 
the TCR and its co-receptors (CD4 or CD8) includes the activation of Src family protein 
tyrosine kinases (SFKs). All SFK family members share a common molecular architecture 
composed of highly homologous regions denoted by Src homology domains 1-4 (SH1-
SH4). The SH1 domain confers kinase activity, the SH2 and SH3 domains recognize and 
bind to phospho-tyrosine motifs and proline-rich regions, respectively, and the SH4 
domain mediates fatty acid modifications. In T lymphocytes the SFK family members Lck 
and Fyn are expressed (Kiefer et al., 2002). 
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Figure 1.1 | TCR proximal signaling events. Engagement of the TCR and its co-receptors by 
cognate ligand leads to TCR/CD3 aggregation followed by recruitment and activation of Src and 
Syk family PTKs, such as Lck and ZAP-70, respectively. Activated ITAM-bound ZAP-70 
phosphorylates the adapter proteins LAT and SLP-76. In turn, SLP-76 interacts with phospho-LAT 
via Gads leading to the assembly of a membrane and TCR proximal core signalosome containing 
several effector enzymes (grey circle). Recruitment of PLC1 to the trimeric LAT-Gads-SLP-76 
scaffold facilitates its phosphorylation and activation by PTKs and increases access to its substrate, 
the membrane phosphatidylinositol PtdIns(4,5)P2. Activated PLC1 then catalyzes phospho-
inositide breakdown giving rise to the second messengers DAG and IP3. TCR-induced IP3 
production triggers intracellular Ca2+ mobilization and ultimately results in activation of the 
transcription factor NFAT. TCR-induced generation of DAG leads to PKC activation which in turn 
triggers several downstream pathways, such as the ERK or NF-B pathway. In addition to its 
activation by PKC, Ras activity relies on the GEF SOS that is recruited in a phosphorylation-
dependent manner to the TCR proximal core signalosome via the adapter Grb2. Activation of the 
MAPKs ERK and JNK through upstream phosphorylation cascades culminates in AP-1 activity. 
Activation of the MAPK p38 involves the PTKs Lck and ZAP-70 and proceeds via a PKC-
independent mechanism. 
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TCR-induced activation of SFKs constitutes a first wave of protein tyrosine kinase (PTK) 
activation. Activated SFKs that are intracellularly associated with the TCR co-receptors 
CD4 and CD8 subsequently phosphorylate ITAMs within the cytoplasmatic tails of the 
TCR-associated CD3 complex (Weiss and Littman, 1994). In turn, doubly phosphorylated 
ITAMs (ppITAMs) provide spatially defined docking sites for a second class of PTKs, the 
spleen tyrosine kinase (Syk) PTKs (Latour and Veillette, 2001). Among the Syk PTK 
family members Syk itself is most prominently found in B cells, whereas its homologue, 
the  chain-associated kinase of 70 kDa (ZAP-70), is predominantly expressed throughout 
the whole T cell compartment (Chan et al., 1994). Binding of the tandemly-arranged SH2 
domains to a ppITAM recruits ZAP-70 to the activated TCR allowing for its 
phosphorylation and activation by SFKs (Wange and Samelson, 1996). Among the most 
important immediately downstream targets of ZAP-70 are the transmembrane adapter 
protein linker of activated T cells (LAT) (Zhang et al., 1998a) and the cytosolic adapter 
protein SH2 domain-containing leukocyte phosphoprotein of 76 kDa (SLP-76) (Bubeck et 
al., 1996). The indispensable role of these two adapter proteins in TCR signaling is 
documented by in vitro and in vivo studies showing that loss of either LAT or SLP-76 
nearly completely abrogates TCR-induced signal transmission and T cell activation 
(Zhang et al., 1999; Yablonski et al., 1998; Clements et al., 1998). By virtue of 
palmitoylation LAT is constitutively raft-resident (Zhang et al., 1998b), and tyrosine 
phosphorylation creates docking sites for the adapter protein Grb2-related adaptor 
downstream of Shc (Gads) (Wonerow and Watson, 2001). Gads constitutively interacts 
via its SH3 domain with SLP-76, and, consequently, binding of Gads to phospho-LAT 
relocalizes SLP-76 to the activated TCR (Liu et al., 1999). Formation of the membrane 
proximal trimeric LAT-Gads-SLP-76 complex serves as a backbone for the nucleation of a 
multimolecular signalosome that contains several effector proteins, such as 
phospholipase C1 (PLC1), the guanine-nucleotide-exchange factor (GEF) Vav1, the 
adapter non-catalytic region of tyrosine kinase (Nck), the tyrosine kinase IL-2 inducible 
Tec kinase (Itk), the adhesion- and degranulation-promoting adapter protein (ADAP), Lck 
as well as the haematopoietic progenitor kinase 1 (HPK1) (Leo and Schraven, 2001; 
Koretzky et al., 2006). This core signaling complex, also termed the Ca2+ signalosome, 
collects and integrates signals from the activated TCR and co-receptors in a regulated 
spatiotemporal manner to allow for the initiation of diverging downstream signaling 
cascades, including Ca2+ and diacylglycerol (DAG)-induced responses as well as 
cytoskeletal rearrangements and integrin signaling (Smith-Garvin et al., 2009). 
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1.2.3 Activation of PLC1 
PLC1 is a central TCR proximal effector molecule. Upon TCR engagement PLC1 is 
recruited to the trimeric LAT-Gads-SLP-76 complex via binding of its SH2 domain to 
phospho-LAT (Zhang et al., 2000). Membrane relocalization is further promoted and 
stabilized by binding of its PLC1 pleckstrin homology (PH) domain to specific membrane 
phosphoinositides (Kiefer et al., 2002). Activation of PLC1 requires dual phosphorylation 
by Itk and ZAP-70 (Liu et al., 1998a). Additionally, complete phospholipase activity of 
PLC1 seems to require its constitutive association with the proline-rich domain of SLP-76 
(Yablonski et al., 2001). Enzymatically active membrane-associated PLC1 then catalyses 
hydrolysis of the membrane lipid phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) 
giving rise to the second messengers inositol 1,4,5-trisphosphate (IP3) and DAG. 
Generation of these two second messengers leads to the amplification of the TCR signal 
and serves as a bifurcation point to induce separate signaling cascades. 
 
1.2.4 TCR-induced Ca2+ signaling 
The mobilization of intracellular and extracellular calcium ions (Ca2+) into the cytoplasm 
occurs in two steps. (i) PLC1-generated IP3 is highly diffusible and binds to tetrameric 
Ca2+ permeable ion channel receptors (IP3R) located within the endoplasmic reticulum 
(ER) membrane. This leads to the depletion of ER Ca2+ stores into the cytoplasm. (ii) The 
transient mobilization of intracellular Ca2+ in turn stimulates opening of Ca2+ release 
activated channels (CRACs) in the plasma membrane, a process referred to as store-
operated Ca2+ entry (SOCE). Thereby, the sustained Ca2+ influx from the extracellular 
space leads to a stabilization of the intracellular Ca2+ signal (Oh-Hora and Rao, 2008). 
Elevated Ca2+ levels mediate the activation of the Ca2+/calmodulin-dependent 
phosphatase calcineurin which results in the dephosphorylation and activation of 
members of the nuclear factor of activated T cells (NFAT) family. In their inactive 
phosphorylated state NFAT transcription factors reside in the cytosol. Calcineurin-
mediated dephosphorylation of several phospho-sites leads to the translocation of the  
NFAT/calcineurin complex into the nucleus. This ultimately results into the initiation of 
various transcriptional programs dependent on the coaction of other transcription factors 
and the context of the TCR signal. Finally, decreasing cytosolic Ca2+ levels cause rapid 
dissociation of NFAT/calcineurin complexes and export of its components into the 
cytoplasm (Serfling et al., 2000). 
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1.2.5 Activation of DAG-dependent pathways 
The TCR-induced generation of the membrane-integral second messenger DAG induces 
activation of two major pathways: the PKC-dependent pathway and the Ras-MAPK 
pathway. PKC-induced signaling is crucial for NF-B activation in T lymphocytes and, 
therefore, will be discussed in section 1.3.5. 
MAPKs are evolutionarily conserved enzymes that regulate important cellular processes 
like proliferation and apoptosis (Tibbles and Woodgett, 1999). MAPK are categorized into 
at least three classes of enzymes: the extracellular signal-regulated kinases 1 and 2 
(ERK1/2), the c-Jun N-terminal kinases (JNKs), and the MAPK p38 (see section 1.2.6). 
MAPKs are activated by dual phosphorylation of threonine and tyrosine residues. 
Phosphorylation of MAPKs is part of a hierachical phosphorylation cascade involving 
upstream MAPK kinases (MAPKKs) and MAPKK kinases (MAPKKKs) (Dong et al., 2002). 
In T cells the Ras-MAPK pathway has been shown to play a crucial role in the initiation of 
proliferation and differentiation programs (Rincon, 2001). (Ras is a plasma membrane- 
associated guanine nucleotide-binding protein that acts upstream of the serine-threonine 
kinase Raf-1. Raf-1 acts as a MAPKKKs and activation of Raf-1 by Ras induces a 
mitogen-associated protein kinase (MAPK) activation cascade that ultimately results in the 
phosphorylation and activation of the MAPKs ERK1 and ERK2. ERK kinase activity leads 
to the activation of the transcription factor Elk1 that, in turn, drives the expression of the 
transcription factor c-Fos and thereby contributes to the activation of the activator   
protein-1 (AP-1) (c-Jun/c-Fos) transcription factor complex (Smith-Garvin et al., 2009). 
Ras is only active in its GTP-bound conformation. Its activation is induced by the action of 
GEFs and counteracted by GTPase-activating proteins (GAPs). Two distinct GEFs, the 
GEF son of sevenless (SOS) and the Ras guanyl nucleotide-releasing protein (RasGRP), 
have been described to catalyze Ras activation in T lymphocytes (Ebinu et al., 2000; 
Egan et al., 1993). SOS is recruited via its constitutive interaction with the adapter growth 
factor receptor-bound protein 2 (Grb2) to phospho-LAT upon TCR stimulation. 
Subsequently, membrane-proximal SOS catalyzes the GDP-GTP exchange of Ras 
thereby leading to Ras activation (Egan et al., 1993). Additionally, RasGRP is recruited to 
the plasma membrane by virtue of its DAG-binding domain und undergoes 
phosphorylation and activation by PKC (Ebinu et al., 1998; Roose et al., 2005). 
Apparently, these two modes of Ras activation serve distinct and non-redundant functions 
in MAPK signaling since RasGRP seems to be more important in the initial phase of Ras 
activation and SOS cannot compensate for RasGRP deficiency (Dower et al., 2000). 
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1.2.6 TCR-induced JNK and p38 activation 
Besides activation of the ERK kinases TCR ligation also triggers the activation of another 
group of MAPKs, the stress-activated protein kinases (SAPKs) including members of the 
JNK and p38 MAPK families. 
 
(i) TCR-induced JNK activation 
Three members of the JNK family (JNK1-3) have been identified. Whereas expression of 
JNK3 is predominantly confined to non-lymphoid tissues, both JNK1 and JNK2 are 
ubiquitously expressed. However, in resting lymphocytes levels of JNK1/2 are very low 
and their expression is induced upon antigen receptor stimulation. JNK1/2 each exist in 
four distinct isoforms although the relative importance of the individual isoforms for overall 
JNK activity remains unclear (Rincon and Davis, 2009). A major substrate of active JNK 
kinases is the transcription factor c-Jun. Upon phosphorylation on serine 63 and serine 73 
c-Jun gains increased transcriptional activity and heterodimerizes with the c-Fos protein to 
form the active AP-1 transcriptional complex (Davis, 2000). 
JNKs themselves are activated by dual phosphorylation on threonine 183 and tyrosine 
185 in their T loop by MAPKKs, particularly by MKK4/SEK1 and MKK7/SEK2. These 
MAPKKs in turn are activated by several MAPKKKs including MEKK1-4, the mixed-
lineage kinases (MLKs), and the TGF--activated kinase 1 (TAK1) (Davis, 2000). 
Nonetheless, the precise molecular mechanism underlying TCR-induced JNK activation is 
still not well understood. A number of in vitro studies as well as studies from various 
knock-out mice have suggested a crucial role of the PKC-dependent Carma1-Bcl10-
MALT1 (CBM) signalosome in TCR-induced JNK activation (see 1.3.5). First, the ability of 
the PKC-activating phorbolester 12-myristate 13-acetate (PMA) to induce phosphorylation 
of JNK proteins has implicated PKCs in TCR-induced JNK activation (Isakov and Altman, 
2002). Second, overexpression of PKC, but not PKC in Jurkat T cells mediates robust 
induction of AP-1 activity whereas, vice versa, PKC-deficient T cells lack TCR or PMA-
induced c-Jun activation (Baier-Bitterlich et al., 1996; Sun et al., 2000). This is in line with 
reports showing that T cells deficient for the downstream signaling mediators Carma1 or 
Bcl10 are defective in TCR-induced JNK1/2 phosphorylation although the involvement of 
different JNK isoforms remains controversial (Blonska et al., 2007; Hara et al., 2003; 
Rebeaud et al., 2007). Moreover, TAK1 which operates downstream of the CBM complex 
(see 1.3.5) was shown to be mandatory for TCR-induced JNK activation (Wan et al., 
2006). 
Introduction 11
(ii) TCR-induced p38 activation 
The p38 MAPK family consist of four members (p38 , , , and ) of which p38, p38, 
and p38 are expressed in T lymphocytes (Rincon and Davis, 2009). A prominent target 
of p38 kinases is the activating transcription factor 2 (ATF2) that is activated upon 
phosphorylation. Akin to JNK activation, induction of p38 kinase activity is dependent on 
dual phosphorylation of threonine 180 and tyrosine 182 within its activation loop. Direct 
phosphorylation of p38 was shown to be mediated by the dual specificity kinases MKK3 
and MKK6 which in turn are phosphorylated by the upstream activators MEKK3 and 
MEKK6. These signaling constituents are part of the so-called classical MAPK cascade 
that is initiated by the activity of small RHO-family GTPases such as Rac1 and Rac2 
(Ashwell, 2006). However, recently it has been demonstrated that TCR-induced p38 
activation occurs via an MEKK-independent alternative pathway that bypasses the MAPK 
cascade. This alternative pathway relies on direct Lck and ZAP-70-mediated 
phosphorylation of p38 on tyrosine 323 which results in p38 (mono-)autophosphorylation 
on threonine 180 to induce full kinase activity (Mittelstadt et al., 2009; Salvador et al., 
2005). Furthermore, this pathway involves the scaffold protein discs large homolog 1 
(Dlgh1) that inducibly associates with p38 and selectively channels TCR signals towards 
p38, but not JNK or ERK. Interestingly, knock-down of Dlgh1 in T cells does not only block 
TCR-induced p38 activation, but also affects the NFAT signaling pathway in response to 
TCR engagement (Rebeaud et al., 2007; Round et al., 2007). 
 
1.3 Signaling to NF-B 
The transcription factor nuclear factor-kappaB (NF-B) is a crucial determinant of various 
biological processes comprising inflammatory reactions, proliferation, cell death, 
embryonic and tissue development, and tumorigenesis. However, its most important 
functions refer to the regulation of innate and adaptive immune responses. Originally,   
NF-B was identified in the laboratory of David Baltimore more than two decades ago as a 
transcription factor with inducible activity that selectively binds to specific DNA motifs, 
known as B sites, within the kappa light-chain enhancer in B cells (Baeuerle and 
Baltimore, 1988; Sen and Baltimore, 1986). Since then, the role of NF-B in diverse 
cellular processes and in different cellular contexts, including non-immune cells, became 
more and more evident, and NF-B served as a model transcription factor whose 
regulation revealed some generic principles of receptor-induced signaling cascades 
(Hayden and Ghosh, 2008). In T lymphocytes NF-B plays a critical role in activation, 
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differentiation, proliferation, and homing by regulating a wide variety of target genes such 
as different cytokines (e.g. IL-2, IFN, and TNF), chemokines (e.g. IL-8), as well as cell 
adhesion molecules (e.g. ICAM-1) (Bonizzi and Karin, 2004; Ghosh and Karin, 2002). The 
mechanisms and molecular components governing NF-B signaling are subject of the 
following sections with particular emphasis on NF-B regulation in T lymphocytes. 
 
1.3.1 The NF-B core signaling machinery 
(i) The NF-B family of transcription factors 
In mammals the NF-B family of transcription factors consists of five conserved and 
structurally related members: NF-B1 (p50 and its precursor p105), NF-B2 (p52 and its 
precursor p100), RelA (p65), RelB, and c-Rel, encoded by NFKB1, NFKB2, RELA, RELB, 
and REL, respectively (Hayden and Ghosh, 2008). All NF-B proteins share an 
homologous 300 amino acid long N-terminal Rel homology domain (RHD) that contains 
sequences responsible for homo- and heterodimerization, sequence-specific DNA binding 
to B sites, interaction with inhibitory proteins (see below), as well as nuclear translocation 
(Hayden and Ghosh, 2004). Regulation of NF-B-dependent transcription occurs via    
NF-B homo- or heterodimers that bind to promoter or enhancer regions of target genes 
and the recruitment of transcriptional co-activators and co-repressors (Hoffmann et al., 
2006). The co-association with trans-acting factors is mediated through unrelated           
C-terminal transactivation domains (TADs) that are only present in RelA, c-Rel, and RelB. 
By contrast, the p50 and p52 subunits lack TADs and might therefore either contribute to 
transcriptional repression as homodimers or to transcriptional activation as 
transcriptionally competent heterodimers via interaction with TAD-containing NF-B family 
members or other TAD-containing proteins (Ghosh and Hayden, 2004). In principle, the 
ability to undergo homo- and heterodimerization generates a substantial combinatorial 
complexity among NF-B transcription factors with up to 15 different dimer combinations. 
However, the physiological existence and relevance for all possible dimers has not been 
elucidated yet. Clearly, the heterodimer RelA:p50 is the most abundant transcriptionally 
active NF-B complex that is detectable in many cell types (Oeckinghaus and Ghosh, 
2009). Besides the possibility of dimer formation another layer of complexity is added by 
several posttranslational modifications such as phosphorylation and acetylation that have 
been shown to modulate the DNA sequence specificity as well as the transcriptional 
competence of NF-B subunits (Viatour et al., 2005; Perkins, 2006). Moreover, several 
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auxiliary proteins have been identified that function as nuclear regulators of NF-B. A 
particularly intriguing example in T lymphocytes is a recently discovered non-Rel integral 
subunit of NF-B, the ribosomal protein S3 (RPS3), that has been shown to co-translocate 
with RelA into the nucleus upon TCR stimulation and to cause synergistic binding of p65 
to B sites. Consequently, RPS3 deficiency impaired TCR-induced NF-B activity and 
upregulation of target genes (Wan et al., 2007). 
 
 (ii) The IB family 
In most unstimulated cells NF-B proteins are sequestered in the cytoplasm by inhibitors 
of NF-B proteins, the IB proteins. The IB protein family includes classical IBs, such as 
IB, IB, and IB, as well as the inducibly expressed atypical IB proteins IB, B cell 
lymphoma 3 (Bcl-3) and IBNS. All IB proteins are characterized by the presence of five 
to seven ankyrin repeat motifs that mediate binding to the RHD of NF-B dimers. The 
precursor proteins p100 and p105, which can be proteolytically processed to the NF-B 
subunits p52 and p50, respectively, also contain several C-terminal ankyrin repeats that 
allow them to serve IB-like functions. The prototypical and most prominent IB family 
member is IB. Upon various stimuli IB is rapidly degraded via the proteasome 
thereby releasing NF-B dimers to enter the nucleus. p65:p50 heterodimers are most 
likely the primary target of IB (Oeckinghaus and Ghosh, 2009; Vallabhapurapu and 
Karin, 2009). Retention of NF-B dimers in the cytosol is mediated by masking of a 
conserved nuclear translocation sequence (NLS) within the RHD of NF-B subunits. For 
IB this masking is incomplete, but a nuclear export sequence (NES) within IB 
mediates rapid export of NF-B:IB complexes under steady-state conditions. However, 
stimulation-induced degradation of IB drastically shifts this dynamic equilibrium in 
favour of nuclear localization of NF-B transcription factors (Hayden and Ghosh, 2008). 
 
(iii) The IB kinase complex 
Phosphorylation-induced proteasomal degradation of IB proteins is a hallmark of all    
NF-B signaling pathways and an indispensable prerequisite for NF-B activation. 
Phosphorylation of IB proteins is catalyzed by IB kinases (IKKs) that are organized in a 
multimeric complex, known as IKK complex. 
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Figure 1.2 | Molecular architecture of NF-B, IB, and IKK family members. (A) In mammalian 
cells NF-B exists as a group of 5 related transcription factors. All NF-B family members share a 
Rel homology domain (RHD) responsible for dimerization, nuclear export, DNA binding and 
sequestration by IB proteins. The transactivation domain (TAD) is only found in RelA (p65), RelB, 
and c-Rel and mediates transcription initiation at B sites-containing promoters. RelB is unique in 
harbouring an N-terminal leucine zipper (LZ) motif that plays an important transcriptional regulatory 
role. p50 and p52 are generated by proteolytic processing of p105 and p100, respectively. The     
N-termini of these precursor proteins contain the RHD of p50 or p52, followed by a glycine rich 
region (GRR), multiple ankyrin repeat motifs (ANK), and a C-terminal death domain (DD). (B) IB 
proteins are characterized by the presence of multiple ANK motifs mediating interactions with     
NF-B dimers. Therefore, p100 and p105 can be assigned to both the NF-B and IB families. 
Proline (P), glutamic acid (E), serine (S), and threonine (T) residues within IB and IB are 
indicated as PEST. (C) The IKK complex contains the catalytic kinase subunits IKK and IKK, and 
the regulatory subunit NEMO. The kinase domain (KD) of IKK or IKK is followed by a LZ and a 
helix-loop-helix (HLH) motif required for kinase dimerization. The C-terminal NEMO-binding peptide 
(NBP) mediates interaction with the kinase-binding domain (KBD) of NEMO. In addition to its LZ 
and zinc finger (ZF) motifs NEMO harbours a central Ub-binding domain that mediates binding to 
K63-linked pUb chains and is indispensable for NEMO signaling functions. 
Introduction 15
Initially, cytosolic IKK activity had been assigned to a large protein complex of 700-
900 kDa with specificity for serines 32 and 36 within the destruction box of IB (Chen et 
al., 1996). Subsequently, biochemical experiments revealed the presence of two highly 
homologous kinases, IKK (IKK1) and IKK (IKK2), and a regulatory subunit termed IKK 
or NF-B essential modulator (NEMO) (DiDonato et al., 1997; Mercurio et al., 1997; 
Rothwarf et al., 1998; Woronicz et al., 1997). This trimolecular IKK complex forms a 
central nodal point in the receptor-induced activation of the so-called classical or 
canonical NF-B signaling pathway. By contrast, an alternative IKK complex composed of 
IKK homodimers is crucial for activation of a second NF-B pathway, termed the 
alternative or non-canonical pathway (Bonizzi and Karin, 2004) (see 1.3.2). 
IKK and IKK, together with IKKi (IKK) and TBK1, belong to the IKK family of serine-
threonine kinases. IKK and IKK both contain an N-terminal kinase domain followed by a 
C-terminal portion that harbours a conserved leucine-zipper and putative helix-loop-helix 
(HLH) motifs. IKK and IKK display large sequence identity of 52%, with a greater extent 
of homology (65%) in the catalytic domain (Woronicz et al., 1997; Hacker and Karin, 
2006). Dimerization of IKK and IKK is required for kinase activity and dependent on the 
leucine zipper domain (Karin, 1999). The HLH is dispensable for kinase dimerization, yet 
crucial for full kinase activity (Zandi et al., 1998). Apparently, IKK and IKK preferentially 
form heterodimers in vivo, and in vitro studies demonstrated that IKK/IKK heterodimers 
posses a higher catalytic activity than either homodimer (Huynh et al., 2000). Both kinases 
can be inactivated by a point mutation of lysine 44 within the ATP-binding site (Hayden 
and Ghosh, 2004). However, there are important biochemical differences between IKK 
and IKK, especially with respect to substrate specificity. IKK is responsible for 
phosphorylation of most NF-B-bound IB proteins, whereas IKK confers p100 
phosphorylation (Scheidereit, 2006). Both kinases are able to phosphorylate IB and 
IB, although IKK is both necessary and sufficient to phosphorylate IB on serine 32 
and serine 36, as well as IB on serine 19 and serine 23 (Hayden and Ghosh, 2004). 
Moreover, in knock-out studies IKK could not compensate for IKK deficiency. Yet, in the 
absence of IKK, IKK is able to mediate some residual IB kinase activity (Li et al., 
1999), whereas, vice versa, IKK deficiency has no impact on canonical IB 
phosphorylation (Hu et al., 1999). 
The third component of the trimolecular IKK complex is NEMO, a regulatory subunit of 
48 kDa that lacks intrinsic catalytic activity and is not structurally related to IKK and IKK 
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(Rothwarf et al., 1998; Yamaoka et al., 1998). It is composed of N- and C-terminal coiled-
coil (CC) domains, a leucine-zipper motif, and an N-terminal zink finger-like domain. The 
C-terminal portion of NEMO is important for IKK activation and interactions with upstream 
signaling constituents whereas the N-terminus mediates the physical association with 
IKK and IKK (Oeckinghaus and Ghosh, 2009). A recently identified ubiqutin (Ub)-
binding domain (UBD) classifies NEMO as a receptor for K63-linked Ub chains and is 
mandatory for its signaling functions (Israel, 2010; Wu et al., 2006). IKKs themselves bind 
to NEMO via a short hexapeptide sequence (LDWSWL), known as NEMO binding domain 
(NBD). Competition experiments using a NBD peptide indicated that IKK has a higher 
affinity to NEMO than IKK which is consistent with the idea that IKK is the dominant IKK 
in the NEMO-dependent canonical NF-B pathway (May et al., 2000; May et al., 2002). 
The stoichiometry of the IKK complex is still controversially discussed. The high apparent 
molecular weight of 700-900 kDa of the natively purified IKK complex suggests that the 
IKK complex either contains additional molecules or exists in an oligomeric state. 
Tegethoff et al. have proposed tetrameric oligomers of NEMO in vitro (Tegethoff et al., 
2003) while other studies have shown that IKK is able to form dimers and trimers, but no 
tetramers, in a cell type-specific manner (Agou et al., 2004). It has also been assumed 
that NEMO is monomeric in resting cells while upon stimulation multimeric structures of 
the stoichiometry IKK3/IKK/IKK are assembled (Hayden and Ghosh, 2004). However, 
recent models support the idea of an octameric IKK complex composed of two IKK/IKK 
heterodimers each bound to two IKK molecules with the stoichiometry  
(IKK2IKK1IKK1)2 (Hayden and Ghosh, 2008). 
Although IKK, IKK and IKK are considered as the core elements of the IKK complex, 
there is evidence for two other proteins potentially being part of the IKK complex, including 
the chaperone HSP90/Cdc37 (Chen et al., 2002) and ELKS (Ducut Sigala et al., 2004). 
Both proteins have been co-purified with the IKK complex; however, their exact IKK-
related functions have not been precisely defined yet (Hayden and Ghosh, 2004). 
 
1.3.2 Activation of IKK: the canonical and non-canonical NF-B signaling pathway 
Two distinct NF-B activation pathways have been described: the classical or canonical 
and the alternative or non-canonical NF-B activation pathway. These signaling cascades 
proceed via activation of IKKs and phosphorylation and degradation of IBs although they 
differ with regard to the triggering stimuli, IKK components involved and the targeted    
NF-B subunits. 
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Figure 1.3 | The canonical and non-canonical pathway of NF-B activation. The canonical 
pathway (left) is induced by a variety of surface receptors, such as antigen receptors on 
lymphocytes or the TNFR1, that converge on the activation of the trimeric IKK complex composed 
of IKK, IKK, and NEMO. IKK activity leads to phosphorylation of IB proteins which, in turn, 
induces K48-linked polyubiqitination of IBs and their subsequent proteasomal degradation. 
Liberated p65/p50 dimers then traffic into the nucleus to turn on transcription of target genes. The 
non-canonical pathway (right) depends on NIK-induced activation of IKK homodimers. Activated 
IKK phosphorylates p100 to induce its partial proteolysis to p52 by the proteosome. 
Transcriptionally active p52 preferentially heterodimerizes with RelB to translocate into the nucleus 
and to promote transcription of target genes. 
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(i) The canonical NF-B pathway 
The canonical NF-B signaling pathway is the major activation pathway triggered by most 
proinflammatory cytokines (e.g. TNF, IL-1), PRRs, and antigen receptors (Bonizzi and 
Karin, 2004) (see 1.3.4 and 1.3.5). This pathway centers around the trimolecular IKK 
complex composed of IKK, IKK, and NEMO and primarily involves activation of 
RelA:p50 NF-B transcription factors (Vallabhapurapu and Karin, 2009). In the context of 
canonical signaling IKK is the predominant IB-targeting IKK, although there are 
exceptions, for instance receptor activator of NF-B ligand (RANKL)-stimulated mammary 
epithelial cells, which rely on IKK for stimulation-induced IB phosphorylation (Cao et 
al., 2001). The overall role of IKK in this pathway remains unclear. It has been 
speculated that IKK serves structural functions within the IKK complex. Furthermore, 
IKK plays an important nuclear role in NF-B dependent gene expression in all canonical 
NF-B pathways (Hayden and Ghosh, 2008). The general importance of the canonical 
pathway in the immune system has been revealed by genetic studies demonstrating that 
conditional IKK or RelA knock-out mice show a significantly higher susceptibility to 
infections (Gerondakis et al., 1999; Pasparakis et al., 2006). 
Receptor-induced IKK activation primarily results in IB phosphorylation leading to its 
recognition and polyubiquitination at lysine 19 by the Skp1, Cdc53/Cullin1, and F-box 
protein  transducin repeat-containing protein (TRCP)SCFIB E3 Ub ligase complex. 
K48-linked polyubiquitin (pUb) chains mark IB for degradation via the 26S proteasome, 
thereby liberating NF-B dimers (Karin and Ben-Neriah, 2000). 
 
(ii) The non-canonical pathway 
The non-canonical pathway is triggered by a more restricted number of receptors 
including TNFR family receptors such as BAFF-R (B cell activating factor receptor), CD40 
and RANK on B cells, as well as the lymphotoxin  receptor (LTR) on splenic stromal 
cells (Bonizzi and Karin, 2004). In marked contrast to the canonical pathway, it does not 
rely on IKK and NEMO but depends on the activity of IKK (Senftleben et al., 2001). 
Although still substantial evidence is missing, it is generally assumed that an alternative 
IKK complex composed of IKK homodimers that are not bound to NEMO forms the 
receptor-activated IKK signaling entity in analogy to the trimeric IKK complex in the 
canonical pathway (Scheidereit, 2006; Hayden and Ghosh, 2008). The primary IB-like 
target of IKK is p100 which upon phosphorylation on serines within its C-terminal ankyrin 
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repeat domain is polyubiquitinated by the SCFIB E3 Ub ligase complex (Amir et al., 2004; 
Senftleben et al., 2001). This in turn leads to the limited proteasomal proteolysis of p100, 
a process with some similarity to the proteasomal editing of p105, and to the generation of 
active RelB/p52 heterodimers. However, generation of p50 subunits by proteasomal 
processing of the precursor protein p105 is a constitutive co-translational process 
(Oeckinghaus and Ghosh, 2009). Interestingly, there is cross talk between the canonical 
and non-canonical pathways as the former leads to upregulated expression of RelB and 
p100 and therefore feeds into the non-canonical pathway (Scheidereit, 2006). 
 
1.3.3 Mechanisms and principles of IKK activation 
Activation of the IKK complex requires phosphorylation of two serine residues within the 
activation T loop of both kinases which presumably induces a conformational change 
leading to kinase activation. Mutation of these residues in IKK (S177/S181) and IKK 
(S176/180), respectively, to alanines prevents kinase activation, whereas the replacement 
with phosphomimetic glutamates in IKK (IKK(SS/EE)) results in a constitutively active 
enzyme (Delhase et al., 1999; Hacker and Karin, 2006). However, the mechanisms 
through which these phosphorylation events occur are still controversially discussed. A 
crucial question that remains to be answered is whether IKK activation depends on 
transautophosphorylation and/or phosphorylation by upstream IKK kinases (IKK-Ks). 
The most compelling evidence for the existence and action of an IKK-K comes from the 
non-canonical pathway. The NF-B-inducing kinase (NIK) is a MAPKKK family member 
and directly phosphorylates IKK on its T loop serines leading to IKK activation (Regnier 
et al., 1997). Although NIK has been shown to associate with IKK and NEMO 
(Bouwmeester et al., 2004; Lin et al., 1998), genetic studies from NIK knock-out mice and 
transgenic mice expressing a dominant negative version of NIK clearly proof an exclusive 
role of NIK in the alternative pathway (Shinkura et al., 1999). 
Other studies have provided evidence for a role of the upstream MAPKKKs MEKK3 and 
TAK1 as IKK-Ks. MEKK3 phosphorylates and activates IKK and IKK at their activation 
loops, and murine embryonic fibroblasts (MEFs) lacking MEKK3 exhibit impaired IB 
degradation upon TNF stimulation (Yang et al., 2001a). MEKK3 inducibly associates with 
IKKs and is required for the assembly of the active IKK complex with IB (Schmidt et al., 
2003). However, a direct phosphorylation of IKK by MEKK3 has not been shown yet, and 
it is conceivable that MEKK3 serves different functions, for example by bridging of IKK 
with IB, phosphorylation of IKK-activating substrates (e.g. ELKS), or by directly acting 
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as a scaffold protein. Moreover, a role of MEKK3 as an essential IKK-K in immune cells 
remains elusive (Hayden and Ghosh, 2004). TAK1 is another putative IKK-K that has 
been particularly implicated in TCR-induced NF-B signaling. Akin to MEKK3, TAK1 
overexpression induces NF-B activation although TAK1 needs co-expression of its 
regulatory subunits TAB1, TAB2, or TAB3. TAK1 seems to be recruited to the activated 
TNF receptor (TNFR) and to phosphorylate the activation loops of the IKK catalytic 
subunits (Ishitani et al., 2003; Wang et al., 2001). Moreover, small interfering RNA 
(siRNA)-mediated silencing of TAK1 reduced IB phosphorylation and blocked IL-2 
production upon TCR triggering in Jurkat T cells in vitro (Sun et al., 2004). However, the 
analysis of TAK1-deficient mice did not support a general role of TAK1 in antigen 
receptor-dependent IKK activation. BCR-induced NF-B activation in the absence of 
TAK1 is not impaired (Sato et al., 2005), and TAK1 seems to selectively control TCR-
induced NF-B activation in thymocytes, but not in effector T cells (Liu et al., 2006; Wan et 
al., 2006). In concert, these data suggest a cell type-specific role for TAK1 and MEKK3 in 
NF-B activation, and these kinases might rather lead to the amplification of IKK activity 
following initial IKK activation via transautophosphorylation. 
Indeed, the concept of transautophosphorylation of IKKs by induced proximity and/or 
conformational changes has attracted more and more attention with the description of 
macromolecular scaffolding platforms that recruit IKK complexes, leading to their 
oligomerization and thereby activation. In this context, the discovery of non-degradative 
K63-linked polyubiquitination has led to a substantial improvement of the understanding of 
canonical IKK activation (Chen et al., 1996; Chen, 2005; Wertz and Dixit, 2010). 
Stimulation-dependent K63-linked ubiquitination of NEMO and various upstream signaling 
mediators in the canonical NF-B signaling pathway is thought to mediate the assembly 
and stabilization of multi-protein complexes which in turn provide a scaffold for IKK 
oligomerization (Inohara et al., 2000). In support of this concept, it was recently 
demonstrated that even free and unanchored K63-linked pUb chains are sufficient to 
promote activation of TAK1 and IKKs in vitro (Xia et al., 2009). The assembly of these 
high-molecular IKK-containing complexes substantiates a role for transauto-
phosphorylation of IKKs; however it is possible and not mutually exclusive that in a cell 
type and pathway-specific manner these signalosomes integrate IKK-Ks to catalyze IKK 
activation. 
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1.3.4 TNFR-induced NF-B activation 
Signaling by TNF has long been a prototypic model for receptor-induced canonical IKK 
activation. TNF binds to two receptors, TNFR1 and TNFR2, of which TNFR1 plays a 
much more prominent role in the immune system. TNFR1 is expressed on haematopoietic 
and non-haematopoietic cells with the strongest expression on epithelial cells whereas its 
ligand, TNF, is secreted by activated DCs, macrophages, and T cells. TNFR1 ligation 
induces receptor trimerization and recruitment of the adapter protein TNFR1-associated 
death domain protein (TRADD). TRADD in turn enables binding of the serine threonine 
kinase receptor-interacting protein 1 (RIP1) and of the E3 ligases TNFR-associated factor 
2 (TRAF2) and TRAF5 to the activated TNFR. Finally, these molecules co-recruit the E3 
ligases cellular inhibitor of apoptotic proteins 1 (c-IAP1) and c-IAP2. Together, this 
conglomerate of molecules at the engaged TNFR1 forms the so-called complex 1 or 
TNFR-signaling complex (TNF-RSC) (Micheau and Tschopp, 2003). RIP1 is important for 
NF-B activation downstream of TNFR1 although its kinase activity is completely 
dispensable (Meylan et al., 2004; Ting et al., 1996). Upon recruitment into the TNF-RSC 
RIP1 is covalently modified by the attachment of K63-linked pUb chains (Ea et al., 2006). 
Initially, TRAF2 was assumed to be the E3 ligase for RIP1; however novel studies support 
a role for TRAFs as adaptors for c-IAPs that in turn serve E3 ligase functions in TNFR1 
signaling (Bianchi and Meier, 2009; Wu et al., 2007). The K63-linked pUb chains 
associated with RIP1 then induce the recruitment of two Ub-binding complexes, the 
TAK1/TAB complex (TAK1/TAB2/TAB3), and the IKK complex via the Ub receptors TAB2 
and NEMO, respectively (Ea et al., 2006; Kanayama et al., 2004; Li et al., 2006a; Wu et 
al., 2006). Subsequently, TAK1 is believed to activate IKK, most probably through 
proximity-induced phosphorylation. However, two recent studies have led to a substantial 
refinement of the current dogma of TNFR1-induced IKK activation. Haas et al. and 
Tokunaga et al. reported independently the identification of an additional E3 ligase 
complex within the TNF-RSC, termed the linear Ub chain assembly complex (LUBAC) 
(Haas et al., 2009; Tokunaga et al., 2009). Unlike c-IAPs this complex catalyzes the 
polyubiquitination and attachment of linear Ub chains to NEMO and most likely other 
components of complex 1. In addition to initial K63-linked ubiquitination, this novel mode 
of linear ubiquitination has been suggested to stabilize the TNF-RSC and to support the 
recruitment, retention, and ubiquitination of the IKK complex (Bianchi and Meier, 2009). 
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1.3.5 TCR-induced NF-B activation 
Activation of NF-B following triggering of antigen receptors is a crucial step for the 
regulation of antigen-specific proliferation, survival, maturation, and the effector functions 
of lymphocytes. Genetic deficiencies in the activation pathway coupling the TCR to NF-B 
has been linked to immune deficiencies, whereas aberrant and constitutive NF-B activity 
in lymphocytes is associated with autoimmune disorders and causative for the 
development of lymphoid malignancies (Li and Verma, 2002) (see section 1.5). 
Antigen receptor-induced NF-B activation involves the canonical machinery of NF-B 
signaling. Engagement of the TCR/CD3 complex leads to the recruitment of the IKK 
complex into the immunological synapse (IS) (Khoshnan et al., 2000). However, the 
molecular events coupling the activated TCR to the IKK complex remained elusive until 
the identification of three interacting proteins known as Carma1 (caspase recruitment 
domain (CARD), membrane-associated guanylate kinase (MAGUK) protein 1), Bcl10 
(B cell lymphoma10), and MALT1 (mucosa-associated lymphoid tissue lymphoma 
translocation protein 1). The PKC-dependent Carma1-Bcl10-MALT1 (CBM) complex is a 
central gateway in TCR-induced NF-B activation. Deficiencies of either proteins cause 
profound defects in BCR- and TCR-induced NF-B signaling and lymphocyte activation 
(for review see Thome, 2004). 
Immunofluoresence studies using Carma1 knock-out mice demonstrated that the IKK 
complex is recruited into the IS in a Carma1-dependent manner (Hara et al., 2004). 
Carma1 belongs to the MAGUK family that is characterized by the presence of several 
protein interaction (PDZ) domains, an SH3 domain and guanylate kinase (GUK) domain 
(Dimitratos et al., 1999). Additionally, Carma1 possesses a CARD domain and a coiled-
coil motif at its N-terminus that is separated by an extended linker region from the C-
terminal MAGUK domains (Thome, 2004). A small fraction of Carma1 constitutively 
resides in lipid rafts and becomes further enriched upon stimulation (Gaide et al., 2002). 
The linker region of Carma1 is a major substrate of PKC. Following TCR engagement 
PKC-mediated phosphorylation of critical residues within the Carma1 linker region, also 
known as PKC-regulated domain (PRD), is thought to impose a conformational change 
within Carma1 that enables the direct and inducible interaction with Bcl10 (Matsumoto et 
al., 2005; Sommer et al., 2005; Wang et al., 2004). The association between Carma1 and 
Bcl10 is based on a homophilic interaction between the CARD domains of both proteins. 
Bcl10 operates downstream of Carma1 since deletion of the Carma1 CARD domain 
interferes with Bcl10 recruitment into lipid rafts and TCR-induced NF-B activation (Gaide 
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et al., 2001). Bcl10 in turn is constitutively associated with MALT1 involving the Ig-like 
domains of MALT1 and a short C-terminal sequence within Bcl10. Both proteins are 
targets of chromosomal rearrangements linked to development of MALT1 lymphomas, 
underscoring their functional interaction in a common pathway (Lucas et al., 2001; Uren et 
al., 2000) (see 1.5.2). 
Activation of the Carma1 signalosome is thought to induce an oligomerization cascade 
(Sun et al., 2004) which is substantiated by the observation that overexpression of 
Carma1, Bcl10, or MALT1 alone is sufficient to induce their activation and NF-B signaling 
(Rawlings et al., 2006). The E3 ligases TRAF2 and TRAF6, which were predominantly 
implicated in TNFR- and IL-1R-induced IKK activation, are important downstream targets 
of MALT1 linking the CBM complex with the IKK complex. Oligomerization and 
recruitment of TRAF6 to the CBM complex leads to TRAF6 activation and K63-linked 
ubiquitination of TRAF6 itself and its major target NEMO (Sun et al., 2004). Moreover, 
recently MALT1 has been reported to contain an E3 ligase activity that catalyzes both its 
K63-linked autoubiquitination as well as Bcl10-dependent transubiquitination of NEMO 
(Oeckinghaus et al., 2007; Zhou et al., 2004a), although this activity is enhanced in the 
presence of TRAF6 (Sun et al., 2004). Ubiquitination of NEMO as well as recruitment and 
oligomerization of the IKK complex to the polyubiquitinated CBM signalosome then trigger 
IKK activation, most probably involving IKK transautophosphorylation and TAK1-mediated 
IKK phosphorylation (Rawlings et al., 2006). The complexity of the NF-B-activating 
signalosome is further increased by the fact that caspase-8 is required for TCR-induced 
NF-B activation. Caspase-8 binds to the activated CBM complex, and T lymphocytes 
lacking caspase-8 show diminished NF-B activation (Bidere et al., 2006; Su et al., 2005). 
Interestingly, the rare disorder caspase-8 deficiency (CED) is due to a lack of caspase-8 
expression and is associated with several immune defects (Chun et al., 2002). 
Phosphorylation of Carma1 by PKC is a critical step in activation of the CBM complex, 
but the molecular details of the interactions between these upstream components have 
long been elusive. However, the finding that the 3-phosphoinositide-dependent kinase 1 
(PDK1) mediates PKC phosphorylation and itself inducibly associates with Carma1 has 
significantly contributed to a more precise understanding of this signaling pathway (Lee et 
al., 2005). PDK1 is a plasma membrane-associated serine threonine kinase that is 
activated and recruited to the TCR via a CD28 co-stimulation-dependent mechanism 
involving phosphoinositide-3 kinase (PI3K) and Vav1 (Park et al., 2009). 
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Figure 1.4 | TCR-induced signaling to NF-B. Triggering of the TCR results in the activation of a 
receptor proximal core signalosome leading to activation of serine/threonine kinases PKC and 
HPK1. In addition, co-engagement of CD28 results in the activation and membrane recruitment of 
PDK1. PDK1 phosphorylates and activates PKC and inducibly associates with Carma1 in lipid 
rafts. Recruitment of the scaffold Carma1 to the plasma membrane facilitates its phosphorylation 
by PKC and HPK1 unleashing its adaptor functions. Activated Carma1 presumably undergoes a 
conformational change allowing for the association with BCL10 and MALT1 and the formation of a 
stable macromolecular signaling platform, known as CBM complex. Assembly of the CBM complex, 
in turn, leads to the recruitment, oligomerization and activation of the E3 ligase TRAF6. TRAF6-
dependent K63-linked polyubiquitination of MALT1, NEMO, and TRAF6 itself facilitates the 
recruitment and activation of the IKK complex, most likely involving transautophosphorylation of 
IKKs by induced-proximity. The activated IKK complex then phosphorylates and marks IB for 
proteasomal degradation leading to nuclear translocation of transcriptionally active p65/p50 NF-B 
heterodimers. 
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PDK1 phosphorylates and activates PKC. PKC-dependent phosphorylation of Carma1 
results in membrane recruitment of the CBM complex; however, PDK1 seems to 
contribute to this process by interacting with Carma1 independently of PKC (Lee et al., 
2005). Thus, PDK1 is a linker between PKC and the CBM complex and integrates TCR 
and CD28-induced signals to mediate NF-B activation in T lymphocytes. 
Although PKC seems to be the most dominant kinase targeting Carma1, other kinases 
have been described to contribute to CBM-dependent NF-B signaling. Recently, a 
kinase-independent adaptor function of the casein kinase 1 (CK1) has been shown to 
be important for antigen receptor-induced NF-B activation (Bidere et al., 2008). Moreover, 
stimulation-dependent phosphorylation of the Carma1 linker region by HPK1 on serine 
residues that are different from PKC-phosphorylated sites seems to be crucial for TCR-
induced CBM activation in vitro, although HPK1 might play a role as modulator rather than 
as indispensable trigger of TCR-induced NF-B signaling (Brenner et al., 2009). 
 
1.4 Mechanisms of negative regulation and signal termination 
Signal initiation and propagation are based on rapid biochemical reactions that can be 
categorized into some generic themes of signaling such as phosphorylation, ubiquitination, 
localization, oligomerization, conformational regulation, and degradation. The reversion of 
these processes by counteracting negative regulatory mechanisms is a fundamental cell-
intrinsic principle of signal transduction ensuring proper signal shaping, control, and 
termination (Acuto et al., 2008). Aberrations of these opposing mechanisms in T cells and 
other immune cells are associated with autoimmune disorders and cancer (see also 
section 1.5). 
 
1.4.1 The human phosphatasome and its expression in T cells 
Since its discovery by Edmond Fischer and Erwin Krebs more than 50 years ago it has 
become clear that reversible protein phosphorylation – catalyzed by kinases and their 
opposing counterparts phosphatases, respectively – is one of the most versatile 
posttranslational modifications that pervades nearly all aspect of cell physiology (reviewed 
in Bennett et al., 2006). Whereas kinases predominantly serve activating functions within 
diverse signaling cascades, phosphate removal by phosphatases is often, albeit not 
generally involved in negative regulation of signaling events. The human genome encodes 
in minimum 518 protein kinases with 90 PTKs and 428 protein serine/threonine kinases 
(PSKs) (Manning et al., 2002). By contrast, the number of phosphatase genes is 
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significantly lower and not yet precisely defined. Strikingly, 107 protein tyrosine 
phosphatases (PTPs) have been identified, whereas far fewer protein serine/threonine 
phosphatases (PSPs) (about 30) are known (Alonso et al., 2004; Shi, 2009). The 
dichotomy in the numbers of PSKs and catalytic subunits of PSPs can be explained by the 
combinatorial formation of PSP holoenzymes that are composed of one catalytic subunit 
and several non-enzymatic regulatory subunits. The most prominent class of PSPs are 
the phosphoprotein phosphatases (PPPs). There are only 13 genes encoding for catalytic 
subunits of PPPs in the human genome (Virshup and Shenolikar, 2009). However, by 
proteomic and genetic approaches interactions between more than 160 regulatory 
subunits and their corresponding PPP catalytic subunits have been already mapped 
(Bennett et al., 2006). Regulatory subunits are thought to govern phosphatase activity by 
regulating substrate targeting, subcellular localization, and enzymatic activity (Janssens et 
al., 2005; Mumby, 2007). Furthermore, small subfamilies of PTPs are known that catalyze 
the dephosphorylation of phospholipids (Wishart and Dixon, 2002). Whereas most PPP 
catalytic subunits are ubiquitously expressed, about 40 different gene products of PTPs 
have been detected in T lymphocytes (Mustelin et al., 2004). 
 
1.4.2 Negative regulation of proximal TCR signaling by phosphatases 
The assembly of the TCR proximal signalosome (see section 1.2) primarily involves the 
activation and activity of an array of protein tyrosine kinases (PTKs). Consequently, most 
phosphatases found to be associated with the upstream TCR signaling machinery are 
phosphatases of the PTP family (reviewed in Mustelin et al., 2004). The most prominent 
TCR proximal phosphatases will be shortly discussed in the following. 
CD45 is the most abundantly expressed transmembrane PTP on T cells that has been 
primarily implicated in the positive regulation of Lck activity. In resting cells Lck is 
rendered inactive through phosphorylation on its inhibitory tyrosine residue by the           
C-terminal Src kinase (Csk). This inhibitory phosphorylation is counteracted by CD45 
although it has been shown that CD45 also contributes to negative regulation of Lck by 
dephosphorylating its active site (Hermiston et al., 2003). Protein tyrosine phosphatase, 
receptor type, A (PTPRA) is a homologue of CD45 that, similar to CD45, appears to 
regulate Fyn activity in thymocytes (Maksumova et al., 2005). In addition, protein tyrosine 
phosphatase, non-receptor type 22 (PTPN22) has been shown to inhibit Lck activity 
(Hasegawa et al., 2004), and PTPN22 mutations have been linked to an increased risk for 
several autoimmune diseases in humans (Vang et al., 2005). 
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Another prominent cytoplasmic PTP in lymphocytes is the SH2 domain-containing 
phosphatase 1 (SHP1, also termed PTPN6). SHP1 contributes to the negative regulation 
of Lck (Stefanova et al., 2003), but has been implicated in the dephosphorylation and 
inactivation of ITAM-bound ZAP-70 as well (Acuto et al., 2008). SHP1-deficient (so-called 
motheaten) mice display aberrant lymphocyte development, T cell hyperactivation, and 
autoimmunity (Tsui et al., 1993). Furthermore, the suppressor of TCR signaling (Sts) 
family of proteins consisting of Sts1 and Sts2 play an important role in negative regulation 
of the TCR signalosome. Sts1 and Sts2 contain phosphatase activity to ZAP-70, Syk and 
SFKs although their precise mode of action is still unclear. Sts1 and Sts2 double-deficient 
mice show increased phosphorylation of ZAP-70, LAT, and SLP-76 which is likely to 
explain their phenotype of T cell hyperproliferation and increased susceptibility to 
autoimmunity (Carpino et al., 2004; Mikhailik et al., 2007). 
The inositol phosphatases phosphatase and tensin homolog (PTEN) and the SH2 
domain-containing inositol phosphatase 1 (SHIP1) dephosphorylate the second 
messenger PtdIns(3,4,5)P3 within the plasma membrane and thereby counteract 
activation of PI3K and downstream signaling pathways (Harris et al., 2008). PTEN plays a 
rather ubiquitous role as tumor suppressor (Cully et al., 2006). T cell-specific PTEN 
knock-out mice exhibit splenomegaly and enlargement of the thymus (Suzuki et al., 2001) 
while the impact of SHIP1 deletion on T cell biology is less well studied (Helgason et al., 
1998; Liu et al., 1998b). Importantly, the human model T cell line Jurkat lacks expression 
of both proteins although the PI3K-Akt pathway is still inducible upon TCR stimulation 
(Abraham and Weiss, 2004). This argues for a role of both phosphatases in defining 
thresholds of lymphocyte activation (Harris et al., 2008). 
 
1.4.3 The NF-B-regulating phosphatasome 
The negative regulation of MAPK signaling cascades by a number of MAPK 
phosphatases (MKPs) – among which members of the dual specificity phosphatase 
(DUSP) family play the most prominent role – is well-established (Liu et al., 2007). In 
contrast, only few phosphatases have been implicated in the regulation of NF-B activity. 
These phosphatases have been characterized in the context of different cellular systems 
and NF-B-triggering stimuli, and most studies rely on overexpression of phosphatases 
and the use of phosphatase inhibitors. However, only scattered reports have provided 
genetic data that help to understand the role of phosphatases in the dephosphorylation of 
specific substrates within the NF-B signaling pathway. 
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The most prominent phosphatase implicated in the regulation of NF-B activity is PP2A. 
PP2A is an ubiquitously expressed phosphatase entity that exists as a collection of 
holoenzymes composed of one catalytic subunit PP2Ac (PP2Ac or PP2Ac) and a 
regulatory A subunit (PR65  or  isoform) that together form the core dimer, as well as 
multiple associated B subunits conferring and increasing substrate specificity (Janssens 
and Goris, 2001). 
Several early reports have associated PP2A activity with negative regulation of NF-B 
based on the observation that PP2A inhibitors induced activity and phosphorylation of the 
IKK complex and RelA, respectively, and led to enhanced and prolonged TNF-
dependent phosphorylation of IB. Vice versa, purified PP2A was shown to inhibit IKK 
kinase activity and to promote RelA dephosphorylation in vitro (DiDonato et al., 1997; Fu 
et al., 2003; Sun et al., 1995; Yang et al., 2001b). Moreover, PP2A seems to operate at 
different levels since physical interactions between PP2A and components of the IKK 
complex or RelA have been described (Fu et al., 2003; Yang et al., 2001b). Consistent 
with these results, a recent study has shown that siRNA-mediated silencing of PP2A 
catalytic or regulatory subunits enhanced TNF-induced NF-B activation (Li et al., 
2006b). Whereas PP2Ac and PP2R1A subunits were demonstrated to directly impinge 
on IKK phosphorylation and activation, PP2Ac/PP2R1B entities were shown to 
dephosphorylate RelA on serine 536, thereby inhibiting NF-B activity in vitro. In addition, 
the PP2Ac/PP2R1A/ PP2R5C module was shown to interact with TRAF2 and to inhibit 
its activity by dephosphorylation of threonine 117 (Li et al., 2006b). However, this report 
did not provide evidence for a direct interaction and dephosphorylation of endogenous IKK 
and other NF-B signaling constituents by PP2A. Indeed, more recently it has been 
suggested that PP2A-mediated IKK inhibition is rather due to direct dephosphorylation 
and inactivation of the upstream IKK-K MEKK3 (Sun et al., 2010). Instead, the 
magnesium-dependent phosphatases PPM1A and PPM1B were described as IKK 
phosphatases (Prajapati et al., 2004; Sun et al., 2009). Interestingly, PP2A has also been 
implicated in positive regulation of IKK activity, presumably by removing inhibitory 
phosphate groups (Kray et al., 2005). 
Moreover, a recent study demonstrated that the PSP PP1 negatively regulates TNF-
induced phosphorylation and activation of IKK in murine macrophages and is inducibly 
recruited to the IKK complex (Li et al., 2008). IKK dephosphorylation was shown to 
depend on a ternary complex composed of the catalytic subunit PP1c, the PP1 regulatory 
subunit GADD34, and the adapter protein CUEDC2. The same authors, however, could 
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not verify a role for PP2A in negative regulation of IKK activity. Although all experimental 
systems were based on TNF-induced NF-B activation, these discrepancies might be 
explained by cell type-specific expression and/or functions of different phosphatase 
subunits. 
Few other phosphatases have been linked to the negative regulation of NF-B. The PSP 
catalytic subunit PP6c has been shown to interact with and to dephosphorylate IB, 
thereby interfering with TNF-induced NF-B activation (Bouwmeester et al., 2004; 
Stefansson and Brautigan, 2006). More recently, the phosphatase WIP1 (also known as 
PPM1D) has been identified as a negative regulator of nuclear RelA activity, probably by 
promoting its specific dephosphorylation on serine 536 (Chew et al., 2009). However and 
in contrast to these results, WIP1-deficient T cells exhibited even decreased TCR-induced 
proliferation arguing against a general and non-redundant negative regulatory function of 
WIP1 (Choi et al., 2002). 
So far, most studies have been conducted using non-immune epithelial cell lines on the 
basis of TNF-mediated stimulation. Hence, the involvement of these and most likely 
other phosphatases in the regulation of NF-B activity in T lymphocytes still remains to be 
addressed. 
 
1.4.4 Non-phosphatase-based negative regulation of canonical NF-B 
Besides the regulatory functions of phosphatases a number of distinct mechanisms are 
involved in terminating the NF-B response that operate on different levels within the    
NF-B pathway. Most of these mechanisms rely on rapid and highly efficient negative 
feedback inhibition of NF-B. 
Perhaps the most prominent example of IKK proximal feedback inhibition of NF-B 
involves the transcriptional control of IB proteins. For instance, IB is a bona fide NF-B 
target gene, and NF-B activity promptly causes upregulated expression of IB (Sun et 
al., 1993). De novo synthesized unphosphorylated IB then enters the nucleus and 
associates with DNA-bound p50:RelA dimers to promote their export into the cytosol 
(Vallabhapurapu and Karin, 2009). 
A20 is another NF-B target gene that in turn acts as negative feedback regulator of     
NF-B (Coornaert et al., 2009; Hymowitz and Wertz, 2010). A20 is an Ub-editing enzyme 
that serves dual functions. On the one hand, it contains a deubiquitinase domain (DUB) 
that catalyzes removal of activating K63-linked Ub chains from NF-B signaling proteins, 
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such as RIP1 and MALT1. On the other hand, it mediates destructive K48-linked 
ubiquitination of NF-B effector proteins thereby shutting down the NF-B response 
(Duwel et al., 2009; Lee et al., 2000; Wertz et al., 2004). A20 deficiency in T cells causes 
enhanced and prolonged TCR-induced IKK and IB phosphorylation in vitro (Duwel et al., 
2009), and T cells from A20-deficient mice display a hyperactivated phenotype in vivo 
(Song et al., 2008). Similar to A20, the familial cylindromatosis tumor suppressor (CYLD) 
acts a deubiquitinating enzyme that inhibits NF-B by removing K63-linked pUb chains 
from NEMO and TRAF proteins (Brummelkamp et al., 2003; Kovalenko et al., 2003; 
Trompouki et al., 2003). Unlike A20, CYLD exerts constitutive activity and, therefore, it 
might predominantly control basal NF-B activity, whereas A20 operates in a stimulation-
dependent manner (Sun, 2008). 
Another IKK-regulating negative feedback mechanism in T lymphocytes involves the 
proteolytic processing of HPK1. In resting T cells HPK1 exists in its full length form while 
in vitro expansion of primary T cells is accompanied by cleavage of HPK1 giving rise to its 
non-catalytic cleavage product HPK1-C. Whereas HPK1 acts as Carma1-activating kinase, 
HPK1-C sequesters the IKK complex and blocks NF-B activation in a dominant negative 
manner (Brenner et al., 2005; Brenner et al., 2009). 
In addition to these negative regulatory mechanisms that mainly target receptor and IKK 
proximal components, several other modes of NF-B inhibition have been described, 
including the nuclear degradation of RelA and the disruption of NF-B transcriptional 
complexes (Wan and Lenardo, 2010). 
 
 
1.5 NF-B and lymphoid malignancies 
 
1.5.1 Target genes of NF-B and their implications in tumorigenesis 
Besides its crucial physiological role in the immune system, a large body of evidence has 
clearly established a connection between NF-B and cancer development and 
progression. It is now widely accepted that NF-B activity predominantly serves pro-
oncogenic functions since the majority of NF-B target genes promote cell survival, 
proliferation and apoptosis resistance, as well as cell adhesion, migration, invasion, and 
tumor angiogenesis (Karin, 2009). Dysregulated and constitutive NF-B activity results in 
aberrant expression of these target genes conferring or promoting the independency on 
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paracrine growth factors for survival and the capability to evade programmed cell death, 
or apoptosis. Indeed, these events have been identified as hallmarks of cancer (Hanahan 
and Weinberg, 2000) establishing a causative role of NF-B not only in immune 
physiology, but also in tumorigenesis. 
Apoptosis is a fundamental physiological process that regulates cellular and tissue 
homoestasis through removal of superfluous, damaged, or transformed cells (Vaux and 
Korsmeyer, 1999). Induction and execution of apoptosis are mediated and regulated by a 
variety of pro- and anti-apoptotic gene products. Relative expression and activity of these 
proteins determine the balance between apoptosis sensitivity and apoptosis resistance. 
Apoptosis can be induced via the so-called extrinsinc pathway that relies on engagement 
of death receptors, such as TNFR and CD95, by cognate ligands (Krammer, 2000). In 
addition, the intrinsic apoptosis-inducing pathway is triggered by a variety of stimuli, such 
as DNA damage and UV-irradiation, and involves the permeabilization of the outer 
mitochondrial membrane and cytochrome c (cyt c) release. However, both pathways 
converge on the activation of a related family of proteases, known as cysteine-aspartate-
specific proteases (caspases) that execute the apoptotic program (Hengartner, 2000). 
NF-B target genes encoding for anti-apoptotic proteins include c-IAP1 and c-IAP2, XIAP, 
the cellular FLICE inhibitory protein (c-FLIP), Bcl-2, Bcl-XL, survivin, TRAF1, as well as 
TRAF2 (Braun et al., 2006). 
As outlined above, TRAF proteins are important for TNF-induced NF-B activation, and 
their anti-apoptotic functions might rather be attributed to their NF-B-activating effects 
than to a direct intervention in the apoptosis-inducing machinery (Baud and Karin, 2001). 
By contrast, c-IAPs directly interfere with apoptosis induction in vitro by inhibition of the 
initiator and effector caspases caspase-9, and caspase-3, respectively (Deveraux et al., 
1999). The c-IAP2 promoter contains two B-sites which explains the NF-B dependent 
expression of c-IAP2 (Hong et al., 2000). c-IAP inhibition causes c-IAP autoubiquitination 
and degradation leading to sensitization towards TNF-dependent apoptosis 
(Varfolomeev et al., 2007). Transgenic overexpression of XIAP, another IAP family 
member, however, was shown to confer resistance of thymocytes towards multiple death 
stimuli (Conte et al., 2001). Moreover, overexpression of c-FLIP directly impinges upon 
death receptor-induced apoptosis (Scaffidi et al., 1999), and MEFs from FLIP-deficient 
mice exhibit hypersensitivity towards TNF and CD95 ligand (CD95L)-induced apoptosis 
(Yeh et al., 2000). The Bcl-2 family members Bcl-2A1 and Bcl-XL oppose the intrinsic 
mitochondrial pathway by blocking of mitochondrial membrane permeabilization and 
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prevention of subsequent caspase 9 activation (Strasser, 2005; Wang et al., 1999). The 
bfl1 promoter, which controls expression of Bcl-2A1, contains one B element, and Bcl-
2A1 expression is inducible via the canonical NF-B pathway (Grumont et al., 1998; Zong 
et al., 1999). Moreover, NF-B target genes that drive proliferation include cyclin D1, 
cyclin D2, c-Myc, c-Myb, as well as cytokines, such as IL-2 and IL-6, that act as 
lymphocyte growth factors (Duyao et al., 1992; Hinz et al., 1999; Sasaki et al., 2006; Toth 
et al., 1995). 
In addition, overactivation of the NF-B pathway seems to be involved in invasion of tumor 
cells by upregulation of genes encoding for matrix metalloproteinases (MMPs) (Bond et al., 
1998) and angiogenic factors (Levine et al., 2003). 
 
1.5.2 Mutations associated with constitutive NF-B activity  
Mutations of NF-B regulators and/or aberrant NF-B activity have been described for cell 
lines and primary patient material both derived from lymphoid tumors and solid cancers. 
The role of NF-B in tumorigenesis and malignant progression is based on cell-intrinsic 
and cell-extrinsic mechanisms. So far, oncogenic mutations that lead to constitutive      
NF-B activity have only been identified in a variety of lymphoid cancers (see below). 
However, NF-B activation has also been observed for many solid tumors although no 
tumor-intrinsic NF-B-activating mutations have been detected (Karin, 2009). In these 
types of solid cancers NF-B activity is often induced by inflammatory cytokines in an 
autocrine and/or paracrine manner as the result of the formation of an inflammatory 
microenvironment promoting tumor maintenance and progression (Ammirante et al., 2010; 
Karin, 2006). 
Given the crucial role of NF-B in lymphocyte physiology, it is not surprising that 
constitutive NF-B activity has been implicated in a number of lymphoid malignancies. 
The first link between NF-B and cancer came from studies showing that expression of 
the viral oncogene v-Rel (the viral homolog of c-Rel) can cause aggressive leukemia and 
lymphoma (Gilmore et al., 2003). Subsequently, constitutive NF-B activity and genetic 
aberrations affecting NF-B activity have been identified in a variety of B and T cell 
malignancies (reviewed in Jost and Ruland, 2007; Karin, 2009; Staudt, 2010). 
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Disease 
Dysregulated/mutated 
genes 
Reference 
Activated B cell-like 
diffuse large B cell 
lymphoma (ABC-DLBCL) 
Carma1; A20; 
CD79A; CD79B 
(Compagno et al., 2009; Davis et al., 2010; 
Davis et al., 2001; Lenz et al., 2008)  
Adult T cell lymphoma/ 
leukemia (ATL) 
Tax (HTLV-1 
oncogene) 
(Cann et al., 1985; Carter et al., 2001; 
Ross et al., 1996; Sun and Ballard, 1999) 
Childhood/T cell acute 
lymphoblastic 
leukemia (ALL/T-ALL) 
Notch1; p100; RelB (Kordes et al., 2000; Vilimas et al., 2007) 
Cutanous T cell lymphoma 
(CTCL) 
p100 (Sors et al., 2006; Zhang et al., 1994) 
Hodgkin lymphoma (HL) 
CD30; CD40; 
RANK/RANKL 
IB; IB; c-Rel; A20 ; 
LMP1 (EBV protein) 
(Bargou et al., 1996; Bargou et al., 1997; 
Barth et al., 2003; Cabannes et al., 1999; 
Deacon et al., 1993; Emmerich et al., 
2003; Fiumara et al., 2001; Horie et al., 
2002; Joos et al., 2002; Martin-Subero et 
al., 2002) 
MALT lymphoma MALT1; Bcl10; A20 
(Akagi et al., 1999; Dierlamm et al., 1999; 
Lucas et al., 2001; Willis et al., 1999) 
Multiple myeloma (MM) 
CD40; NIK; p100; p105;
LTR; TRAF2; 
TRAF3; c-IAP1/2; 
CYLD 
(Annunziata et al., 2007; Bharti et al., 
2004; Keats et al., 2007; Ni et al., 2001) 
Table 1.1 | Lymphoid malignancies that are associated with constitutive NF-B activity. 
Listed are different types of lymphomas and leukemias for which constitutive NF-B activity has 
been reported in cell lines and/or primary patient material. As far as identified, genetic lesions, 
mutated gene products, and oncogenes that are associated with aberrant NF-B signaling are 
depicted (for details see text). EBV: Epstein-Barr virus; LMP1: latent membrane protein 1. 
 
Multiple myeloma (MM) is a prominent example of a neoplastic disorder, for which 
constitutive NF-B activity has been described, both in cell lines as well as in MM patient 
samples (Ni et al., 2001). Two recent reports demonstrated that 10-20% of several 
hundred MM cell lines and patient samples have mutations which lead to activation of  
NF-B. These genetic alterations comprise gain-of-function mutations of NF-B activators, 
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as well as loss-of-function mutations of negative regulators of NF-B, both inducing 
chronic NF-B signaling in MM tumor cells (Annunziata et al., 2007; Keats et al., 2007). 
In marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT) that is 
predominantly seen in the gastric mucosa, several specific genetic alterations have been 
identified that cause constitutive NF-B activity. These mutations primarily include 
chromosomal translocations affecting genes encoding for MALT1 and Bcl10 (see 1.3.5). 
Translocations either cause the generation of a chimeric cIAP2-MALT1 fusion protein or 
increased expression of MALT1 and Bcl10 genes under control of the Ig heavy chain 
enhancer, both leading to Bcl10-MALT1 complex formation and NF-B activation 
independent of antigen receptor engagement (Liu et al., 2001; Lucas et al., 2001). 
Similarly to MALT lymphomas, aberrant activity of the IKK-inducing CBM complex has 
been identified as a frequent event in the development of diffuse large B cell lymphoma 
(DLBCL), the most common type of non-Hodgkin lymphoma (NHL) (Lenz and Staudt, 
2010). Based on correlations of microarray gene expression profiling and clinical outcome 
Staudt and colleagues have classified the majority of DLBCLs into three subentities 
termed activated B cell-like DLBCL (ABC-DLBCL), germinal centre B cell-like DLBCL 
(GCB-DLBCL), and an unclassified group of DLBCLs (Alizadeh et al., 2000; Wright et al., 
2003). Relative to the GCB subtype, ABC-DLBCL is a much more aggressive disease 
(Wright et al., 2003). Importantly, the ABC-DLBCL subtype displays upregulation of a 
large series of NF-B target genes, consistent with the observation that ABC-DLBCL cell 
lines exhibit constitutive NF-B activity in contrast to cells derived from GCB-DLBCLs 
(Davis et al., 2001). The strict dependence of ABC-DLBCL cells on chronic NF-B 
signaling for survival, a phenomenon known as “oncogenic addiction” (Luo et al., 2009b; 
Weinstein, 2002), was demonstrated by an RNA interference (RNAi) screen showing that 
knock-down of either Carma1, Bcl10, or MALT1 specifically causes spontaneous cell 
death of ABC-DLBCL cells (Ngo et al., 2006). Constitutive NF-B activity in these cells is 
largely due to somatic mutations of genes encoding for positive and negative regulators of 
the BCR-induced NF-B signaling machinery. For instance, activating mutations of 
Carma1 have been found in 7 out of 73 ABC-DLBCL biopsies rendering Carma1 a bona 
fide oncogene in lymphocytes (Lenz et al., 2008). Vice versa, biallelic inactivation of the 
negative regulator A20 was demonstrated to be a frequent pathogenetic event in ABC-
DLBCL biopsies (Compagno et al., 2009), although inactivation of the A20 gene has also 
been implicated in the pathogenesis of other types of B cell malignancies (Kato et al., 
2009). More recently, somatic mutations in CD79A and CD789B, both detected in ABC-
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DLBCL biopsy samples and cell lines, were shown to increase BCR surface expression, 
thereby leading to receptor clustering and chronic active BCR signaling in ABC-DLBCL 
cells (Davis et al., 2010). 
Adult T cell lymphoma/leukaemia (ATL) is an aggressive malignant disease of T cells 
caused by the human T-lymphotropic virus type I (HTLV-1) (Poiesz et al., 1981). In HTLV-
1-infected T cells the viral oncoprotein Tax drives constitutive activation of the IKK 
complex and upregulation of NF-B-dependent genes (Sun and Ballard, 1999). In the 
case of T cell acute lymphocytic leukaemia (T-ALL), it could be shown that activating 
mutations in Notch1 resulted in direct activation of the IKK complex (Vilimas et al., 2007). 
Moreover, Notch1 activity leads to increased transcription of NFKB2 and RELB, activating 
the non-canonical pathway (Vilimas et al., 2007). 
In summary, aberrant NF-B activation is a frequent pathogenic event in leukemogenesis 
and lymphomagenesis. Targeting the NF-B pathway might open up new avenues for the 
treatment of lymphoid malignancies, and a number of recently developed NF-B inhibitors 
are already subject of clinical studies (Karin and Lin, 2002; Karin et al., 2004). 
 
1.5.3 The Sézary syndrome and its link to NF-B 
The Sézary syndrome and mycosis fungoides belong to a rare group of 
lymphoproliferative disorders, called cutaneous T cell lymphoma (CTCL). The more 
common variant mycosis fungoides (MF) is confined to the skin and characterized by skin 
plaques and tumors. MF is a slowly progressive disease defined through indolent clinical 
behaviour compared to the more aggressive and systemic Sézary syndrome that can be 
considered as a leukemic subtype of CTCL (Booken et al., 2008; Diamandidou et al., 
1996; Dippel et al., 2003; Kim et al., 2005; Klemke et al., 2005). 
The Sézary syndrome was first described by Albert Sézary (1880-1956) in 1938 and is 
characterized by the triad of generalized erythoderma, lymphadenopathy, and the 
presence of 5% or more malignant T cells with cerebriform nuclei (known as Sézary cells) 
in peripheral blood lymphocytes (Hwang et al., 2008). However, it is now proposed by the 
International Society for Cutaneous Lymphoma (ISCL) that the diagnosis of Sézary 
syndrome is made by flow cytometric evidence of a clonal population of T cells in the 
blood in addition to erythroderma (Hwang et al., 2008). Sézary syndrome runs an 
aggressive course with a high mortality rate and a median survival of 2-4 years. A 
confining criteria for the survival of patients is the breakdown of the T cell repertoire 
together with the clonal expansion of Sézary cells leading to a state of immune 
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suppression and high susceptibility to infections which ultimately result in lethal systemic 
infections (sepsis) (Hwang et al., 2008). 
The first hint that the pathogenesis of the Sézary syndrome is associated with abnormal 
regulation of NF-B was reported more than one decade ago (Zhang et al., 1994). This 
report described a rearrangement of chromosomes in the CTCL cell line Hut78 which led 
to a truncated p100 protein devoid of the C-terminus. The truncated p100 protein 
accumulated abnormally in the nucleus indicating that it lost cytoplasmatic retention and 
thereby contributes to chronic NF-B signaling (Zhang et al., 1994). These observations 
were further corroborated by a study showing constitutive activation of NF-B by 
electrophoretic mobility gel shift assay (EMSA) in the CTCL cell lines HH, Hut-78, MyLa, 
and SeAx, as well as in peripheral blood lymphocytes from patients with Sézary syndrome 
(Izban et al., 2000; Sors et al., 2006). Further, overexpression of IB and treatment with 
a proteasome inhibitor induced apoptosis in cell lines and patient cells. Moreover, 
targeting NF-B by a specific IKK inhibitor prevented the nuclear translocation of p65 
and induced apoptosis of both, CTCL cell lines MyLa and SeAx, and malignant T cells 
from patients suffering from Sézary syndrome (Sors et al., 2006). Interestingly, viability of 
both peripheral blood lymphocytes from healthy donors and of non-malignant T cells 
derived from Sézary patients remained unchanged, indicating that the constitutively 
activated NF-B pathway in tumor cells can be targeted specifically (Sors et al., 2008). 
Recently, Kiessling et al. provided a molecular explanation for the selective apoptosis 
sensitivity of CTCL cells in response to NF-B inhibition (Kiessling et al., 2009). Targeting 
of the NF-B pathway by chemical compounds immediately led to the downregulation of 
ferritin heavy chain (FHC), an iron storage protein whose expression critically depends on 
NF-B. Subsequently, the increase in the free intracellular iron pool led to the massive 
generation of reactive oxygen species (ROS), and to ROS-dependent cell death in vitro 
and in vivo (Kiessling et al., 2009). Nonetheless, the molecular and genetic mechanisms 
underlying constitutive NF-B activity in CTCL cells still remain largely elusive. 
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2 Aims of the study 
TCR-induced activation of the NF-B signaling cascade involves a plethora of kinases and 
phosphorylated substrates, ranging from upstream protein complexes to the IKK core 
signaling machinery and transcriptionally active NF-B dimers. Whereas in some cases 
phosphorylation is followed by protein degradation, most phosphorylation events are 
transient, implying the activity of phosphatases in shaping and reversing the 
phosphorylation signal. However, to date only little is known about the existence and 
identity of NF-B-modulating phosphatases, their targeted phospho-substrates, and their 
putative functions in regulating and terminating NF-B activity in T lymphocytes. 
Therefore, the current study aimed at gaining a comprehensive and systematic 
understanding of the role of individual phosphatases in the regulation of TCR-induced  
NF-B activity. To this end, an RNAi-based genetic screening approach was adopted in 
order to identify NF-B-modulating phosphatases in T lymphocytes. Subsequently, 
physical and functional interactions between validated phosphatases and components of 
the T cell NF-B signaling machinery were elucidated. In detail, the current experimental 
study included the following objectives: 
 
(i) Generation of a cell-based NF-B activity reporter system that allows for high 
throughput screening on a subgenome-wide scale in T cells. 
(ii) Design and implementation of an RNAi-based screen for phosphatases that 
regulate TCR-induced NF-B activity. 
(iii) Validation of primary candidate phosphatase genes by secondary screening. 
(iv) Genetic and biochemical analysis of individual phosphatases with respect to 
physiology, function and mechanism underlying NF-B regulation. 
(v) Investigation of expression and function of NF-B-regulating phosphatases in 
malignant Sézary T cells and potential implications in disease pathogenesis. 
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3  Materials 
 
3.1 Chemicals, reagents, and kits 
3.1.1 Chemicals 
Unless otherwise indicated, chemicals were purchased from Serva (Heidelberg), Fluka 
(Neu-Ulm), Sigma (München), Roth (Karlsruhe), and Merck (Darmstadt). Radioactive 
reagents were purchased from Amersham (Braunschweig). 
 
3.1.2 Consumables 
Consumables Company 
96-well plates for qRT-PCR Applied Biosystems 
Amersham HyperfilmTM ECL  Amersham Bioscience 
Cell culture plates and flasks TPP/Greiner 
Electropuration cuvettes (4 mm) BioRad 
ELISA 96-well plates costar® 
LS columns Miltenyi Biotec 
Nitrocellulose membrane HybondTM-ECLTM Amersham Bioscience 
Pipette tips TipOne 
Reaction tubes (1.5, 2 ml) Eppendorf 
Reaction tubes (5, 15, 50 ml) BectonDickinson/Nunc/TPP 
Reaction tubes for PCR TipOne 
Sealing foil Roche 
Sealing strips Applied Biosystems 
Serological pipettes Becton Dickinson/Greiner 
Sterile filters (0.22 μm, 0.45 μm) Millipore 
Whatman Blotting paper Biorad/Schleicher & Schuell 
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3.1.3 Commercial kits and reagents 
Kit Company 
Cell Line 96-well Nucleofector® Kit SE Lonza 
Cell Line Nucleofector® Kit V Lonza 
CellTiter-Glo® Luminescent Cell Viability Assay Promega 
Dual-Light® System Applied Biosystems 
Gaussia-Glow Juice p.j.k. 
Gene RulerTM 1 kb DNA ladder Fermentas 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Human IFN, IL-2, TNF ELISA BD Bioscience 
Human IL-8 ELISA Immunotools 
Human T Cell Nucleofector® Kit Lonza 
KOD Hot Start DNA Polymerase Kit Novagen® 
LightCycler® 480 Probes Master Kit Roche 
o-Phenylenediamine dihydrochloride tablets for ELISA Sigma 
Power SYBR® Green PCR Master Mix Applied Biosystems 
Protein A sepharose beads Sigma 
Protein molecular weight standard New England Biolabs (NEB) 
Proteinase Inhibitor Cocktail Tablets Roche 
QIAEX II Gel extraction Kit Qiagen 
Qiagen® Plasmid Maxi Kit Qiagen 
Qiagen® Plasmid Mini Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
RealTime ready Custom Panel 386 Roche 
RNAqueous®-Micro Kit Applied Biosystems 
Roti®-Quant Bradford assay Roth 
SensoLyte® pNPP Protein Phosphatase Assay AnaSpec 
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TNT® T7 Coupled Reticulocyte Lysate System Promega 
Transcriptor High Fidelity cDNA Synthesis Kit Roche 
Western LightningTM Plus-ECL reagent PerkinElmer 
 
3.1.4 Reagents and kits for isolation of T cells 
Reagent/Kit Company 
CD4 MicroBeads Miltyenyi Biotec 
CD4+ T cell isolation kit II, human Miltyenyi Biotec 
CD25 MicroBeads Miltyenyi Biotec 
Ficoll Biochrom 
 
3.1.5 Reagents for treatment of cells 
Reagent Company/Reference 
Ionomycin Sigma 
NEMO binding peptide (NBP) Calbiochem; (May et al., 2000) 
NF-B activation inhibitor Calbiochem; (Kiessling et al., 2009) 
Phorbol 12-myristate 13-acetate (PMA) Sigma 
Phytohemagglutinin (PHA) Sigma 
Polybrene Millipore 
Recombinant human IL-2 Cell line LBRM-33 5A4; (Gillis et al., 
1980) 
Recombinant human TNF BASF/Invitrogen 
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3.2 Buffers and solutions 
All solutions and buffers were made in double destilled water (ddH2O). Lysis buffers for 
lysis of eukaryotic cells were freshly supplemented with Proteinase Inhibitor Cocktail 
Tablets (Roche) with 1 tablet per 50 ml of lysis buffer. 
 
Buffer Composition 
ACK buffer (10x) 41.45 g NH4Cl 
5.0 g KHCO3 
0.186 g EDTA 
pH 7.27 
ad 500 ml ddH2O 
Citrate buffer (ELISA) 6.9 g Citric acid 
20.95 g Sodium citrate dihydrate 
pH 5.0 
ad 1 l ddH2O 
Coating Buffer (ELISA) 8.4 g NaHCO3 
3.56 g Na2CO3 
pH 9.6 
ad 1 l ddH2O 
DNA sample buffer (6x) 30 % (v/v) glycerine 
0.36 % (w/v) bromophenol blue (BPB) or orange G 
FACS buffer 5% FCS 
0.1% NaN3 
in PBS 
HBS (10x) 1.4 M NaCl 
100 mM KCl 
500 mM HEPES 
20 mM Na2HPO4 
22.2 mM Glucose 
pH 6.5  
KCM buffer (5x) 500 mM KCl 
150 mM CaCl2 
250 mM MgCl2 
Kinase buffer 50 mM Tris/HCl pH = 8.0 
5 mM MgCl2 
2 mM MnCl2 
0.5 mM DTT 
Lysis buffer (for phospho-blots) 50 mM Tris/HCl pH 7.8 
137 mM NaCl 
0.5 mM EDTA  
1 mM NaF 
1 mM Na3VO4  
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10% (v/v) glycerol 
1% NP-40
MACS buffer 0.5% BSA 
2 mM EDTA 
in PBS 
PBS 137 mM NaCl 
8.1 mM Na2HPO4 
2.7 mM KCl 
1.5 mM KH2PO4 pH 7.4 
PBST PBS 
0.05% (v/v) Tween 
Reducing sample buffer (3x) 62.5 mM Tris/HCl pH 6.8 
2 % (w/v) Sodium dodecylsulfate (SDS) 
2 mM EDTA 
20 % (v/v) glycerol 
0.025 % (w/v) BPB 
5 % (v/v) 2-mercaptoethanol
Phosphatase buffer 
(Marley et al., 1996) 
50 mM Tris-HCL pH 7.5 
0.1 mM EDTA 
60 mM MgCl2 
0.5 mM DTT 
RIPA lysis buffer (2x) 120 mM NaCl 
50 mM Tris/HCl pH 7.5 
0.5% (w/v) Desoxycholate 
1 mM Dithiothreitol 
SDS PAGE running buffer 25 mM Tris 
0.19 M Glycin 
1% (w/v) SDS 
SDS separating gel buffer 37.5 mM Tris-HCl pH = 8.8 
8-12% (w/v) Acrylamid/Bisacrylamid 37,5:1 
0.1% (w/v) SDS 
0.03% (w/v) Ammonium persulfate (APS) 
0.1% (w/v) Tetramethylethylendiamin (TEMED) 
SDS stacking gel buffer 24 mM Tris-HCl pH 6,8 
5 % (w/v) Acrylamid/Bisacrylamid 37,5:1 
0.1% (w/v) SDS 
0.1% (w/v) APS 
0.1% (w/v) TEMED 
Stripping buffer 62.5 mM Tris/HCl pH 6.8 
2% (w/v) SDS 
100 mM 2-mercaptoethanol 
TAE buffer (1x) 40 mM Tris/HCl 
20 mM Acetic acid 
1 mM EDTA 
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pH 8.3 
Transfer buffer (immunoblotting) 25 mM Tris/HCl 
0.19 M Glycine 
20% (v/v) Methanol 
0.037% (w/v) SDS 
Triton lysis buffer 150 mM NaCl 
30 mM Tris-HCl, pH 7,5 
1 mM Phenylmethylsulfonyl fluorid (PMSF) 
10% (w/v) Glycerol 
1% (w/v) Triton X-100 
TSB solution 10 mM MgCl2 
10 mM MgSO4 
5% (v/v) DMSO 
10% (v/v) PEG 6000 
in LB medium 
 
 
3.3 Culture media 
3.2.1 Media for bacteria 
Media for E. coli were autoclaved and stored at 4°C. Autoclavation of liquids was carried 
out at 125°C for 30 min. To ensure plasmid propagation LB medium and LB agar plates 
were supplemented with 50-100 µg/ml ampicillin or 30 µg canamycin. 
 
Medium Composition 
LB medium 10 g tryptone 
5 g yeast extract 
10 g NaCl 
pH 7.0 
ad 1 l ddH2O 
LB agar 20 g agar per 1 l LB medium 
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3.3.2 Media and supplements for eukaryotic cell culture 
Unless otherwise indicated, media were supplemented with 10% (v/v) heat-inactivated 
FCS. IMDM medium for Jurkat cell lines was supplemented with 1.0% (v/v) 
penicillin/streptomycin. For selection of stably transfected/transduced Jurkat cells, media 
were supplemented with 2.0 µg/ml G418 (neomycin) and 1.0 µg/ml puromycin, 
respectively. All media were stored at 4°C until use. 
 
Reagent Company 
Dulbecco’s Modified Eagle Medium (DMEM) Gibco/Sigma 
Fetal calf serum (FCS) Biochrom/Gibco 
Freezing medium 90 % (v/v), 10 % (v/v) DMSO
G418 (neomycin) Roth 
Iscove's Modified Dulbecco’s Medium (IMDM) Gibco 
Penicillin/Streptomycin Sigma 
Puromycin Roth 
Roswell Park Memorial Institute (RPMI) 1640 medium Gibco/Sigma 
Trypsin/EDTA Gibco 
X-Vivo 15 medium Cambrex 
 
 
3.4 Biological material 
3.3.1 Bacteria 
For plasmid propagation the E. coli strains DH5 and TOP10F’ were utilized. 
 
E. coli strain Company 
DH5 Invitrogen 
TOP10F’ Invitrogen 
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3.3.2 Mammalian cell lines 
Cell line (ATCC number) Description/Reference 
CEM (CRL-2265) Human T lymphoblastic cell line derived from acute 
lymphoblastic leukemia (Kapoor et al., 1995). 
Gluc-J16 Reporter T cell line derived from J16-145 with stable 
genomic integration of a NF-B-dependent Gaussia 
luciferase cassette (this study). 
HEK293T (CRL-11268) Human embryonic kidney cell line (Pear et al., 1993). 
HeLa (CCL-2) Human cervix adenocarcinoma cell line (Boshart et 
al., 1984). 
Hep3B (HB-8064) Human epithelial cell line derived from hepatocellular 
carcinoma (Aden et al., 1979). 
HH (CRL-2105) Human CTCL dell line derived from a patient with 
Sézary syndrome (Starkebaum et al., 1991). 
HT (CRL-2260) Human Non-Hodgkin lymphoma cell line (diffuse 
mixed small and large cell) (Beckwith et al., 1990). 
Hut78 (TIB-161) Human CTCL cell line derived from a patient with 
Sézary syndrome (Gootenberg et al., 1981). 
J16-145 Subclone of the human lymphoblastoid cell line J16 
JE6.1 (TB-152) Human lymphoblastoid cell line derived from acute T 
cell leukemia cell line (Schneider et al., 1977). 
MyLa Human CTCL cell line (Dummer et al., 1994). 
OCI-Ly3 Human DLBCL cell line (ABC subtype) (Tweeddale et 
al., 1987). 
Phoenix ampho HEK293T-derived packaging cell line engineered for 
rapid production of retroviruses (Swift et al., 2001). 
Raji (CCL-86) Human Burkitt’s lymphoma cell line (Epstein et al., 
1966). 
SeAx Human CTCL cell line derived from a patient with 
Sézary syndrome (Kaltoft et al., 1984). 
SUDHL-5 Human DLBCL cell line (ABC subtype) (Epstein et 
al., 1976). 
SUDHL-6 (CRL-2959) Human DLBCL cell line (GC subtype) (Epstein et al., 
1978). 
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3.5 Materials for molecular biology 
3.5.1 Phosphatase siRNA library 
For RNAi screening the Silencer® Select Human Phosphatase siRNA Library V4 (Applied 
Biosystems) was used. The library contained three single siRNA oligos targeting 298 
known or predicted phosphatases. siRNAs were dissolved in RNase-free H2O with a final 
concentration of 20 µM. Three independent, pre-aliquoted siRNAs sets (894 individual 
siRNAs for 298 genes) were stored in 96-well plates at -80°C until use. 
 
3.5.2 siRNA sequences 
siRNA  Gene targeted Sequence (5’→3’) Company 
siA20#1 TNFAIP3 CCGAGCTGTTCCACTTGTTAA Qiagen 
siA20#2 TNFAIP3 CAGATGTATGGCTAACCGGAA Qiagen 
siCarma1#1 CARD11 ACUCGAGAUCGAUCAGCUATT Qiagen 
siCarma1#2 CARD11 Not available Qiagen 
siCarma1#3 CARD11 Not available Qiagen 
siCtrl nontargeting UUCUCCGAACGUGUCACGUTT Qiagen 
siCYLD CYLD GAUUGUUACUUCUAUCAAATT Applied Biosystems 
siPP4R1#1 PPP4R1 GCCGCAUCUGCUAACCUUATT Applied Biosystems 
siPP4R1#2 PPP4R1 GGAUAGGUGUUCUUAAACATT Applied Biosystems 
siPP4R1#3 PPP4R1 GGAGCUCAUUGAACGAUUUTT Applied Biosystems 
siPP4R1#4 PPP4R1 CCUACAAGUUGGUCAGCGA Dharmacon 
siPP4R1#5 PPP4R1 UGUGAGAUGUGCUGCGAUU Dharmacon 
siPP4R1#6 PPP4R1 GAUUAUAAUUGUCACCGAA Dharmacon 
siPP4R1#7 PPP4R1 GCCCGGAGUUUGCUCGAUA Dharmacon 
siRelA RELA CCAUCAACUAUGAUGAGUUTT Applied Biosystems 
siTNFR1 TNFRSF1A CAAAGGAACCUACUUGUACUU Dharmacon 
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3.5.3 shRNA sequences 
All shRNA clones encoding for shRNAs targeting PP4R1 were obtained as glycerol stocks 
from Sigma. As a negative control a Non-Target shRNA Control Vector was used. All 
shRNA vectors are pLKO.1-puro derivatives. 
 
shRNA  TRC# Sequence (5’→3’) 
shPP4R1#1 TRCN0000052763 CCGGGCGTTGTTAGATCAGTATTTACTCGAGTAAATACT
GATCTAACAACGCTTTTTG 
shPP4R1#2 TRCN0000052764 CCGGCGGACCAAATTATCAGCACTTCTCGAGAAGTGCT
GATAATTTGGTCCGTTTTTG 
shPP4R1#3 TRCN0000052765 CCGGCCCAGAGATGTTTATGACTATCTCGAGATAGTCAT
AAACATCTCTGGGTTTTTG 
shPP4R1#4 TRCN0000052766 CCGGGCAGCTAGTAATGAGAATGATCTCGAGATCATTCT
CATTACTAGCTGCTTTTTG 
shPP4R1#5 TRCN0000052767 CCGGGCTGCAAGTGAGAACATATTTCTCGAGAAATATGT
TCTCACTTGCAGCTTTTTG 
 
3.5.4 PCR primers for gene cloning 
For cloning of HA-tagged versions of human PP4R1, HA-tagged human PP4c, FLAG-
tagged PP4c as well as HA-tagged PP2Ac the primers listed below were used. Amplicons 
were BamHI/NotI-digested and ligated into derivatives of the pEF4 expression vector 
(Invitrogen) containing 5’-HA or 5’-FLAG-epitope tags (pEF4:HA/pEF4:FLAG) (see 4.5.7). 
PP4R1 cDNA, cloned into the pEF4:HA expression vectors, was used as a template for 
generation of various HA-tagged PP4R1 deletion mutants. In addition, cDNA of PP4R1, 
PP4c, and PP2Ac , cloned into the pEF4:HA vector, served as a template for cloning of 
HA-tagged gene sequences into the pMX-IRES-GFP vector using a pMX-specific 
universal forward primer (pMX-univ-for) and gene-specific pMX-reverse PCR primers via 
EcoRI/NotI restriction digests of PCR amplicons. PCR primers were synthesized by MWG 
Biotech or Sigma. 
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Primer Target vector Sequence (5’→3’) 
P4R1-for pEF4:HA CGCGGATCCGCGGGCGCGGACCTCTCGCTGCTTCAG 
P4R1-rev pEF4:HA/ 
pMX-IRES-GFP 
ATAGTTTAGCGGCCGCCTACTAGTAGGTTGAGGACGCTG 
P4R1(133)-for pEF4:HA CGCGGATCCGCGGGCCTACCTATTGTGGTTAGATACC 
P4R1(213)-for pEF4:HA CGCGGATCCGCGGGCATCCTCCCTAGGTTTTGTG 
P4R1(663)-rev pEF4:HA ATAGTTTAGCGGCCGCCTAGCAGTGCCAATTCTGTCTTCC 
P4R1(313)-rev pEF4:HA ATAGTTTAGCGGCCGCCTACTGAAAAGCTGCTTGGCGAAC
P4R1(314)-for pEF4:HA CGCGGATCCGCGGGCTCTCTGGGACCTTTCATATC 
P4c-for pEF4:HA/FLAG CGCGGATCCGCGGGCGCGGAGATCAGCGACCTG 
P4c-rev pEF4:HA/FLAG/ 
pMX-IRES-GFP 
ATAGTTTAGCGGCCGCTCACAGGAAGTAGTCGGCCACGG 
P2Ac-for pEF4:HA CGCGGATCCGCGGGCGACGAGAAGGTGTTCACCAAG 
P2Ac-rev pEF4:HA/ 
pMX-IRES-GFP 
ATAGTTTAGCGGCCGCCTATTACAGGAAGTAGTCTGGG 
pMX-univ-for pMX-IRES-GFP CCGGAATTCCGGGGCCCCAAGCTGGCTAGTTAAGC 
P4R1-pMX-rev pMX-IRES-GFP ATAGTTTAGCGGCCGCCTACTAGTAGGTTGAGGACGCG 
P4c-pMX-rev pMX-IRES-GFP ATAGTTTAGCGGCCGCTCACAGGAAGTAGTCGGCCACGG 
P2Ac-pMX-rev pMX-IRES-GFP ATAGTTTAGCGGCCGCCTATTACAGGAAGTAGTCTGGG 
 
 
3.4.5 qRT-PCR primers 
Primers for SYBR Green qRT-PCR were designed using the online primer designing tool 
Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). For UPL-based qRT-PCR 
assays the Universal ProbeLibrary Assay Design Center (https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000) provided by Roche was used. In 
general, all primer pairs were designed to be intron-spanning with primer efficiencies 
between at least 1.7 and 2.0. Al primers for qRT-PCR were synthesized by MWG Biotech 
or Sigma. 
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(i) SYBR Green qRT-PCR primer pairs 
Gene  Primer Sequence (5’→3’) 
CYLD forward 
reverse 
CTAAACACTGCACCCGTCCAA 
CAATGAGCCCACTTCTAGACCAT 
GAPDH forward 
reverse 
GCAAATTCCATGGCACCGT 
TCGCCCCACTTGATTTTGG  
HPRT1 forward 
reverse 
TGACACTGGCAAAACAATGCA 
GGTCCTTTTCACCAGCAAGCT 
IFNG forward 
reverse 
TTCAGCTCTGCATCGTTTTGG 
TCCGCTACATCTGAATGACCTG 
IL2 forward 
reverse 
AAGTTTTACATGCCCAAGAAG 
AAGTGAAAGTTTTTGCTTTGAGCT 
IL8 forward 
reverse 
GAATGGGTTTGCTAGAATGTGATA 
CAGACTAGGGTTGCCAGATTTAAC 
NFKBIA forward 
reverse 
CGCCCAAGCACCCGGATACA 
AGGGCAGCTCGTCCTCTGTGA 
PPP2CA forward 
reverse 
CTTGGTGGATGGGCAGAT 
TCTTGTAGGCGATCAAGTGC 
PPP4R1 forward 
reverse 
GACAAAGTTTCTTCTGTTCGTTGGA 
TCCGAACGTTGGTGGTGTT 
RELA forward 
reverse 
CGGGATGGCTTCTATGAGG 
CTCCAGGTCCCGCTTCTT 
TNFAIP3 forward 
reverse 
TGCGGCACCCTTGGAAGCAC 
TGCGCTGGCTCGATCTCAGTT 
TNFRSF1A forward 
reverse 
GAGAGGCCATAGCTGTCTGG 
GAGGGGTATATTCCACCAAC 
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(ii) Primer pairs for UPL assays 
Gene Primer UPL probe# Sequence (5’→3’) 
CYLD forward 
reverse 
11 CAGTCTCCGGAATATTCTTTGG 
CAGTGAAACCTTGACCACGA 
GAPDH forward 
reverse 
60 AGCCACATCGCTCAGACAC 
GCCCAATACGACCAAATCC 
HPRT1 forward 
reverse 
73 TGACCTTGATTTATTTTGCATACC 
CGAGCAAGACGTTCAGTCCT 
IFNG forward 
reverse 
21 GGCATTTTGAAGAATTGGAAAG 
TTTGGATGCTCTGGTCATCTT 
IL2 forward 
reverse 
65 AAGTTTTACATGCCCAAGAAGG 
AAGTGAAAGTTTTTGCTTTGAGCTA 
IL8 forward 
reverse 
72 AGACAGCAGAGCACACAAGC 
ATGGTTCCTTCCGGTGGT 
NFKBIA forward 
reverse 
38 GTCAAGGAGCTGCAGGAGAT 
GATGGCCAAGTGCAGGAA 
PPP2CA forward 
reverse 
47 CTTGGTGGATGGGCAGAT 
TCTTGTAGGCGATCAAGTGC 
PPP4R1 forward 
reverse 
56 CCCCACATTGATGATCCAG 
CAGGCTGGAAGCACGTAGT 
RELA forward 
reverse 
47 CGGGATGGCTTCTATGAGG 
CTCCAGGTCCCGCTTCTT 
TNFAIP3 forward 
reverse 
74 TGCACACTGTGTTTCATCGAG 
ACGCTGTGGGACTGACTTTC 
TNFRSF1A forward 
reverse 
59 GAGAGGCCATAGCTGTCTGG 
GAGGGGTATATTCCACCAAC 
 
 
3.4.6 Enzymes 
All restriction endonucleases were purchased from Fermentas or New England Biolabs 
(NEB). KOD DNA polymerase was from Novagen®. T4 DNA ligase as well as calf 
intestinal phosphatase (CIP) were obtained from Fermentas. All enzymes were used 
according to the manufacturer’s instructions. 
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3.4.7 Vectors 
Vector Description Origin/Reference 
pEF4:HA Derivative of the pEF4 eukaryotic expression vector with 
a 5’ single HA tag 
Invitrogen/ 
J. Hoffmann, DKFZ 
pEF4:FLAG Derivative of the pEF4 eukaryotic expression vector with 
a 5’ single FLAG tag 
Invitrogen/ 
J. Hoffmann, DKFZ 
pMX-IRES-GFP Retroviral expression vector containing an IRES-
controlled EGFP reporter cassette 
A. Cerwenka, DKFZ 
Hozumi et al., 2000 
EGFP-C1 Eukaryotic expression vector for C-terminal Enhanced 
Green Fluorescent Protein (EGFP) 
Clontech 
pEF4:HA-
PP4R1-wt 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, full-length protein (aa 1-950) 
This study 
pEF4:HA-
PP4R1-133-950 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, deletion mutant  (aa 133-950) 
This study 
pEF4:HA-
PP4R1-213-950 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, deletion mutant  (aa 213-950) 
This study 
pEF4:HA-
PP4R1-1-663 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, deletion mutant  (aa 1-663) 
This study 
pEF4:HA-
PP4R1-1-313 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, deletion mutant  (aa 1-313) 
This study 
pEF4:HA-
PP4R1-314-950 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, deletion mutant  (aa 314-950) 
This study 
pEF4:HA-
PP4R1-314-663 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, deletion mutant  (aa 314-663) 
This study 
pEF4:HA-
PP4R1-664-950 
pEF4:HA derivative encoding for HA-tagged human 
PP4R1, deletion mutant  (aa 664-950) 
This study 
pEF4:HA- 
PP4c-wt 
pEF4:HA derivative encoding for HA-tagged human  
PP4c, full-length protein 
This study/ 
T. Mock, DKFZ 
pEF4:FLAG-
PP4c-wt 
pEF4:FLAG derivative encoding for FLAG-tagged human 
PP4c, full-length protein 
This study/ 
T. Mock, DKFZ 
pEF4:HA- 
PP2Ac-wt 
pEF4:HA derivative encoding for HA-tagged human  
PP2Ac, full-length protein 
This study 
pMX-PP4R1-wt pMX-derivative encoding for HA-tagged human 
PP4R1, full-length protein 
This study 
pMX-PP4c-wt pMX-derivative encoding for HA-tagged human 
PP4c, full-length protein 
This study 
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pMX-PP2Ac-wt pMX-derivative encoding for HA-tagged human 
PP2Ac, full-length protein 
This study 
pGluc basic Gaussia luciferase vector without promoter sequences New England Biolabs
8xNF-B-pGluc pGluc basic derivative with a Gaussia reporter cassette 
under control of the mouse c-fos promoter and eight B 
sites 
This study/ 
Arnold et al., 2001 
8xNF-B-pGL pGL derivative with a firefly reporter cassette under 
control of the mouse c-fos promoter and eight B sites 
Arnold et al., 2001 
3xAP-1-Luc Derivative of the pTATA-Luc vector encoding for firefly 
luciferase under control of three copies of the AP-1 
binding site from the SV40 enhancer 
Li-Weber et al., 2002 
pfosLacZ pSDK derivative encoding for -galactosidase under 
control of the mouse c-fos promoter 
Arnold et al., 2001 
FLAG:IKK pCR derivative encoding for FLAG-tagged murine IKK D. Goeddel 
FLAG:IKK pCR derivative encoding for FLAG-tagged murine IKK D. Goeddel 
FLAG:NEMO pCMV derivative encoding for FLAG-tagged human 
NEMO 
R. Marienfeld 
FLAG:IKK
(SS/EE) 
Expression vector for a FLAG-tagged dominant active 
kinase mutant of IKKb with SS/EE T loop mutations 
D. Goeddel 
HA:HPK1 pcDNA3 derivative encoding for HA-tagged HPK1 Arnold et al., 2001 
HA:HPK1 
(K46E) 
pcDNA3 derivative encoding for a HA-tagged kinase 
inactive mutant of HPK1 with a K46E mutation 
Arnold et al., 2001 
pIB pDNA3 derivative encoding for IB Weil et al., 1997/ 
M. Kiessling, DKFZ 
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3.5 Antibodies 
3.5.1 Antibodies for immunoblotting (IB) and immunoprecipitation (IP) 
For IB analysis primary antibodies were diluted, as indicated, in PBST, containing 1% 
BSA and 0.01% NaN3. Secondary, horseradish peroxidase (HRP)-conjugated antibodies 
were diluted 1:10,000-1:20,000 in PBST containing 1% milk powder. Unless otherwise 
indicated, all antibodies are mouse monoclonal antibodies. 
 
(i) Primary antibodies for IB and antibodies for IP 
Name/Clone Species/Isotype Antigen Application/Reference 
Anti--actin Mouse, 
IgG2a 
-actin IB (1:10,000), Sigma 
Anti-Carma1 Rabbit, 
polyclonal 
Carma1 IB (1:1,000), ProSci 
Anti-ERK1/2 
(MK12) 
Mouse, IgG1 ERK1/2 IB (1:1,000), BD Bioscience 
Anti-FLAG (M2) Mouse, IgG1 FLAG epitope IB (1:1,000), IP (2 µl per IP), Sigma 
Anti-HA 
(12CA5) 
Mouse, IgG2b HA epitope IP (100 µl of hybridoma supernatant per IP) 
Anti-HA (3F10) Rat, monoclonal HA epitope IB (1:1,000), Roche 
Anti-IB (C-21) Rabbit, 
polyclonal 
IB IB (1:500), Santa Cruz Biotechnology 
Anti-IKK Rabbit, 
polyclonal 
IKK IB (1:1,000), Cell Signaling 
Anti-IKK 
(10A9B6) 
Mouse, IgG1 IKK IB (1:500), Imgenex 
Anti-NEMO 
(FL-419) 
Rabbit, 
polyclonal 
NEMO (IKK) IP (10-20 µl per IP), Santa Cruz 
Biotechnology 
Anti-p-ERK1/2 
(E10) 
Mouse, IgG1 Phospho-
thr202/tyr204 
and phospho-
thr185/tyr187 
of ERK1/2 
IB (1:1,000-1:2,000), Cell Signaling 
Anti-p-IB 
(5A5) 
Mouse, IgG1 Phospho-
ser32/36 of 
IB 
IB (1:1,000), Cell Signaling 
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Anti-p-IB 
(14D4) 
Rabbit, 
monoclonal IgG 
Phospho-
ser32 of IB 
IB (1:1,000), Cell Signaling 
Anti-p-IKK/ Rabbit, 
polyclonal 
Phospho-
ser180/181 of 
IKK/ 
IB (1:1,000), Cell Signaling 
Anti-PP1 (4G3) Mouse, IgG2a PP1 IB (1:2,000), Santa Cruz Biotechnology 
Anti-PP2Ac Rabbit, 
polyclonal 
PP2Ac IB (1:1,000), Thermo Scientific 
Anti-PP4c 
(#A300-893A) 
Rabbit, 
polyclonal 
PP4c IB (1:1,000), Bethyl 
Anti-PP4R1 
(#A300-836A) 
Rabbit, 
polyclonal 
PP4R1 
(N-terminus) 
IB (1:2,000), Bethyl 
Anti-PP4R1 
(#A300-837A) 
Rabbi,  
polyclonal 
PP4R1 
(C-terminus) 
IB (1:1,000), Bethyl 
Anti-RelA (A) Rabbit, 
polyclonal 
RelA IB (1:300), Santa Cruz Biotechnology 
Anti-TNFR1 
(H-5) 
Mouse, IgG2b TNFR1 IB (1:1,000), Santa Cruz Bioctenology 
Anti-Tubulin 
(B-5-1-2) 
Mouse, IgG1 Tubulin IB (1:2,000-1:5,000), Sigma 
 
(ii) Conjugated antibodies for IB and flow cytometry 
Name/Clone Species/Isotype Antigen Application/Reference 
Anti-CD69-PE Mouse, IgG1 CD69 Flow cytometry (1:25), BD Bioscience 
Anti-IgG-HRP Goat, polyclonal Mouse IgG IB, Southern Biotechnology 
Anti-IgG1-HRP Goat, polyclonal Mouse IgG1 IB, Southern Biotechnology 
Anti-IgG2a-HRP Goat, polyclonal Mouse IgG2a IB, Southern Biotechnology 
Anti-IgG2b-HRP Goat, polyclonal Mouse IgG2b IB, Southern Biotechnology 
Anti-rabbit IgG-
HRP 
Goat, polyclonal Rabbit IgG IB, Santa Cruz Biotechnology 
Anti-rat IgG-
HRP 
Goat, polyclonal Rat IgG IB, Santa Cruz Biotechnology 
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3.5.2 Antibodies for T cell stimulation 
Name/Clone Species/Isotype Antigen Reference 
Anti-CD3 
(OKT3) 
Mouse IgG CD3 Prepared from hybridoma 
Anti-CD28 Mouse IgG CD28 Prepared from hybridoma 
C305 Mouse IgM Jurkat TCR 
 chain 
Upstate/ 
Weiss and Stobo, 1984 
Goat anti-mouse Goat, polyclonal Mouse IgG Southern Biotechnology 
 
 
3.6 Instruments 
Instrument Company 
Agarose gel electrophoresis apparatus Gibco BRL 
Analytical and precision balances Mettler 
Bacteria culture incubator/shaker CH-403 Infors AG 
Centrifuges: 
- Biofuge Fresco 17 
- Biofuge A 
- Megafuge 3.0R 
- Sorvall Evolution RC 
 
Heraeus 
Heraeus 
Heraeus 
Heraeus 
Chemilumescence detector Chemi-Smart 5100 Vilber Lourmat 
CO2-cell culture incubator Stericult  Forma Scientific 
Developing system for Roentgen films Curix 160 Agfa-Gevaert 
Electrophoresis power supply PS 500 Renner 
Electroporation System Gene Pulser II Bio-Rad 
FACSCantoII  Becton Dickinson 
Freezer: 
- -20°C 
- -80°C 
 
Liebherr 
Forma Scientific 
Gel documentation system Bio-Rad 
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Laminar chambers SG600 Baker Company 
Luminometer: 
- Orion L Microplate Luminometer 
- Mithras LB940 plate reader  
 
Berthold Detection Systems 
Berthold Technologies 
Microplate Reader Model 680 BioRad 
Microscopes: 
- Fluorescence microscope Labovert FS 
- Light microscope ID 02 
 
Leica 
Zeiss 
Microwave oven HMG 730B Bosch 
Neubauer cell-counting chamber Brand 
pH-meter Calimatic LHD Labortechnik 
Polyacrylamide gel electrophoresis apparatus 
PROTEAN II Cell 
Bio-Rad 
Quartz cuvettes Suprasil Hellma 
Semi-Dry blotting system: 
- Power supply, Consort E865 600V-500mA 
- Semi-dry transfer cell Trans-Blot SD  
Bio-Rad 
Spectrophotometer BioPhotometer Eppendorf 
Thermocycler DNA Engine DYAD MJ Research 
Thermomixer Compact Eppendorf 
Thermostated hot-block 5320 Eppendorf 
Water baths Köttermann 
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3.7 Software 
Software Company 
Bio-1D Vilber Lourmat 
Chemi-Capt Vilber Lourmat 
CorelDraw 14 Corel Cooperation 
FACSDIVA Becton Dickinson 
Light cycler 480® software Roche 
MS Office 2007 Microsoft 
Photoshop CS4 Adobe 
Simplicity 4.10 Berthold Detection Systems 
Windows XP Microsoft 
7.500 Software version 2.0.1 Applied Biosystems 
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4 Methods 
 
4.1 Methods in Molecular Biology 
4.1.1 Cultivation and storage of bacteria 
Bacteria were cultured aerobically at 37°C and 180 rpm in a rotary shaker. Therefore, LB-
medium, supplemented with either ampicillin (100 µg/ml) or kanamycin (30 µg/ml), was 
inoculated with cells of a single colony of transformed bacteria. For the long term strain 
storage 1-2 ml of a freshly saturated bacterial culture were centrifuged at 3000 g for 5 min. 
The supernatant was removed and the bacteria were resuspended in ¼ volume of 
LB/ampicillin. Then, ¼ volume of 87 % glycerol was added and the cell suspension was 
mixed. The bacteria were stored at -80°C until use. 
 
4.1.2 Generation of KCM-competent bacteria  
For the generation of transformation competent E. coli cells 100 ml LB medium without 
antibiotics were inoculated with 1 ml overnight culture. The culture was grown until an 
OD600 value of 0.5-0.6 was reached. Subsequently, the bacteria suspension was 
incubated on ice for 10 min and then harvested at 1,500 g and 4°C for 15 min. The 
supernatant was removed and the bacterial pellet was resuspended in 7.5 ml TSB 
solution. After incubation on ice for 1 h the bacteria were shock-frozen with liquid nitrogen, 
and aliquots of 100 µl were stored at -80 °C until use. 
 
4.1.3 Transformation of KCM-competent bacteria 
For transformation aliquots of KCM-competent E. coli were thawed on ice for 2 min. 
Subsequently, 100 µl of 1x KCM solution containing an appropriate amount of plasmid 
DNA (100-500 ng) or a complete ligation sample were added. Bacteria were carefully 
resuspended. The transformation sample was incubated on ice for 20 min, followed by 
10 min of incubation at RT. For regeneration, 1 ml of RT LB medium without antibiotics 
was added. Cells were incubated at 37°C for 30-60 min on a rotary shaker. Subsequently, 
the bacteria were centrifuged at 2,000 g and resuspended in 100 µl of remaining medium. 
The suspension was spread onto LB plates containing appropriate antibiotics and 
incubated at 37°C overnight.  
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4.1.4 Plasmid preparation on analytical scale (miniprep) 
For the analytical plasmid isolation 5 ml of LB medium, supplemented with an appropriate 
antibiotic, were inoculated with a single bacterial colony and the culture was grown at 
37°C in a shaker overnight. The next day the plasmid DNA was isolated using the 
Qiagen® Plasmid Mini Kit according to the manufacturer’s instructions. 
 
4.1.5 Plasmid preparation on preparative scale (maxiprep) 
For the production of larger amounts of plasmid DNA, 100-250 ml of LB medium 
containing appropriate antibiotics were inoculated and the cultures were grown at 37°C in 
a shaker overnight. The preparation of plasmid DNA was carried out with the Qiagen® 
Plasmid Maxi Kit according to the manufacturer’s instructions. 
 
4.1.6 Photometric determination of DNA concentrations 
DNA concentrations were determined photometrically using a Biophotometer (Eppendorf). 
DNA concentrations can be approximately calculated by the following formula: OD260 = 1 
refers to 50 µg/ml DNA (layer thickness of the cuvette: 1 cm). The ratio OD260/OD280 
characterizes the purity of DNA with values between 1.7 and 2.0 for pure DNA. 
 
4.1.7 Isolation of total cellular RNA 
Total cellular RNA was isolated using the RNAqueous®-Micro Kit (Applied Biosystems) 
according to the manufacturer’s protocol. Essentially, approximately 1-2x105 cells were 
pelleted (1,500 rpm, 5 min), the supernatant was discarded, and cells were resuspended 
in 100 µl lysis buffer. Subsequently 50 µl of 100% ethanol were added, followed by brief 
vortexing of the sample.The lysate/ethanol mixture was passed through a micro silica filter 
and centrifuged for 2 min at 14,000 g. The filter was then washed once with 180 μl of 
wash solution 1 and twice with 180 μl of wash solution 2/3. After each wash the filter was 
centrifuged at 14,000 g for 2 min. Subsequently, the flow through was discarded and the 
filter was centrifuged at 14,000 g for 2 min to remove residual fluid and to dry the filter. For 
elution of RNA the filter was transferred into a micro elution tube. In a first step, 15 μl of 
elution buffer – pre-heated to 75°C – was applied to the center of the filter and incubated 
for 2 min before centrifugation for 2 min at 14,000 g. In a second step, the procedure was 
repeated with 10 μl of elution buffer. To remove traces of contaminating genomic DNA the 
RNA elution was treated with recombinant DNase I. Therefore, 2.6 μl of 10x DNase I 
buffer and 1 μl of DNase I were added to 25 µl of RNA solution and incubated for 30 min 
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at 37°C. To inactivate DNase I, 2.8 μl of DNase Inactivation reagent was added. The mix 
was briefly vortexed, incubated for 1 min at RT, vortexed again and incubated for another 
minute. Finally, the DNase inactivation reagent was pelleted by centrifuging at 14,000 g 
for 2 min. The RNA-containing supernatant was transferred into a fresh tube and stored at 
-20°C until use. All steps were done on ice and centrifuges were pre-cooled to 4°C. 
Optionally, RNA content was measured photometrically at a wavelength of 260 nm using 
a Biophotometer (Eppendorf). RNA purity was assayed by measurement of the 
260/280 nm ratio. 
 
4.1.8 Reverse transcription of RNA into cDNA 
To synthesize cDNA from total RNA the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) was used according to the manufacturer’s protocol. For one reaction 
0.5-1.0 µg total RNA or 10 µl of RNA elution were employed in a total reaction volume of 
20 µl. 10 µl of 2x RT master mix containing 2.0 µl 10x RT buffer, 0.8 µl 25x dNTP mix (100 
mM), 10x random primers, 1.0 µl of MultiScribeTM reverse transcriptase, 1.0 µl of RNase 
inihibitor, and 3.2 µl nuclease-free H2O were mixed with 10 µl of RNA sample. RT 
reactions were performed using the conditions below. Synthesized cDNA was stored at     
-20oC and used for quantification of gene expression by qRT-PCR (see 4.1.10). 
 
Step Temperature/Time
Annealing 25°C; 10 min 
Elongation 37°C; 120 min 
Denaturation 85°C; 5 min 
Table 4.1 │ Standard protocol for reverse transcription. 
 
For cloning of genes total RNA was extracted from Jurkat T cells (see 4.1.7) and cDNA 
was synthesized using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche). The 
Transcriptor High Fidelity Transcriptase is a recombinant reverse transcriptase conferring 
proofreading activity for high accuracy of transcription of RNA. 10 µl of RNA elution was 
mixed with 1 µl of anchored-oligo(dT)18 primers (50 pmol/µl) and filled up with 0.4 µl 
ddH2O to make a total volume of 11.4 µl. For denaturation the template-primer mixture 
was heated for 10 min at 65°C. Subsequently, the sample was cooled on ice, and the 
following components of the RT mix were added to get a final volume of 20 µl: 10 µl 5x RT 
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buffer, 0.5 µl Protector RNase inhibitor, dNTP mix (10 mM each), DTT (100 mM) and 
1.1 µl Transcriptor High Fidelity Reverse Transcriptase (10 U). Reagent were mixed and 
RT reactions were performed using the conditions below. 
 
Step Temperature/Time
Elongation 50°C; 30 min 
Denaturation 85°C; 5 min 
Table 4.2 │ Conditions for high accuracy reverse transcription. 
 
4.1.9 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) enables the cyclic enzymatic amplification of 
defined DNA fragments in vitro (Mullis et al., 1986). Short oligonulceotide fragments which 
anneal to the complementary strains of the DNA template in an inverse orientation 
determine the ends of the amplified DNA fragment. In the presence of dNTPs 
thermostable DNA polymerases extend these forward- and reverse-primers along the 
denaturated single stranded DNA generating a complementary DNA strand. 
For cloning of tagged versions of human PP4R1, PP4c, and PP2Ac as well as for 
mutagenesis of PP4R1 the KOD Hot Start DNA Polymerase Kit (Novagen®) was used. 
The KOD polymerase is a thermostable DNA polymerase derived from the 
hyperthermophilic archaeon Thermococcus kodakaraensis (KOD) (Benson et al., 2003). 
KOD Hot Start DNA Polymerase is a pre-mixed complex of the high fidelity KOD DNA 
Polymerase and two monoclonal antibodies that inhibit the DNA polymerase at ambient 
temperatures (Mizuguchi et al., 1999). Similar to the Pfu DNA polymerase KOD DNA 
polymerase possess a 3’→5’ proofreading capacity which replaces mismatched 3’-
terminal nucleotides from primer-template complexes. The following standard protocol 
was applied according to the manufacturer’s recommendations: 
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Component Amount/Volume
Final 
concentration 
Template DNA 30 ng (1 µl) 30 ng/50 µl 
Primer fwd (50 µM) 0.5 µl 0.75 µM 
Primer rev (50 µM) 0.5 µl 0.75 µM 
dNTPs (2 mM each) 5 µl 0.2 µM (each) 
25 mM MgSO4 3 µl 1.5 mM 
KOD buffer (10x) 5 µl 1x 
ddH2O 34 µl  
KOD Hot Start DNA 
Polymerase (1 U/µl) 1 µl 0.02 U/µl 
Total reaction volume 50 µl  
Table 4.3 │ Standard protocol for PCR. 
 
The following cycling conditions were applied: 
 
Step Temperature/Time Cycles 
Polymerase activation 95°C; 2 min 1 
Denaturation 95°C; 20 sec   
Annealing Lowest primer Tm°C for 10 sec 35 
Elongation 70°C; 1for 20 sec/kB   
Storage 4°C; ∞  
Table 4.4 │ Standard cycling conditions for PCR. 
 
Oligonucleotides were designed with about 40-60 % GC content, no internal secondary 
structure, and complementarities at the 3’-ends. PCRs were prepared on ice. Optionally, 
gradient PCRs were performed to determine optimal annealing temperatures. 
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4.1.10 Quantitative Real Time-PCR (qRT-PCR) 
Similar to conventional PCR quantitative real-time PCR (qRT-PCR) enables the 
amplification of specific DNA sequences. However, by use of fluorescent reporter 
molecules DNA amplification products are already detected during synthesis and 
therefore allow for the relative or absolute quantification of the amplified DNA. 
 
(i) SYBR Green-based qRT-PCR 
In general, relative gene expression levels were determined by SYBR Green-based qRT-
PCR. This method relies on the detection of the incorporated DNA-intercalating 
fluorescent dye SYBR Green. SYBR Green specifically fluoresces upon light excitation 
when bound to double-stranded DNA. During PCR the detectable fluorescence is 
amplified by each PCR cycle. Gene expression was analyzed using the Power SYBR® 
Green PCR Master Mix in combination with the 7.500 Real-Time PCR System and the 
7.500 Software version 2.0.1 (Applied Biosystems). Relative expression was determined 
from cycle threshold (Ct) values by normalization to hypoxanthine phosphoribosyl-
transferase 1 (HPRT1) and/or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
levels as reference genes. Fold expression was calculated according to the Ct method 
(Pfaffl, 2001). 
Reactions were carried out in 96-well plates in triplicates with a final volume of 25 µl per 
reaction. Master mixes for triplicate measurements were prepared according to the 
following protocol: 
 
Component Amount/Volume 
Template cDNA 1-2 µl 
SYBR Green PCR master mix (2x) 42.5 µl 
Primer mix (5 µM each) 10.2 
ddH2O 30.3 µl 
Total reaction volume 85 µl 
Table 4.5 │ Standard protocol for SYBR Green qRT-PCR. 
 
The Power SYBR® Green PCR Master Mix contains 300 µl 110x SYBR Green buffer, 
360 µl 25 mM MgCl2, 240 µl dNTP (10 mM each), 15 µl U/µl Hot Gold Star Taq 
polymerase and 30 µl U/µl uracil-N-glycosylase. 
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(ii) Universal probe library assays 
For some experiments Univeral Probe Libray (UPL) assays (Roche) were designed using 
the ProbeFinder Software (www.universalprobelibrary.com), and qRT-PCR was 
performed using the LightCycler® 480 Probes Master Kit and the LightCycler ® 480. 
System (Roche). UPL assays rely on a probe-based qRT-PCR, also known as TaqMan 
PCR. In contrast to SYBR Green qRT-PCR, this method requires a set of transcript-
specific PCR primers and an additional fluorogenic 3’ non-extendable hydrolysis probe for 
real-time PCR detection. The hydrolysis probe consists of a sequence-specific 
oligonucleotide that is covalently labeled with a fluorescent reporter dye at the 5’-end and 
a quencher label at the 3’-end. As long as the probe is intact any fluorescence signal is 
quenched. During PCR the probe hybridizes to the amplified sequence and the 5’→3’-
exonuclease activity of the Taq DNA polymerase cleaves the hydrolysis probe. As a result, 
the fluorophore is liberated and fluorescence is detected. The amount of detectable 
fluorophore is directly proportional to the amount of template and can be used for 
quantification of transcript levels. Relative gene expression was calculated according to 
the Ct method as described before using the LightCycler® 480 software with 
normalization to HPRT1 levels as endogenous reference. 
qRT-PCR reactions were performed in 384-well plates in triplicate with a final volume of 
11 µl per reaction according to the following protocol: 
 
Component Amount/Volume
Template cDNA 25 ng (1.1 µl) 
Probes Master mix 4.5 µl 
UPL probe 0.114 µl 
Primer mix (20 µM each) 0.436 µl 
ddH2O 3.85 µl 
Total reaction volume 11 µl 
Table 4.6 │ Standard protocol for UPL-based qRT-PCR. 
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For the LightCycler® 480 System the following qRT-PCR program was used: 
 
Step Temperature/Time Cycles
Initial denaturation 95°C; 10 min 1 
Denaturation 95°C; 10 sec   
Annealing 55°C; 20 sec 45 
Elongation 72°C; 1 sec   
Final cooling 40°C; 20 sec 1 
Table 4.7 │ Standard cycling conditions for qRT-PCR 
using the LightCycler® 480 System. 
 
4.1.11 Gene expression profiling 
cDNA from Jurkat, SeAx, Hut78, and HH cells was prepared (see 4.1.7 and 4.1.8). Gene 
expression was measured using a customized RealTime ready expression panel based 
on UPL assays (see 4.1.10) and the LightCycler® 480 System (Roche) according to the 
manufacturers’ instructions. Relative expression was calculated using the LightCycler® 
480 software with triple normalization to HPRT1, GAPDH, and 18S rRNA levels. 
 
4.1.11 Enzymatic manipulation of DNA 
(i) Digestion of DNA with restriction endonucleases 
For the sequence-specific cleavage of DNA molecules the samples were incubated with 
restriction endonucleases under appropriate reaction conditions. The amount of enzyme 
and DNA, the choice of buffer, temperature and duration of the reaction were adjusted 
according to the manufacturer’s instructions. 
 
(ii) Dephosphorylation of linearized vector DNA 
Restriction of vector DNA with a single enzyme may lead to subsequent religation. 
Therefore, 5’ termini of vector DNA were dephosphorylated using calf intestinal 
phosphatase (CIP) according to the manufacturer’s instructions. 
 
(iii) Ligation of DNA fragments 
For the ligation of linearized vectors with DNA-fragments the T4 DNA ligase was used. 
This enzyme catalyzes the formation of phosphodiester bonds between adjacent 3’-OH 
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and 5’-P ends in double-stranded DNA. For ligations of cohesive ends a molar ratio 
between 1:3 and 1:5 (vector vs. insert DNA) was chosen. 
 
4.1.12 Agarose gel electrophoresis 
DNA samples were separated, characterized and purified by agarose gel electrophoresis. 
For preparation of agarose gels 1% agarose (w/v) was dissolved in 1x TAE buffer by 
boiling and supplemented with 6 µl ethidium bromide/100 ml solution. Prior to loading 
DNA samples were mixed with 6x DNA loading buffer. Additionally, 5-10 µl of a DNA 
molecular weight standard (Gene RulerTM 1 kB DNA ladder, Fermentas) was loaded. The 
voltage was set to 5 V/cm electrode distance and electrophoresis was performed in a 
horizontal gel chamber filled with TAE buffer. DNA fragments stained with ethidium 
bromide were visualized by UV-excitation at  = 312 nm (fluorescence at = 590 nm). 
 
4.1.13 Extraction of DNA from agarose gels 
DNA fragments and linearized vectors for transfections were isolated from agarose gels 
and purified using the QIAEX II Gel extraction Kit (Qiagen). Alternatively, double-stranded 
DNA fragments from PCR or other enzymatic reactions were purified using the QIAquick 
PCR Purification Kit (Qiagen). 
 
4.1.14 DNA sequencing 
DNA sequencing was conducted by Seqlab or GATC Biotech according to the didesoxy 
method (Sanger et al., 1977). 
 
 
4.2 Methods in mammalian cell culture 
4.2.1 General culture conditions 
All used cell lines were cultured at 37°C in an atmosphere with a relative humidity of 90% 
and a CO2 content of 5%. For the inactivation of complement factors FCS was heated to 
56°C for 30 min before use. Unless otherwise indicated, all media contained 10% (v/v) 
FCS and were supplemented with antibiotics. Cells were harvested by centrifugation for 
4 min at 1,500 rpm and 4°C. Cell culture work was performed under sterile conditions 
using a laminar flow hood. 
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4.2.2 Culture of adherent cells 
Adherent growing cell lines HEK293T, HeLa, Hep3B, and Phoenix were maintained in 
DMEM medium. At a confluence of about 80% cells were split in a ratio of 1:3-1:10. To 
this end, the supernatant was discarded and 2-5 ml of trypsin/EDTA solution were added 
for 3-5 min at RT. Detached cells were resuspended in fresh DMEM medium and seeded 
with a confluence of 10-25% onto new plates. 
 
4.2.3 Culture of suspension cell lines 
For the culture of suspension cell lines or primary human T lymphocytes the following 
media were used.  
 
Cell line/type Cell culture medium 
Jurkat-derivatives JE6.1, J16-145, 
Gluc-J16 
IMDM 
CEM, SeAx, MyLa, Hut78, HH, SUDHL-5,
BJAB, SUDHL-6, HT, Raji 
RPM1 1640 
OCI-Ly3 RPM1 1640 (with 20% FCS) 
Primary human peripheral 
blood T lymphocytes 
RPMI 1640 with IL-2 (25 U/ml) or 
X-Vivo 15 medium with IL-2 (25 U/ml) and 1% Glutamax
Table 4.8 │ Media for mammalian cell culture. 
 
Media were replaced every 2-3 days. The suspension cell lines JE6.1, J16-145, and Gluc-
J16 were cultured with a density of 1.5-4x105 cells/ml. 
 
4.2.4 Thawing and freezing of eukaryotic cells 
The cells were harvested and resuspended in freezing medium containing 90% (v/v) FCS 
and 10% (v/v) DMSO. The cell density was adjusted to 1-1.5x107 cells/ml. 1 ml cell 
suspension was transferred into a cryo-tube and immediately stored at -80 °C (-140°C for 
long term storage). Cells were rapidly thawed at 37°C and immediately resuspended in 
10 ml of RPMI or IMDM medium to dilute the DMSO. Afterwards, cells were centrifuged at 
1,500 rpm for 4 min at 4°C and resuspended in an appropriate volume of fresh culture 
medium. 
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4.2.5 Determination of the cell density 
The cell density of a culture was determined by use of a Neubauer chamber slide. If 
necessary, cells were diluted prior to counting. 
 
4.2.6 Preparation of AET-erythrocytes 
A solution of 2-aminoethylisothiouroniumbromide (AET) (pH=9.0) was prepared using 
pyrogen-free, sterile water (0.5 g of AET diluted in 12.5 ml of water). Sheep blood 
erythrocytes were suspended in a 1:1 ratio in Alsever solution. After washing with PBS for 
three times, 25 ml of the sheep blood erythrocytes were mixed with 12.5 ml of the AET 
solution and incubated for 15 min at 37°C. Cells were then washed four times with PBS. 
Finally, cells were diluted in FCS-containing RPMI medium to prepare a 4% suspension. 
All centrifugation steps were performed at 500 g and 20°C for 10 min. AET-treated sheep 
blood erythrocytes were stored at 4°C for up to three days. 
 
4.2.7 Ficoll gradient isolation of human mononuclear cells 
Primary human mononuclear cells were isolated from 500ml total blood or buffy coats 
according to the following protocol. 1 ml of heparin was added to 500 ml of whole blood to 
inhibit coagulation. Buffy coats were adjusted to 300ml with PBS. 50ml tubes filled with 
15 ml Ficoll were slowly overlayed with 35 ml blood and centrifuged at 650 g and 20°C for 
20 min without break. Peripheral blood leukocytes (PBLs) were collected from the 
interphase and washed twice with PBS and resuspended in RPMI medium. PBLs were 
transferred into cell culture flasks and cultured for 30-45 min in the incubator for the 
depletion of adherent cells (i.e. monocytes and macrophages). Non-adhering lymphocytes  
were collected, spun down (500 g, 10 min, RT) and suspended in RPMI medium with a 
cell density adjusted to 1x107 cells/ml. Lymphocytes were used for the further purification 
of human peripheral blood T lymphocytes by rosetting with 2-amino-ethylisothyo-uronium-
bromide-treated sheep red blood cells as described before (Gulow et al., 2005). 
Alternatively, CD4+CD25- T lymphocytes were purified by magnetic sorting (see 4.2.8). 
 
4.2.8 Isolation and culture of human peripheral T cells 
(i) T cell isolation by T cell rosetting with AET-erythrocytes 
PBLs were mixed in a 2:1 ratio with 4% AET-erythrocytes for a “rosetting” reaction. The 
mixture was centrifuged (500 g, 10 min, RT, slow breaking). The pellet (containing 
“rosettes”) was resuspended, carefully layered on top of pre-warmed Ficoll solution 
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(15 ml) and centrifuged for 20 min at 2420 rpm and RT (without breaks). The pellet, 
consisting of T cells and erythrocytes, was washed with pre-warmed PBS or medium 
(500 g, 10 min, RT, slow breaking). The erythrocytes were lysed by addition of 4x volume 
(acc. to the pellet) of ACK buffer. The lysis is indicated by a colour change of the mixture 
from turbid light red to clear dark red. Subsequently, cells were washed twice with pre-
warmed PBS or medium, resuspended in 50 ml of RPMI, counted and diluted to a 
concentration of 2x106 cells/ml. 
 
(ii)  Magnetic-activated cell separation of CD4+ T lymphocytes 
The isolation of T cells was accomplished by means of magnetic-activated cell separation 
(MACS). Cells can be separated by MACS either by positive or negative selection. 
In a first step, CD25+ T cells were removed by positive selection. For that, the PBL 
suspension was incubated with a limiting amount (2 µl/107 cells) of bead-coupled anti-
CD25 monoclonal antibodies. After a subsequent washing step, the cell suspension was 
loaded onto a column in a magnetic field. The magnetic beads retain the CD25+ cells in 
the column, while the remaining cell types flow through. Outside of the magnetic field, 
CD25+ cells were eluted from the column. In a second step, CD4+CD25- T cells were 
isolated from the CD25+-depleted fraction using the CD4 Isolation kit II and additionally 
depleted from CD25+ cells with 6 µl of anti-CD25 MACS beads per 107 cells. 
Alternatively, bulk CD4+ T cells were isolated from total PBLs by positive selection using 
CD4 MicroBeads (Miltyenyi Biotec) according to the manufacturer’s protocol. Briefly, PBLs 
were resuspended in 80 µl of buffer per 1x107 total cells. 20 µl of CD4 MicroBeads 
conjugated to anti-CD4 monoclonal antibodies were added per 1x107 total cells. The 
suspension was mixed and incubated for 15 min at 4°C. Subsequently, cells were washed 
by addition of 2 ml of buffer per 1x107 cells, followed by centrifugation at 300 g for 10 
minutes. Finally, up to 1x108 cells were resuspended in 2 ml of buffer. Magnetic 
separation of bead-labeled CD4+ cells was performed as described before. Isolated 
T cells were rested overnight in X-Vivo 15 medium and diluted to a concentration of 2x106 
cells/ml. 
 
4.2.9 In vitro expansion of T lymphocytes 
For activation, resting peripheral blood T lymphocytes were cultured at a concentration of 
2x106 cells/ml in the presence of 1 µg/ml PHA for 16 h. Alternatively, T cells were 
stimulated by soluble anti-CD3 (0.5 µg/ml) and anti-CD28 (2 µg/ml) agonistic antibodies. 
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T cells were then cultured in RPMI medium supplemented with 10% FCS and 25 U/ml IL-2 
for 6-8 days (day 6 T cells). In general, all experiments were performed with T cells 
isolated from 2-3 independent healthy donors. 
 
4.2.10 T cells from Sézary patients 
T lymphocytes were isolated from peripheral blood of patients suffering from Sézary 
syndrome and PP4R1 mRNA levels were analyzed by SYBR Green qPCR with dual 
normalization for GAPDH and HPRT1 expression. For transcriptional analyses only those 
samples were included that showed tumor loads of generally at least 60% as determined 
by microscopical evaluation of blood smears. At large, the percentage of Sézary T cells 
relative to whole lymphocytes in peripheral blood samples was about 70% with CD4+ to 
CD8+ T cell ratios between 11 and 99 as evaluated by flow cytometry (Klemke et al., 
2008). As controls, T cells from 10 age-matched normal healthy donors were investigated. 
cDNAs were kindly provided by N. Booken and C.-D. Klemke (University Hospital 
Mannheim). CTCL was diagnosed according to the WHO-EORTC classification of 
cutaneous lymphomas (Willemze et al., 2005) and the criteria of the international society 
of cutaneous lymphomas (Vonderheid et al., 2002). The study was conducted according 
to the ethical guidelines of German Cancer Research Center (DKFZ, Heidelberg) and the 
Helsinki Declaration, and approved by the ethics committee II of the Ruprecht-Karls-
University of Heidelberg, Germany. 
 
 
4.3 Cell biological methods 
4.3.1 Transient and stable transfections by electroporation 
Electroporation is a method for the direct transfer of macromolecules (i.e. DNA) into target 
cells by perforating the plasma membrane with a short electric pulse. 
For generation of stably-transfected Gluc-J16-15 reporter cells the 8xNF-B pGluc vector 
was linearized by ScaI restriction digest. For transient transfection of Jurkat and HH cells 
circular plasmid DNA was used. For each sample about 5-30 µg of plasmid DNA were 
transfected. 1-3x107 cells were harvested and washed once with cold and sterile PBS. 
Cells were resuspended in 400 µl of IMDM medium without FCS and antibiotics and 
mixed with the plasmid sample. Subsequently, the cell-plasmid mixture was transferred 
into an electroporation cuvette. Cells were electroporated at 250 V and 950 µF. Then, 
cells were resuspended in 5-10 ml of pre-warmed medium in 6-well plates or 10 cm 
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dishes. After 24-48 h cells were subjected to further analyses. For selection of stable 
integrants Gluc-J16-156 cells were cultured in IMDM medium supplemented with             
2-4 mg/ml G418 in 96-well plates. Single clones were subloned twice by limiting dilutions 
according to Poisson statistics. 
 
4.3.2 Nucleofection and siRNA-mediated gene silencing 
For siRNA-mediated gene silencing J16-145 T cells as well as primary human T 
lymphocytes were transiently transfected by nucleofection using the Cell Line 
Nucleofector® Kit V and the Human T Cell Nucleofector® Kit (Amaxa), respectively, 
according to the manufacturer’s instructions. 2x106 J16-145 T cells or 5x106 primary 
human T cells were resuspended in appropriate nucleofection solutions containing 1µM 
siRNA. Nucleofection was performed using program X-01 for J16-145 cells or program   
U-14 for primary human T lymphocytes. After 72 h, knock-down efficacy was assessed 
and cells were subjected to further analyses. 
 
4.3.3 Nucleofection of siRNA under HTS conditions 
For large-scale RNAi screening and subsequent validation experiments Gluc-J16 reporter 
cells or J16-145 cells were nucleofected in a 96-well plate format. siRNA transfections 
were performed using  the Nucleofector® 96-well Shuttle® system in combination with the 
Cell Line 96-well Nucleofector® Kit SE (Lonza). Cells were kept in logarithmic growth 
phase prior to transfection. For one nucleofection well 5 x 105 cells, resuspended in 20 μl 
of Cell Line 96-well Nucleofector® Solution SE, were transfected with 1 μl of 20 μM siRNA 
solution. Before transfection 1 μl of siRNA solution was pre-spotted into 96-well V-bottom 
plates. For transfection of one 96-well plate the content of five T75 flasks grown to a 
density of 2 x 105 cells/ml was centrifuged at 1.500 rpm for 5 min and cell pellets were 
subsequently pooled to obtain a total cell number of about 5 x 107 cells. Residual medium 
was completely removed from the cell pellet and cells were resuspended in 2.2 ml 
Nucleofector® Solution SE. Next, cells 20 μl of the cell-nucleofector suspension were 
transferred to the 96-well V-bottom plate and mixed gently with the pre-spotted siRNAs by 
carefully pipetting up and down. Subsequently, the siRNA-cell suspension was transferred 
into NucleocuvetteTM plates and transfection was immediately initialized using program  
96-CL-120. After transfection 100 μl of pre-warmed medium per 96-well was added, cells 
were resuspended and divided into two technical replicates. Cells were grown in 200 µl 
medium in 96-well plates for about 72 h and then subjected to further analyses. 
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4.3.4 siRNA library screening 
Primary RNAi screening was based on Gluc-J16 NF-B reporter cells and the 
commercially available Silencer® Select Human Phosphatase siRNA Library V4 (Applied 
Biosystems) targeting 298 known or putative phosphatase genes encoding for regulatory 
or catalytic phosphatase subunits. The library contained three single, independent siRNA 
oligos per gene yielding a total of 894 phosphatase-specific siRNAs. Each individual 
siRNA was arrayed in a 96-well plate format and transfected in biological dublicates. For 
the phosphatase RNAi screen the HTS siRNA transfection protocol was applied using the 
Nucleofector® 96-well Shuttle® system as described before (see Fig. 4.1 and section 
4.3.3). For each 96-well transfection plate a constant panel of positive and negative 
control siRNAs (i.e. siRNA oligos specific for CYLD, RelA, and Carma1, as well as non-
targeting siRNA) and mock transfections (H2O) were included. In total, 22 96-well plates 
were transfected with more than 2,000 consecutive single transfections. Subsequent to 
the transfection procedure, cells were divided into equivalent fractions (two technical 
replicates per biuological replicate), incubated for about 72 h and then subjected to 
different stimulation conditions. To this end, cells from each well (technical replicate) were 
again separated into equivalent fractions and were either left untreated (medium control) 
or stimulated with agonistic anti-CD3, anti-CD28 and goat-anti-mouse antibodies 
(0.1 µg/mL final concentration each) for 5 h. Subsequently, Gluc activity in cell 
supernatants determined (see section 4.4.9). In addition, cell viability was measured for 
normalization of the luciferase signal (see section 4.4.10). 
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Figure 4.1 │ Schematic representation of work-flow for primary siRNA library screening. 
Gluc-J16 reporter cells, transfected with 1 µM of phosphatase-specific siRNA or control siRNA, 
were either left untreated (medium control) or stimulated with agonistic anti-CD3, anti-CD28, and 
anti-goat-anti-mouse antibodies (TCR; 0.1 µg/ml final concentration each). For details see text. 
 
4.3.5 Transfection of HEK293T cells by the Ca3(PO4)2 method 
Cells were grown to 70-80% confluence in 10 cm cell culture dishes. 5-20 µg plasmid 
DNA were mixed with 1 ml 1x HBS and 50 µl 2.5 M CaCl2 were carefully added. After 
10 min of incubation the mix was added dropwise to the cells. After 24 h the transfection 
efficiency was analyzed by fluorescence microscopy using cells that had been              
(co-)transfected with cDNA encoding for the green fluorescent protein (GFP) as control. 
After additional 24 h cells were harvested, lysed and exogenous protein expression was 
examined. 
 
4.3.6 Production of recombinant retroviruses 
Retroviral supernatants were prepared by transfection of pMX IRES-GFP expression 
vectors into amphotropic Phoenix cells. The Phoenix cell line is a HEK293T-derived 
helper cell line for the production of recombinant retroviruses (Swift et al., 2001). For 
production of lentiviral particles HEK293T cells were used. 
Phoenix-Ampho cells and 293T cells were seeded with a density of 1.5x106 and 1.0x106 
cells/ml, respectively, in 4 ml of DMEM medium in T25 flasks and cultured overnight up to 
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a confluence of about 75%. Prior to transfection 293T cells were pre-treated for 1 h with 
25 µM chloroquin. Cells were transfected by the Ca3(PO4)2 method as described before 
using 600 µl 1x HBS and 30 µl 2.5 M CaCl2. For transfection of Phoenix cells 10 µg of 
pMX-based expression vector were transfected. 293T cells were transfected with 6.3 µg of 
TRC-derived shRNA vectors, 4.3 µg of psPAX2 (encoding for gag, pol, and env proteins), 
and 2.3 µg of pMD2 (encoding for VSV-G) for pseudotyping. 8 h post transfection the 
medium was removed from packaging cells and replaced by 4 ml of fresh DMEM medium. 
Virus production was continued for additional 24 h. 
 
4.3.7 Viral transduction of target cells 
Two days after transfection of packaging cells, the supernatant was collected and 
centrifuged at 1,500 rpm for 4 min at 4°C to remove cell debris. In addition, the 
supernatant was passed through a 0,45 µM filter. 1x105 target cells resuspended in 100 µl 
of RPM1 1640 medium were added to 1 ml of viral supernatant supplemented with 
Polybrene (8 µg/ml). Cells were infected in 24-well plates by spin occulation. To this end, 
cells were centrifuged at 2.500 rpm for 2 h and 30°C. 24 h later cells were collected, 
washed three times with medium, resuspended in fresh medium, and transferred into 
fresh tissue culture flasks. 48 h post transduction, stably shRNA-transduced Jurkat cells 
were selected by puromycin resistance (1 µg/ml puromycin). 
 
4.3.8 Retroviral reconstitution assays 
The toxicity of ectopic phosphatase expression was examined by retroviral reconstitution 
of the CTCL lines SeAx, MyLa, Hut78, and HH. For the reconstitution assay CTCL cell 
lines were retrovirally transduced with pMX-IRES GFP vectors either expressing GFP 
alone (ctrl) or co-expressing wild type human PP4R1, PP4c, or PP2Ac. The frequency of 
transduced (GFP-positive) cells was monitored over time by flow cytometry. For a single 
assay cells were transduced and analyzed in triplicate. The percentage of phosphatase-
reconstituted cells was normalized to that of control-transduced cells at the same day. In 
addition, the ratio of GFP-positive cells at various time points was normalized to the initial 
ratio at day 3-5 post transduction. 
 
4.3.9 Determination of CD69 cell surface expression 
Cell surface expression of CD69 on J16-145 cells was analyzed by immunofluorescence 
staining and flow cytometry. 1-2x106 J16-145 cells, that had been transiently co-
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transfected with plasmid DNA and a GFP-encoding control plasmid (10 µg each) (see 
4.3.1), were stimulated with anti-CD3, anti-CD28 and goat-anti-mouse antibodies (1µg/mL 
each) in 6-well plates for 8 h. Subsequently, cells were collected and incubated one ice for 
30 min with a PE-conjugated anti-human CD69 antibody (diluted 1:25 in FACS buffer) in a 
total volume of 20 µl per sample. To remove unbound antibodies cells were washed twice 
with 1 ml of PBS. Finally, cells were resuspended in 200 µl of FACS buffer and subjected 
to FACS analysis. CD69 levels of plasmid-transfected cells were determined by gating on 
GFP-positive viable cells. Fluorescence intensities were monitored on a flow cytometer 
(FACSCanto II) and the analysis was accomplished using the software FACSDIVA. 
Fluorescence emission was detected on the FL1-H and FL2-H channel. For each diagram 
2x104 cells were analyzed on a logarithmic scale. 
 
 
4.4 Biochemical and immunological methods 
4.4.1 In vitro stimulation of T cells 
Cells were harvested and resuspended in fresh culture medium. Cells were stimulated 
with agonistic soluble anti-CD3 (Okt3), anti-CD28, and anti-goat-anti-mouse monoclonal 
antibodies (TCR stimulation) with final concentrations between 0.1 and 1.0 µg/ml. 
Alternatively, cells were stimulated with PMA (10 ng/ml), ionomycin (10 µM), and 
recombinant TNF (20 ng/ml), respectively. For stimulations in 96-well plates, 1-2x105 
Jurkat or Gluc-J16 cells were resuspended in 100 µl medium and 100 µl of 2-fold-
concentrated stimulation medium was added. For biochemical experiments, 1-5x107 cells 
were resuspended in 4-5 ml of medium in 6-well plates or T25 flasks. For stimulation 1 ml 
of 4-5-fold-concentrated stimulation mix was added. Cells were stimulated for the 
indicated time periods. To stop stimulation, cells were transferred into 1,5 ml Eppendorf 
tubes or into 15 ml tubes and centrifuged at 5,000 rpm for 1 min or at 1,500 rpm for 4 min 
at 4°C. The supernatant was drawn off and cells were lysed as described in 4.4.2. 
 
4.4.2 Cell lysis 
Cells were harvested and the supernatant was drawn off. Then, 20 µl of ice-cold lysis 
buffer per 1x106 cells were added, and the lysates were incubated on ice for at least 
20 min. The lysates were cleared from insoluble cell debris by centrifugation at 14,000 g 
and 4°C for 10 min. Protein concentrations of whole cell lysates were measured by Roti®-
Quant Bradford assay (Roth) according to the manufactures’ instructions and adjusted to 
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equal levels. For gel electrophoresis lysates were mixed with 10 µl of 3x reducing SDS 
sample buffer per 1x106 cells (Laemmli et al., 1970) and heated to 95°C for 5 min or 
subjected to immunoprecipitation (see 4.4.3). 
 
4.4.3 Immunoprecipitation 
For immunoprecipitation (IP) cleared lysates of 1-6x107 cells were incubated with the 
desired antibody at 4°C on a rotator for 1 h. Subsequently, 40 µl of protein A-sepharose 
beads were added and the suspension was incubated at 4°C on a rotator for at least 3 h 
or overnight. The matrix was washed 1-5 times with 1 ml of ice-cold lysis buffer or PBS to 
remove unspecifically adsorbed proteins. Subsequently, beads were resuspended in 50 µl 
of lysis buffer and heated in 25 µl 3x sample buffer at 95°C for 5 min. (Co-)purified 
proteins were detected by SDS-PAGE and immunoblotting (see 4.4.4 and 4.4.5). 
 
4.4.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The analytical separation of proteins was accomplished by discontinous SDS-PAGE 
under reducing conditions (Laemmli et al., 1970). Sodium dodecyl sulphate (SDS) is an 
anionic detergent. SDS denatures proteins and concomitantly confers to them a net 
negative charge. On average, proteins bind 1.4 g SDS per gram of protein. Thus, 
migration of the SDS-protein complexes through polyacrylamide gels in an electric field 
largely depends on their molecular mass. 
For electrophoresis 8-12% polyacyrlamide separating gels and 5 % polyacrylamide 
stacking gels were prepared. The polymerisation was started by adding 0.1% (v/v) 
TEMED and the polymerizing solution was used immediately. The separating gel was 
covered with isopropanol. After 15 min the isopropanol was removed by washing with 
water, the gel surface was dried and the stacking gel was added. Proteins were 
electrophoretically separated at a constant current of 25-30 mA/gel for 1-1.5 h.To estimate 
apparent molecular weights of analyzed proteins an appropriate molecular weight marker 
(NEB) was used. Subsequent to SDS-PAGE, the polyacrylamide gel was subjected to 
immunoblotting (see 4.4.5). 
 
4.4.5 Immunoblot analysis 
For immunoblot (IB) analysis, proteins separated by SDS-PAGE were electrophoretically 
transferred onto a nitrocellulose membrane (Amersham Bioscience) using a semidry-
transfer system (Biorad) (transfer conditions: 0.8 mA/cm2; 2 h). Gel and membrane were 
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pre-incubated in transfer buffer. After electroblotting the transferred proteins are bound to 
the membrane providing access for the detection by specific antibodies. To avoid 
unspecific binding the membrane was incubated in blocking solution (5 % (w/v) nonfat 
dried milk in PBST or 5 % (w/v) BSA in PBST) at RT for 1 h on a shaker. The membrane 
was briefly washed three times with PBST. For specific detection of proteins the 
membrane was incubated with a primary antibody solution for at least 1 h at RT or 
overnight at 4°C on a shaker. After washing three times with PBST the membrane was 
incubated with a HRP-conjugated -immunoglobulin secondary antibody for 0.5-1 h at RT 
on a shaker. Finally, the membrane was washed three times with PBST for 20 min each 
time. Detection of membrane bound HRP was performed by enhanced 
chemiluminescence (ECL) using the Western LightningTM Plus-ECL reagent (PerkinElmer) 
according to the manufacturer’s instructions. Chemiluminescence was detected using a 
digital chemiluminescence acquisition system (Vilber Lourmat). Analysis was 
accomplished using the software Chemi-Capt (Vilber Lourmat) and Photoshop CS4. 
Protein quantification was performed using the Bio-1D software (Vilber Lourmat). For 
specific detection of further proteins the enzymatic activity of the HRP was inactivated by 
incubation with 0.01 % (w/v) NaN3 in PBST at RT for 1 h. Thereafter, the membrane was 
incubated with the subsequent primary antibody and the visualization procedure was 
continued as described above. Alternatively, the nitrocellulose membrane was incubated 
for 15 min at 55°C in stripping buffer to denaturate primary and secondary antibodies, 
followed by extensive washing with ddH20 and PBST. Then, the membrane was blocked 
again for 1 h and the procedure was continued as described above. 
 
4.4.6 In vitro kinase assay 
All in vitro kinase assays were performed as described previously (Brenner et al., 2005). 
FLAG:IKK or the endogenous IKK complex were immunoprecipitated by anti-FLAG and 
anti-NEMO antibodies, respectively. Immunoprecipitates were washed 1-3 times with lysis 
buffer, followed by a final washing step with kinase buffer. Immune complexes were 
resuspended in 100 µl kinase buffer in divided into equivalent 50 µl aliquots. One part was 
used to control for protein input by SDS-PAGE and immunoblotting, while the other part 
was subjected to the in vitro kinase reaction. 5 µg of recombinant GST:IB, serving as a 
IKK-specific kinase substrate, were added together with 10 µCi [32P-]ATP. The reaction 
was performed for 30 min at 30°C on a shaker. Subsequently, proteins were separated by 
SDS-PAGE. The gel was dried and subjected to autoradiography. 
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4.4.7 In vitro phosphatase assay 
To obtain phosphorylated FLAG-tagged IKK substrates, FLAG:IKK and FLAG:IKK 
expression plasmids were transiently transfected into HEK293T cells. After 24 h, cells 
were stimulated with PMA/ionomycin for 15 min. Subsequently, IKKs were 
immunoprecipitated from whole cell lysates by anti-FLAG immunoprecipitation. 
Alternatively, the endogenous IKK complex was immunoprecipitated by anti-NEMO 
antibodies from Jurkat T cells that were either unstimulated or stimulated by treatment 
with PMA/ionomycin for 15 min. Phosphorylated IKK proteins were recombined and 
served as substrates in a subsequent phosphatase reaction. For this purpose, HA:PP4R1 
or HA:PP4c were separately overexpressed in HEK293T cells and purified by anti-HA 
immunoprecipitation. Anti-HA immunoprecipitates were then co-incubated with equivalent 
portions of FLAG-tagged IKK substrates for 1 h in phosphatase buffer. Subsequently, 
combined immune complexes were resolved by SDS-PAGE and IKK phosphorylation was 
analyzed by immunoblotting. For cell lysis and immunoprecipitation, a lysis buffer without 
phosphatase inhibitors was used. To measure phosphatase activity of exogenous or 
endogenous PP4R1 and anti-PP4c immunoprecipitates the colorimetric SensoLyte® pNPP 
Protein Phosphatase Assay (AnaSpec) was used according to the manufacturer’s 
instructions. For this, phosphatase reactions were performed for 1 h or overnight at 30°C 
in a shaker. For end-point reading the absorbance signal was measured at 415 nm using 
the Microplate Reader Model 680 (Biorad). Relative phosphatase activity was calculated 
as (induced phosphatase activity – background activity)/(background activity)x100. 
 
4.4.8 In vitro translation 
HA-tagged PP4R1 as well as FLAG-tagged versions of IKK, IKK, or PP4c were in vitro 
translated in the presence of radioactively labeled 35S-methionine using the TNT® T7 
Coupled Reticulocyte Lysate System (Promega) according to the manufactures’ 
instructions. 
 
4.4.9 Gaussia luciferase reporter assay 
0.5-2x105 GLuc reporter cells or T cells that had been transiently transfected with the Gluc 
expression plasmid were stimulated in 96 well plates. For each sample, 20 µl of 
supernatant was subjected to a Gaussia luciferase assay (p.j.k.) according to the 
manufactures’ instructions. Luciferase activity was measured in 96-well plates using a 
Orion L Microplate Luminometer (Berthold Detection Systems) with an integration time of 
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3.0 sec. In parallel, cell viability was determined (see 4.4.10) and normalized Gluc activity 
was calculated as the ratio between Gluc activity and cell viability counts. 
 
4.4.10 Cell viability assay 
To normalize luciferase expression for variations in cell numbers, cell viability was 
measured in a 96-well format using the CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega). This method determines the number of viable cells based on the relative 
quantification of the intracellular ATP content. The amount of ATP present correlates with 
the amount of metabolically active cells. To perform the CellTiter-Glo® assay, cells were 
resuspended in the remaining medium and 50 μl of the cell suspension were added to 
50 μl of the CellTiter-Glo reagent (1:1 diluted with medium). Subsequently, plates were 
incubated for 20 min at 37 °C in the dark. Luminescence was measured using a Mithras 
LB940 plate reader (Berthold Technologies) (integration time 0.1 sec) or an Orion L 
Microplate Luminometer (Berthold Detection Systems) (integration time 1.0 sec). 
 
4.4.11 Transient reporter assay 
For transient reporter assays 1x107 Jurkat T cells or 2x105 HEK293T cells were co-
transfected with NF-B- or AP-1-specific transcriptional reporter plasmids (pGL8xNF-B-
fos or p3xAP-1-Luc) and pfos-LacZ as described previously (Arnold et al., 2001). Jurkat 
cells were co-transfected with 8 µg of reporter plasmid and 1.5 µg of pfos-LacZ. HEK293T 
cells were co-transfected with 2 µg of reporter plasmid and 0.5 µg of pfos-LacZ. 
Transfection efficiency was normalized to LacZ expression. 24-48 h post transfection cells 
were lysed and luciferase activity was measured using the Dual-Light® System (Applied 
Biosystems) and an Orion L Microplate Luminometer (Berthold Detection Systems) 
according to the manufactures’ instructions. 
 
4.4.12 Enzyme-linked immunosorbent assay (ELISA) 
To measure cytokine secretion of siRNA-transfected or shRNA-expressing Jurkat T cells 
or primary human T lymphocytes, cells were stimulated in 96-well plates with anti-CD3, 
anti-CD28, and anti-goat-anti-mouse monoclonal antibodies overnight or with 
PMA/ionomycin for 8 h. Subsequently, the supernatant was collected, and the levels of 
secreted IFN, IL-2, IL-8, or TNF were determined by enzyme-linked immunosorbent 
assays (ELISA) according to the manufactures’ instructions. For all TCR stimulations, 
50 µl of supernatant was applied, whereas supernatants from PMA/ionomycin-stimulated 
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Jurkat cells were diluted 1:4-1:20 with IMDM medium without supplements, depending on 
the tested cytokine (1:4 for IFN and IL-8, 1:10-1:20 for IL-2). For end-point reading the 
absorbance signal was measured at 490 nm using the Microplate Reader Model 680 
(Biorad). Optionally, the remaining cell suspension was subjected to a cell viability assay 
(see 4.4.10) to normalize cytokine levels to cell numbers. 
 
 
4.5 Computational and statistical analysis 
4.4.1 Statistical normalization 
Statistical analysis of the primary RNAi screen and data pre-processing were conducted 
using the cellHTS2 Bioconductor/R software package (in collaboration with D. Nickles, 
DKFZ) (Boutros et al., 2006; Pelz et al., 2010). For each 96-well two reporter signals were 
measured: channel 1 was representative of overall cell viability and cell numbers, whereas 
channel 2 was based on measurement of NF-B-driven Gluc activity (see also 5.1.5). 
Computational analysis of raw data from each channel revealed in part considerable 
interplate variations as well as systematic intraplate effects (positional effects, such as 
column, row, or edge effects). Therefore, values were statistically normalized using the 
stringent B score algorithm that is suitable to standardize for intraplate and plate-to-plate 
variability (Birmingham et al., 2009; Brideau et al., 2003; Malo et al., 2006). B score 
normalization yielded accurate and similar distributions of median normalized signal 
intensities between replicates and across different plates as assessed by box plot analysis 
(Boutros et al., 2006; data not shown). In addition to statistical normalization, pre-
processed data from either channel were combined in order to calculate values for NF-B-
specific Gluc activity normalized to cell numbers (channel 2/channel 1; biological 
normalization). Subsequently, mean Gluc activity of two biological replicates for each 
siRNA transfection was determined. Mean values, in turn, were transformed into the 
statistical z score for hit selection and post-screen analysis (see 4.4.2). 
 
4.4.2 Candidate selection by analysis of statistical normality 
For identification of candidate phosphatases (hits) quantified RNAi phenotypes (i.e. mean 
values of normalized NF-B activity) were scored for statistical significance. To this end, 
normalized measurements were transformed into the statistical z score (Boutros et al., 
2006). Data transformation helps to further minimize data variability and allows for the 
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analysis of statistical normality which is instrumental in defining appropriate thresholds for 
hit selection. Using a quantile-quantile (QQ) plot analysis (Ramadan et. al., 2007) z scores 
assigned to individual phosphatase siRNAs (sample quantiles) were plotted against 
values from a theoretical normal distribution (theoretical quantiles) (Fig. 5.5 A). z score 
deviations from normally (randomly)-distributed values indicated statistically significant 
RNAi phenotypes. For hit selection z scores > +1.5 and < -1.5 were defined as cut-offs 
values (Fig. 5.5 A and B). 
 
4.4.3 Student’s t-test 
The unpaired Student’s t-test (independent two-sample t-test; unequal sample sizes and 
unequal variance) was used for statistical analysis of PPP4R1 mRNA expression in 
Sézary patients (12 samples) vs. normal healthy donors (10 samples). A p value of less 
than 0.05 was considered statistically significant. 
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5 Results 
Activation and regulation of NF-B signaling in T cells proceed via the orchestrated action 
of a number of adapter and effector molecules. While multiple kinases and 
phosphorylated target proteins that induce NF-B activity have been identified, the 
molecular machinery involved in the termination of antigen receptor-mediated NF-B 
activation still remains only poorly understood. Since signal transmission emanating from 
engaged cell surface receptors (e.g. TCR and TNFR) to transcriptionally active NF-B 
largely relies on phosphorylation events, it is generally assumed that phosphatases play 
an important role in the modulation and termination of NF-B activity. Yet, the role of 
phosphatases in regulation of TCR-induced NF-B signaling is still not well understood. 
The following study has been conducted with the aim to elucidate the potential role of 
phosphatases in regulation of TCR-induced NF-B signaling. To this end, an RNAi-based 
genetic screening strategy has been adopted in order to systematically uncover 
phosphatase genes that shape the TCR-dependent NF-B signal. Subsequent 
experiments were performed to characterize individual NF-B-modulating phosphatases 
with respect to physiological relevance, biological function as well as the biochemical 
mechanism underlying NF-B regulation. 
 
5.1 Design and implementation of a large-scale RNAi screen for 
phosphatases that regulate TCR-induced NF-B activity 
With the discovery of RNAi-based gene silencing it has become possible to adopt large-
scale reverse genetic screens in mammalian cells in order to identify genetic components 
and interactions underlying basic biological programs or specific signaling pathways. Cell-
based RNAi screens rely on siRNA-mediated silencing of specific target genes and 
provide an efficient and unbiased approach to systematically study loss-of-function 
phenotypes in vitro (Boutros and Ahringer, 2008; Moffat and Sabatini, 2006). 
The quality of information that can be extracted from RNAi-based high throughput 
screening (HTS) experiments critically depends on a number of general technical 
considerations. These include: (i) appropriate means to monitor and quantify RNAi 
phenotypes, (ii) efficient siRNA delivery (transfection) and gene silencing, (iii) screening 
design and procedure under large-scale conditions, and (iv) statistical methods for primary 
hit selection and post-screen analysis (Sharma and Rao, 2009). The optimization and 
adaptation of these experimental parameters was subject of the following analyses. 
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5.1.1 Generation of a novel luciferase-based NF-B activity reporter system 
The activity of specific signaling pathways can be monitored by transcriptional reporter 
assays. Luciferase-based reporter assays are particularly applicable for large-scale RNAi 
screens since they facilitate the rapid quantification of transcriptional activity under HTS 
conditions (Moffat and Sabatini, 2006). 
In order to establish a cell-based NF-B-specific screening system a novel luciferase 
reporter cassette was generated that allows for the NF-B-dependent transcription of the 
Gaussia luciferase (Gluc) reporter gene under control of the basal mouse c-fos promoter 
and eight NF-B-binding (B) sites (Arnold et al., 2001) (Fig. 5.1 A). Importantly, Gluc 
harbours a natural N-terminal secretion sequence mediating quantitative secretion of the 
nascent protein in an active form (Badr et al., 2007; Tannous et al., 2005). Unlike 
conventional luciferase reporter systems, secreted Gluc can be measured directly in the 
cell supernatant omitting the need for cell lysis and allowing for additional cell-based 
assays (Tannous, 2009). 
First, in order to examine the sensitivity and specificity of the Gaussia NF-B reporter 
system, Jurkat T cells were transiently transfected with the Gluc reporter plasmid and 
luciferase activity was determined in response to various NF-B-triggering stimuli (Fig. 
5.1). As shown in Fig. 5.1 B, treatment of Jurkat cells with the potent TCR-mimicking 
stimulus PMA/ionomycin yielded a massive induction of Gaussia reporter activity by more 
than 120-fold compared to unstimulated cells. In marked contrast, Jurkat T cells that had 
been transfected with a Gaussia plasmid lacking NF-B-specific promoter sequences 
virtually displayed no luciferase activity, both in the absence and presence of stimulating 
conditions. Furthermore, stimulation of Jurkat T cells with agonistic antibodies targeting 
the TCR or CD3/CD28 surface proteins led to a clear induction of Gluc activity, albeit to a 
significantly lesser extend compared to PMA/ionomycin-stimulated cells (Fig. 5.1 C). In 
order to directly proof the specificity of the reporter system towards NF-B activity, Jurkat 
T cells were transiently co-transfected with the Gaussia reporter plasmid in combination 
with expression vectors encoding for tagged versions of the NF-B-activating kinases 
HPK1 (Arnold et al., 2001; Brenner et al., 2005) or IKK (Delhase et al., 1999). 24 h post 
transfection luciferase activity was measured without additional stimulation. As expected, 
overexpression of HPK1 or IKK alone was already sufficient to stimulate Gaussia activity, 
whereas overexpression of a kinase inactive mutant form of HPK1 (HPK1:K46E) failed to 
induce any luciferase expression (Fig. 5.1 D). 
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Figure 5.1 | NF-B-dependent induction of Gaussia luciferase (Gluc) reporter activity in 
transiently transfected Jurkat T cells. (A) Schematic representation of the NF-B dependent 
Gluc reporter cassette (sp: secretion peptide). (B) Jurkat T cells were transiently transfected with 
the Gluc reporter plasmid or a control Gaussia plasmid lacking NF-B-targeted promoter 
sequences. Subsequently, cells were stimulated with PMA/ionomycin (PMA/Iono) and luciferase 
activity was measured. (C) Jurkat cells were transfected as in (B) and luciferase activity was 
determined in response to stimulation using anti-CD3/CD28 antibodies or an idiotype-specific anti-
TCR chain antibody (C305). (D) Jurkat cells were co-transfected with the Gluc NF-B reporter 
system and expression vectors encoding for tagged versions of HPK1 or IKK or empty vector for 
control. 24 h post transfection Gluc activity was determined and expression of exogenous proteins 
was verified by SDS-PAGE and immunoblotting. (E) Similar to (D) Jurkat cells were either co-
transfected with an expression vector encoding for IB or with empty vector for negative control. 
Subsequently, cells were stimulated with PMA/Iono for 8 h followed by measurement of luciferase 
activity and determination of IB protein levels in whole cell lysates by SDS-PAGE and 
immunoblotting. Mean and SD of luciferase activity are representative of dublicate measurements. 
 
Specific induction of NF-B-dependent Gluc reporter activity was further demonstrated in 
a reverse experiment in which co-overexpression of the bona fide NF-B inhibitor IB led 
to a marked decrease in Gluc activity in the supernatant of Jurkat T cells upon stimulation 
with PMA/ionomycin (Fig. 5.1 E). 
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In summary, the Gaussia reporter system was shown to be applicable for the detection 
and relative quantification of NF-B activity in Jurkat T cells stimulated with 
PMA/ionomycin and TCR/CD3-triggering antibodies, respectively. Moreover, based on 
transient overexpression experiments, it could be demonstrated that the Gluc reporter 
system properly responds to both specific activation and inhibition of the NF-B signaling 
pathway. 
 
5.1.2 Generation of a NF-B-dependent reporter Jurkat T cell line 
Previous results had established the Gluc reporter system as an appropriate method to 
specifically quantify NF-B activity in Jurkat T cells. So far, all luciferase assays were 
based on transient transfection of Jurkat T cells, thereby limiting the applicability of the 
Gluc reporter system for large-scale RNAi experiments due to two major technical 
constraints. (i) The sensitivity of the transiently transfected reporter system towards TCR-
induced NF-B activity turned out to be rather moderate with about 4-fold induction of 
Gluc activity compared to a more than 120-fold change in luciferase activity upon 
PMA/ionomycin simulation (Fig. 5.1 B,C). (ii) Fluctuations in cell viability and transfection 
efficiency are likely to superimpose the NF-B-dependent Gluc signal associated with a 
specific loss-of-function phenotype. 
In order to circumvent these limitations, a NF-B reporter T cell line with stable genomic 
integration of the Gluc reporter cassette was engineered (Fig. 5.2 A). This cell line was 
derived from the Jurkat variant J16-145 (Gulow et al., 2005) and is hereafter referred to as 
Gluc-J16. Therefore, stable transfectands were positively selected via antibiotic resistance 
and subcloned twice in order to obtain a genetically homogenous cell population. Several 
distinct NF-B-responsive Gluc-J16 reporter subclones were obtained (data not shown) of 
which one clone was characterized in more detail and utilized for all subsequent 
experiments. As seen in Fig. 5.2, treatment of reporter cells with anti-CD3/CD28 agonistic 
antibodies or the PKC-activating phorbolester PMA similarly caused considerable 
induction of luciferase activity by more than 100-fold (Fig. 5.2 B). Whereas the Ca2+ 
ionophore ionomycin alone was insufficient to stimulate any luciferase response, co-
treatment of Gluc-J16 cells with PMA and ionomycin synergistically induced NF-B activity, 
which is in accordance with published observations (Dolmetsch et al., 1997). The high 
sensitivity of Gluc reporter T cells to NF-B-activating reagents was further demonstrated 
by anti-TCR antibodies that induced Gluc activity up to 60-fold in a dose-dependent 
manner (Fig. 5.2 C). 
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Figure 5.2 | Gluc-J16 NF-B reporter Jurkat T cells are highly responsive to TCR and TNFR-
induced NF-B activation. (A) Gluc-J16 cells with stable genomic integration of the NF-B-
dependent Gluc reporter cassette were generated allowing for inducible secretion of Gaussia 
luciferase. (B) and (C) Reporter cells were stimulated with PMA and ionomycin (Iono), alone or in 
combination, as well as with agonistic anti-CD3/CD28 and C305 antibodies for 5 h. Luciferase was 
measured and quantified as fold induction relative to unstimulated cells. (D) Gluc-J16 cells were 
treated with increasing concentrations of anti-CD3 and anti-CD28 antibodies, alone or in 
combination for 5 h (left panel) or were co-stimulated with anti-CD3/CD28 antibodies for the 
indicated time periods (right panel). Luciferase activity is shown as fold induction. (E) Similar to (D) 
Gluc-J16 cells were stimulated with indicated concentrations of TNF for 5 h (left panel) and for 
different time periods (right panel). Subsequently, NF-B-dependent Gluc activity was determined. 
Mean and SD of luciferase activity are representative of triplicate measurements. 
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In order to assess the sensitivity and temporal dynamics of the Gluc reporter system 
towards TCR-induced NF-B activation, Gluc-J16 reporter cells were stimulated with anti-
CD3/CD28 antibodies over a broad range of concentrations and for various time periods 
(Fig. 5.2 D). Anti-CD3 or anti-CD28 antibodies alone caused only moderate luciferase 
expression with maximal inductions of about 20 to 40-fold. Gluc activation in response to 
treatment with anti-CD3 antibodies reached its plateau at already low concentrations, 
whereas the maximal anti-CD28 response required higher titers of antibody. In marked 
contrast, combined crosslinking of CD3 and CD28 surface proteins synergized to induce a 
massive luciferase response by more than 200-fold at highest concentrations (Fig. 5.2 D 
left panel). These results are consistent with the well-proven concept that integration of 
TCR and CD28-delivered signals is required for maximal NF-B activity (Kane et al., 
2002) (see 1.3.5). Moreover, luciferase induction in response to CD3/CD28 engagement 
occurred rapidly with maximal Gluc activity after already 5-6 h post stimulation. Thereafter, 
the Gluc response reached a plateau and did not significantly change over time (Fig. 5.3 
D right panel). 
In addition to TCR engagement the responsiveness of Gluc-J16 cells towards TNFR-
induced NF-B activation was investigated. Stimulation of reporter cells with increasing 
concentrations of TNF resulted in a sigmoid dose-response curve of Gluc activity 
(Fig. 5.2 E left panel). Significant luciferase activity was already detected at TNF 
concentrations as low as 0.5 ng/ml, and reached its maximum of about 120-fold induction 
at concentrations of about 50 ng/ml. As for CD3/CD28 stimulation, Gluc activity was 
rapidly induced in a dose-dependent manner with maximal luciferase expression after     
5-8 h of TNF stimulation (Fig. 5.2 E right panel). 
Collectively, these data show that the reporter T cell line Gluc-J16 reacts to a variety of 
well-established NF-B-triggering stimuli. The luciferase response is highly sensitive and 
synergistic to CD3/CD28 co-crosslinking, and proceeds in a dose-dependent manner with 
rapid kinetics. Thus, Gluc-J16 cells provide an efficient reporter system to study 
stimulation-dependent NF-B activity in T cells in vitro. 
 
5.1.3 Gluc-J16 reporter cells allow for efficient gene silencing and adopt robust 
NF-B-specific RNAi phenotypes 
RNAi screens are based on the systematic generation of loss-of-function phenotypes that 
can be assigned to specific activities and functions of genes or gene products. The 
successful implementation of such a strategy requires (i) appropriate tools for efficient 
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gene silencing and (ii) the availability of a reporter system that precisely responds to 
signal manipulation by adopting distinct and quantifiable RNAi phenotypes. 
As reported for most non-adherent mammalian cells, T cells are difficult to transfect and 
largely refractory to lipofection-based transfection methods (data not shown). Therefore, a 
siRNA transfection protocol was optimized that relies on nucleofection of Jurkat T cells 
(Brenner et al., 2009) (see 5.3.3 and 5.3.4). In a first step, it was aimed to (i) assess 
knock-down efficacies, and (ii) to test whether siRNA-mediated silencing of bona fide 
regulators of the TCR-induced NF-B signaling pathway translates into a measurable and 
robust RNAi phenotype. To this end, reporter cells were transfected with siRNA oligos 
targeting A20 and CYLD, respectively, (Fig. 5.3 A) as well as with oligos specific for 
Carma1 and RelA (Fig. 5.3 B). In addition, non-targeting control siRNA was included. 
Subsequently, cells were stimulated via the TCR with indicated concentrations of anti-
CD3/CD28 antibodies and Gluc activity was measured. 
A20 and CYLD are well-established negative regulators of NF-B activity, while Carma1 
and RelA are known to be indispensable components of the TCR-induced NF-B 
signaling apparatus (Fig. 5.3 D, see 1.3 and 1.4). Indeed, knock-down of both A20 by two 
independent siRNA oligos as well as CYLD similarly resulted in a hyperactivated 
luciferase phenotype with an increase in Gluc activity by almost 2-fold compared to 
control-transfected cells (Fig. 5.3 A left panel). Vice versa, RNAi-mediated decrease in 
Carma1 or RelA protein expression dramatically impaired TCR-dependent luciferase 
activity, irrespective of the strength of the applied stimulus (Fig. 5.3 B left panel). Specific 
knock-down of A20 and CYLD mRNA levels was verified by qPCR (Fig. 5.3 A right panel), 
and efficient silencing of Carma1 and RelA was confirmed by immunoblotting of 
endogenous proteins (Fig. 5.3 B right panel). For Carma1 three independent siRNAs were 
transfected with different knock-down efficacies. Of note, there was a tight positive 
correlation between Carma1 protein levels and Gluc activity, proving a specific and 
graded phenotypic response of the reporter system. 
Moreover, specific inhibition of NF-B activity in Gluc-J16 cells was demonstrated by 
administration of two chemical inhibitors, the NEMO binding peptide (NBP) (May et al., 
2000) (see also 1.3.1) and a synthetic NF-B activation inhibitor (Kiessling et al., 2009). 
As expected, pre-treatment of Gluc reporter cells with either inhibitor caused significant 
reduction of Gluc expression upon stimulation with anti-CD3/CD28 antibodies and 
PMA/ionomycin, respectively (Fig. 5.3 C). 
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Figure 5.3 | Manipulation of the TCR-induced NF-B pathway in Gluc-J16 reporter T cells by 
RNAi or chemical inhibitors translates into a robust phenotypic response. (A) and (B) Gluc-
J16 cells were transfected with non-targeting control siRNA (siCtrl) or with siRNA specific for A20 
(siA20#1 and #2), CYLD, Carma1 (siCarma1#1-3), and RelA, respectively. 72 h post transfection 
cells were stimulated with indicated concentrations of anti-CD3/CD28 antibodies for 5 h and Gluc 
activity was assayed. In parallel, cell viability was measured for normalization of the luciferase 
signal. Right panels: for knock-down control relative mRNA levels of A20 and CYLD were 
determined by qPCR. Carma1 and RelA protein expression was assessed by SDS-PAGE and 
immunoblotting of endogenous proteins using primary antibodies as indicated. Reprobing with anti-
Tubulin antibodies verified equal loading. (C) Gluc-J16 cells were pre-treated with 40 µM NEMO 
binding peptide (NBD) (left panel) or with indicated concentrations of an NF-B activation inhibitor 
(NF-B Inh.) (right panel) for 1 h followed by stimulation with anti-CD3/CD28 antibodies or 
PMA/ionomycin for 5 h. Luciferase activity was measured as fold induction relative to untreated 
cells. Mean and SD of Gluc assays are representative of triplicate measurements. (D) Schematic 
illustration of functional interactions between established NF-B pathway components in T cells. 
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Collectively, these data demonstrate (i) efficient siRNA-mediated gene silencing, and (ii) a 
highly sensitive and specific phenotypic response of the Gluc reporter system with respect 
to functional manipulation of TCR-induced NF-B activity. 
 
5.1.4 Optimization of RNAi screening conditions in a multi-well format 
Next, in preparation for large scale RNAi screening, both the siRNA transfection protocol 
and conditions for stimulation and measurement of reporter activity were optimized in a 
multi-well format. 
For high throughput transfection of siRNA a 96-well shuttle nucleofection system was 
used (see Material and Methods). Again, reporter cells were transfected with siRNAs 
targeting CYLD, Carma1 or RelA. In addition, siRNA specific for TNFR1 was included. For 
negative control, cells were either transfected with non-targeting siRNA or were mock-
transfected (H2O). 72 h post transfection cells were stimulated with anti-CD3/CD28 
antibodies and TNF, respectively, or were left untreated. Subsequently, luciferase was 
measured and normalized to cell numbers. To define optimal conditions for reporter 
activity, Gluc-J16 reporter cells were transfected with various amounts of siRNA and 
subjected to different concentrations of NF-B-triggering stimuli (data not shown). 
As depicted in Fig. 5.4, transfection of Carma1 and TNFR1 siRNA did not affect basal 
luciferase activity compared to control-transfected cells. By contrast, RelA-silenced cells 
exhibited reduced NF-B activity, whereas knock-down of the negative regulator CYLD 
triggered substantial NF-B activation even in the absence of stimulation (Fig. 5.4 A). 
Stimulation of control-transfected reporter cells with anti-CD3/CD28 antibodies led to an 
induction of NF-B activity by about 10-fold (Fig. 5.4 B). As expected and in line with 
preceding experiments, knock-down of Carma1 significantly attenuated the TCR-induced 
luciferase signal, and RelA silencing completely abolished Gluc expression. Conversely, 
CYLD knock-down led to a marked increase in TCR-dependent luciferase activity. Of note, 
silencing of TNFR1 did not affect the TCR-induced reporter signal, but almost completely 
prevented TNF-mediated Gluc upregulation. Analogously, the effect of Carma1 knock-
down was specific for TCR stimulation, while silencing of RelA or CYLD caused similar 
RNAi phenotypes regarding TCR and TNFR1 stimulation (Fig. 5.4 B,C). These results are 
consistent with general functions of RelA and CYLD as positive and negative regulators of 
NF-B signaling, respectively. By contrast, Carma1 and TNFR1 operate in a pathway-
specific manner (Fig. 5.4 D). 
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Figure 5.4 | The Gluc-J16 reporter system allows for RNAi-based manipulation of TCR and 
TNFR-induced NF-B signaling under large-scale screening conditions. Gluc-J16 reporter T 
cells were transiently transfected with indicated siRNAs or were mock-transfected in a 96-well 
format. 72 h post nucleofection cells were either left untreated (A) or were stimulated with anti-
CD3/CD28 antibodies (0.1 µg/ml) (B) and 20 ng/ml TNF (C), respectively. Subsequently, Gluc 
activity in the supernatant was measured and normalized to cell viability. If indicated, transfections 
were performed in two independent replicates (1) and (2). Mean and SD of single Gluc assays are 
representative of dublicate measurements. (D) Synoptic illustration of known regulators of TCR and 
TNFR1-induced NF-B signaling triggering Gluc secretion in Gluc-J16 cells (TNF-RSC: TNFR 
signaling complex). 
 
Importantly, RNAi phenotypes turned out to be highly reliable since deviations of 
normalized Gluc activity between single replicates of siRNA transfection and stimulation 
were marginal. 
In conclusion, a cell-based NF-B luciferase reporter system has been established and 
validated that is well applicable for large-scale RNAi screening strategies in order to 
identify genetic modifiers of NF-B activity in T lymphocytes. 
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5.1.5 Systematic large-scale RNAi screen identifies phosphatases that regulate 
TCR-induced NF-B activity 
In order to identify phosphatase genes that play a role in the regulation of TCR-induced 
NF-B activity a large-scale RNAi screen was performed. To this end, Gluc-J16 reporter 
cells were transfected with a subgenomic, commercially available siRNA library targeting 
298 known or putative phosphatase genes encoding for regulatory or catalytic 
phosphatase subunits. The library contained three single, independent siRNA oligos per 
gene yielding a total of 894 phosphatase-specific siRNAs. Each individual siRNA was 
arrayed in a 96-well plate format and transfected in dublicate (see also 4.3.3 and 4.3.4). 
For each transfection plate several positive and negative control siRNAs encompassing 
siRNA oligos specific for CYLD, RelA, Carma1, and TNFR1 as well as non-targeting 
siRNA and mock transfections (H2O) were included. Subsequent to the transfection 
procedure, cells were incubated for about 72 h and then subjected to different stimulation 
conditions. For this purpose, cells from each well were separated into equivalent fractions 
and were either left untreated or stimulated with anti-CD3/CD28 antibodies. In addition, 
cells were stimulated with TNF. This dual stimulation protocol allowed for the 
simultaneous and synoptical analysis of phosphatase genes involved in the regulation of 
TCR- and/or TNFR1-induced NF-B signaling. The results of the TNFR1-specific 
phosphatase screen are published elsewhere (Frey, 2009). For all stimulation assays cell 
viability was measured for normalization of the luciferase signal (see below). 
The primary RNAi screen yielded two numerical data sets either indicative of TCR-
induced luciferase activity (channel 2) or cell viability (channel 1). Statistical analysis for 
tentative hit selection was conducted using the cellHTS2 software package (Boutros et al., 
2006; Pelz et al., 2010) (for details see 4.5). In order to compensate for systematic inter- 
and intraplate variations, the raw data from each channel was normalized using the 
iterative B score normalization algorithm (Birmingham et al., 2009; Brideau et al., 2003; 
Malo et al., 2006; Ramadan et al., 2007). In addition to statistical normalization, the ratio 
of processed raw data from channel 2 and 1 was calculated for each individual well to 
obtain values for NF-B-specific Gluc activity normalized to cell viability. Subsequently, 
mean Gluc activity of two biological replicates was determined. Mean values, in turn, were 
transformed into the statistical z score for hit selection and post-screen analysis. 
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Figure 5.5 | Summary of results of primary RNAi screen for phosphatases regulating TCR-
induced NF-B signaling. (A) Quantile quantile (QQ) plot analysis of z scores from primary RNAi 
screen. z scores higher +1.5 or lower -1.5 were non-normally distributed indicating RNAi 
phenotypes of enhanced (suppressors, red ellipse) or attenuated (activators, blue ellipse) NF-B 
activity upon TCR stimulation. (B) Graph of z score distribution for individual phosphatase-specific 
siRNAs and control siRNAs. (C) In parallel to the RNAi screen, transfection and knock-down 
efficacy of control siRNA oligos targeting Carma1, RelA, or TNFR1 were determined by SDS-
PAGE and immunoblotting of endogenous proteins using primary antibodies as indicated. 
Reprobing with anti-Tubulin antibodies verified equal loading. (D) Alternatively or in addition, gene 
silencing of CYLD, RelA or TNFR1 was assessed by quantification of mRNA levels by qPCR. 
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The z score provides a statistical mean to quantify the relative strength of an RNAi 
phenotype (Birmingham et al., 2009; Malo et al., 2006; Ramadan et al., 2007). It indicates 
how many standard deviations an individual sample of interest deviates from the 
population mean and thereby allows for comparison of data from different normal 
distributions. Negative and positive z values are indicative of reduced and enhanced 
reporter activity, respectively. The identification of screening-positive RNAi phenotypes 
was based on a quantile-quantile (QQ) plot statistical analysis (Falschlehner et al., 2010; 
Ramadan et al., 2007). Using this method, one can determine thresholds for hit selection 
based on the discrimination of numerical values that are statistically normally or non-
normally distributed. z scores that are non-normally distributed convey RNAi phenotypes 
that might be associated with a real biological effect of signal perturbation. 
According to the QQ plot analysis depicted in Fig. 5.5 A RNAi phenotypes with z scores 
higher +1.5 or lower -1.5 were considered statistically significant, whereas intermediate 
values followed a statistically normal distribution (solid line). To minimize the rate of false 
positives, only those phosphatase genes were qualified as potential hits that scored with 
at least two independent siRNA oligos beyond pre-defined z score thresholds. Based on 
these criteria six phosphatase genes were identified as negative regulators of TCR-
induced NF-B activity (suppressors), whereas six phosphatases were assigned to 
positively regulate NF-B activity (activators) (data not shown and Table 5.1). Fig. 5.5 B 
shows the complete distribution of mean z values for individual siRNAs. Importantly, 
almost all positive control siRNAs, i.e. siRNA specific for CYLD, Carma1, or RelA, scored 
reproducibly demonstrating both the validity and sensitivity of primary RNAi screen and 
statistical analysis. Nonetheless, a number of phosphatases that had been previously 
implicated in regulation of TCR and NF-B signaling, such as PP2Ac, PTPN6, and 
PTPN22, were not identified as regulators of NF-B activity. Similarly, siRNAs specific for 
PTEN did not yield any significant RNAi phenotype, which is consistent with the fact that 
Jurkat T cells lack endogenous PTEN expression (Abraham and Weiss, 2004) (Table 5.1). 
Moreover, a fraction of control-transfected reporter cells was used to determine 
transfection and knock-down efficacies of CYLD, Carma1, RelA, and TNFR1-specific 
siRNA oligos on mRNA and protein levels under real-time HTS conditions. As 
demonstrated in Fig. 5.5 C and D, gene silencing was again proven to be highly efficient 
which is consistent with strong RNAi phenotypes observed for all positive controls (Fig. 
5.5 B and Frey, 2009). 
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Gene ID 
Gene 
Symbol 
Name/Description 
Mean 
z scores 
Specificity/
Function 
Negative regulators (suppressors) 
9989 PPP4R1 Protein phosphatase 4, regulatory subunit 1 3,6; 2,1; -0,5 Regulatory 
5786 PTPRA Protein tyrosine phosphatase, receptor type, A 2,56; 2,32; 0,91 Tyr 
Positive regulators (activators) 
5780 PTPN9 Protein tyrosine phosphatase, non-receptor type 9 -4,07; -4,77; -6,69 Tyr 
5798 PTPRN Protein tyrosine phosphatase, receptor type, N 
 
-1,46; -1,6; (3,34) Tyr 
Reference phosphatases 
5515 PPP2CA Protein phosphatase 2, catalytic subunit (PP2Ac), alpha isozyme 1,69; 0,82; 0,65 Ser/Thr 
5777 PTPN6 Protein tyrosine phosphatase, non-receptor type 6 (SHP1) -0,2; -0,35; -1,83  Tyr 
26191 PTPN22 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) -0,26; 1,33; 1,49 Tyr 
5728 PTEN Phosphatase and tensin homolog -0,25; -0,29; -0,38 Inositol/Tyr 
Table 5.1 | Candidate phosphatase genes associated with TCR-induced NF-B activity. Data 
represent mean z scores of biological dublicates for each three individual siRNAs per phosphatase 
gene. Only those phosphatases were considered potential hits and selected for secondary 
analyses for which two independent siRNAs scored at least twice above (suppressors) and below 
(activators) z scores of +1.5 and -1.5, respectively. Parenthesized z scores indicate outliers with 
inverse phenotypes. A number of reference phosphatases are listed that had been previously 
identified as regulators of TCR and NF-B signaling (PP2Ac, PTPN6, PTPN22), but that were not 
confirmed in the primary screen. In addition, z scores for the negative control phosphatase PTEN 
are depicted that is not expressed in Jurkat T cells. Ser/Thr indicates serine/threonine 
phosphatase; Tyr, tyrosine phosphatase; Inositol, inositol phosphatase; Regulatory; regulatory 
(non-catalytic) phosphatase subunit. 
 
 
 
 
 
 
 
 
 
 Results 96 
5.2 Genetic and biochemical characterization of PP4R1 as a 
negative regulator of NF-B activation in T lymphocytes 
Primary RNAi screening revealed several phosphatases as being potentially involved in 
negative regulation of TCR-induced NF-B activity (suppressors; Table 5.1). Among these 
tentative candidates PP4R1 (protein phosphatase 4, regulatory subunit 1), a regulatory 
subunit of the protein ser/thr phosphatase 4 holoenzyme, was identified as a potent 
negative regulator of TCR-induced NF-B activity. Validation and the detailed functional 
and biochemical characterization of PP4R1 as a negative regulator of NF-B in T 
lymphocytes were subject of the following analyses. 
 
5.2.1 Validation of PP4R1-associated RNAi phenotype by secondary NF-B activity 
assays 
In a first step, it was aimed to confirm the primary PP4R1-associated RNAi phenotype in 
order to exclude non-specific phenotypic effects potentially owing to the luciferase-based 
screening system, the large-scale screening procedure or to off-target effects of siRNA 
oligos directed against PP4R1. For this purpose, Jurkat T cells were transfected with a 
broad panel of PP4R1-targeting siRNAs, including three sequences that had been already 
used for primary library screening (siPP4R1#1-#3) and four additional independent 
siRNAs (siPP4R1#4-#7). Subsequently, cells were stimulated via the TCR or with 
PMA/ionomycin and upregulation of different NF-B target genes as well as stimulation-
dependent secretion of NF-B-regulated cytokines were examined. To correlate the 
strength of individual RNAi phenotypes with knock-down efficacies, gene silencing of 
PP4R1 was monitored on mRNA level by qPCR. 
As seen in Fig. 5.6 A, individual PP4R1-specific siRNAs differed drastically in mediating 
efficient gene silencing. Two independent sequences (siPPP4R#2 and #7) yielded best 
knock-down efficacies of about 60% mRNA reduction compared to control-transfected 
cells (Fig. 5.6 A left panel). Overall, there was a tight inverse correlation between knock-
down efficacies and phenotypic outcome as assessed by TCR-induced upregulation of 
mRNA levels of bona fide NF-B target genes (Fig. 5.6 B). Of note, knock-down efficacies 
of PP4R1 screening oligos (siPP4R1#1-#3) correlated well with z scores obtained for the 
primary screen (Table 5.1). Specific induction of NF-B target genes was controlled by 
knock-down of RelA (Fig. 5.6 A right panel and data not shown). Interestingly, residual 
PP4R1 mRNA levels of more than 60% were equally insufficient to induce any phenotypic 
response irrespective of individual siRNAs. 
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Figure 5.6 | Validation of PP4R1 as a negative regulator of TCR-induced NF-B activity. 
Jurkat T cells were transfected with 7 independent siRNAs targeting PP4R1 (siPP4R1#1-#7) of 
which oligos siPP4R1#1-#3 were already included in the siRNA screening library. In addition, these 
oligos were transfected as equimolar pool. Moreover, mock transfections (H2O) as well as 
transfections of non-targeting siRNA (negative control) or siRNA specific for RelA, Carma1, and 
CYLD, respectively, (positive controls) were included. (A) Knock-down of PP4R1 and control genes 
was assessed by qPCR (left: PP4R1 knock-down; right: knock-down of positive controls). Knock-
down of Carma1 was monitored by immunoblotting of endogenous protein. Reprobing with anti-
ERK antibodies verified equal loading.  (B) Cells were stimulated via the TCR with agonistic anti-
CD3/CD28 antibodies for 1 h or were left untreated. Subsequently, relative mRNA levels of NF-B 
target genes were analyzed by qPCR. mRNA expression is shown as fold induction compared to 
stimulated control-transfected cells. Induction of cytokine transcription was controlled using 
unstimulated control cells (data not shown). (C)-(E) A fraction of transfected cells was stimulated 
with PMA/ionomycin for 8 h and concentrations of IL-2, IL-8, and IFN, respectively, in the 
supernatants were determined by ELISA. In addition, cell numbers and viability were determined 
for normalization of cytokine secretion. Dashed lines indicate mRNA and cytokine levels of control-
transfected cells. (F) Schematic representation of PP4R1 and its potential role in the TCR-induced 
NF-B pathway. 
 
Next, it was tested whether upregulated mRNA levels of IL-2, IL-8, and interferon IFN) 
were reflected by enhanced cytokine secretion on the protein level. Therefore, a fraction 
of siRNA-transfected Jurkat T cells was subjected to PMA/ionomycin stimulation and 
cytokine levels were determined. Indeed, knock-down of PP4R1 led to a marked increase 
in stimulation-dependent secretion of all tested cytokines (Fig. 5.6 C-E). Again, enhanced 
cytokine secretion closely correlated with knock-down efficacies of single siPP4R1 oligos. 
Compared to control-transfected cells, protein secretion of IL-2, IL-8, and IFN was 
increased up to 3-fold, depending on knock-down efficacy and the type of cytokine, and 
even exceeded levels of CYLD-silenced cells for positive control. In contrast, siRNA oligos 
that yielded reduction of PP4R1 mRNA levels to less than 40% did not mediate any 
significant phenotypic changes. As expected, RelA or Carma1 knock-down drastically 
impaired cytokine secretion upon stimulation. 
In summary, these results confirm primary screening data and substantiate a role of 
PP4R1 as a negative regulator of TCR-induced NF-B activation (Fig. 5.6 F). Efficient 
knock-down of PP4R1 both by screening and independent siRNA oligos resulted in 
enhanced stimulation-dependent upregulation of NF-B target genes and cytokine 
secretion. Thereby, phenotypic outcome and PP4R1 mRNA levels demonstrated a tight 
inverse correlation. 
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5.2.2 Knock-down of PP4R1 protein results in enhanced NF-B reporter activity 
upon TCR, PMA, and TNFR1 stimulation 
Previous experiments demonstrated a tight inverse correlation between PP4R1 mRNA 
levels and enhanced NF-B signaling activity in Jurkat T cells. Next, it was examined 
whether the PP4R1-specific RNAi phenotype similarly correlated with reduced PP4R1 
expression on the protein level. Therefore, Gluc-J16 reporter cells were transfected with 
control siRNA as well as with four independent siPP4R1 oligos that had been shown 
before to be most potent in gene silencing (siPP4R1#2, #3, #4, and #7). Subsequently, 
cells were stimulated via the TCR and NF-B-dependent luciferase activity was 
determined. In addition, cells were lysed and knock-down of PP4R1 was assessed by 
SDS-PAGE and immunoblotting of endogenous proteins. Consistent with preceding 
experiments, knock-down efficacies of individual PP4R1 siRNAs differed considerably (Fig. 
5.7 A). As seen for mRNA levels, two independent siPP4R1 oligos (siPP4R1#3 and #7) 
were shown to be most efficient in gene silencing and similarly blocked PP4R1 protein 
expression by about 80% (Fig. 5.7 right panel). Moreover, there was again a remarkable 
inverse correlation between PP4R1 protein quantities and TCR-dependent Gluc 
expression with a maximal increase in NF-B reporter activity by almost 2-fold. 
In extension of the previous experiment it was tested next whether the effect of PP4R1 
silencing on NF-B activity was dependent on the strength of the TCR stimulus. To this 
end, reporter cells were transfected with control siRNA or siRNA specific for PP4R1, 
CYLD, and RelA, respectively, followed by TCR stimulation using a broad range of 
concentrations of anti-CD3/CD28 agonistic antibodies. Again, efficient knock-down of 
PP4R1 was confirmed both by immunoblotting (Fig. 5.7 B upper panel) and qPCR (Fig. 
5.7 B lower panel). Moreover, knock-down of CYLD and RelA was verified by qPCR (Fig. 
5.7 B lower panel). Consistent with previous results, PP4R1-silenced cells displayed 
highly increased NF-B reporter activity irrespective of the strength of TCR stimulation 
(Fig. 5.7 C). The increase in NF-B activity by about 2-fold was similar to that of CYLD-
transfected cells, whereas, as expected, RelA knock-down almost completely blunted 
Gluc expression. Interestingly, lack of PP4R1 expression in Jurkat T cells did not affect 
basal NF-B, but also enhanced NF-B activation in response to treatment with PMA, a 
strong PKC-activating compound, and TNFR1 stimulation by recombinant TNF (Fig. 5.7 
D). As for TCR stimulation, the effect of NF-B hyperactivation upon PMA or TNF 
treatment was well-pronounced and similar to that of CYLD-silenced cells. 
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Figure 5.7 | PP4R1 negatively regulates NF-B activation triggered by TCR, PMA, or TNFR1 
stimulation of Jurkat T cells. (A) Gluc-J16 reporter cells were transfected with four independent 
siRNA oligos specific for PP4R1 (siPP4R1) or non-targeting control siRNA. Subsequently, cells 
were stimulated with anti-CD3/CD28 antibodies for 5 h or were left untreated. Normalized NF-B-
dependent luciferase activity was determined as described before. PP4R1 knock-down was 
assessed by SDS-PAGE of endogenous proteins and immunoblotting using primary antibodies as 
indicated (left panel). Reprobing with anti-Tubulin antibodies verified equal loading. In addition, 
normalized PP4R1 expression relative to control-transfected cells was quantified (right panel).    
(B-D) Cells were transfected as in (A), including siRNAs for PP4R1, CYLD, or RelA. For negative 
control cells were transfected with non-targeting siRNA in two independent replicates (siCtrl1+2). 
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For knock-down control, relative mRNA levels of PP4R1, CYLD, and RelA were determined by 
qPCR. Gene expression is shown as percent of negative control (B, lower panel). Carma1 
expression was assessed by SDS-PAGE and immunoblotting of endogenous proteins using 
primary antibodies as indicated (B, upper panel). (C) Cells were stimulated via the TCR with 
indicated concentrations of anti-CD3/CD28 antibodies for 5 h or were left untreated (D). In addition, 
cells were treated with indicated concentrations of PMA or were stimulated with 20 ng/ml TNFfor 
5 h. Normalized luciferase activity was determined as described before. (E) Schematic illustration 
of TCR and TNFR1-induced NF-B signaling and its negative regulation by PP4R1. 
 
In summary, these data demonstrate proper expression and efficient siRNA-mediated 
knock-down of endogenous PP4R1 protein in Jurkat T cells and further confirm a role of 
PP4R1 as negative regulator of TCR-induced NF-B activation. Importantly, PP4R1 
function was not selectively assigned to TCR-induced signaling, but was also shown to be 
involved in negative regulation of NF-B downstream of PKC and TNFR1 activation (Fig. 
5.7 E). However, basal activity of NF-B did not significantly change in transiently silenced 
cells. Hence, PP4R1 seems to be a shared signaling modulator in activation-induced 
canonical NF-B signaling. 
 
5.2.3 Transient and stable knock-down of PP4R1 results in increased TCR-induced 
upregulation of NF-B target genes and cytokine secretion 
Preceding experiments have shown enhanced upregulation of NF-B target genes upon 
TCR stimulation as a result of PP4R1 deficiency in Jurkat T cells. However, so far cells 
were only stimulated for one hour which does not cover the whole temporal dynamics of 
TCR-induced gene regulation. Therefore, it was aimed to gain a more extended and 
detailed picture of the kinetics of TCR-induced NF-B dependent gene expression in 
PP4R1-silenced vs. non-silenced T cells. 
To this end, Jurkat T cells were again transiently transfected with two independent siRNAs 
targeting PP4R1 or control siRNA. Subsequently, cells were stimulated via the TCR for 
various time periods and mRNA levels of a panel of bona fide NF-B target genes, such 
as IL-2, IL-8, A20, and IB, were determined by qPCR. As shown in Fig. 5.8 A, maximal 
mRNA induction of all tested genes was detected after about 1.5 - 2 h of TCR stimulation. 
However, in PP4R1-silenced cells mRNA upregulation was dramatically increased with   
2-3-fold higher levels for the cytokines IL-2 and IL-8 (upper panels). Enhanced mRNA 
upregulation was also seen for A20 and IB (lower panels). The increase in mRNA 
levels both applied to the kinetics of upregulation and the maximal magnitude of gene 
expression. Of note, this effect was transient since increased mRNA expression was not 
significantly prolonged in PP4R1-silenced cells, but rapidly declined to basal levels at later  
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Figure 5.8 | Transient and stable PP4R1 silencing in Jurkat T cells causes enhanced 
stimulation-dependent upregulation of NF-B target genes and cytokine secretion. (A) Jurkat 
T cells were transiently transfected with siRNAs specific for PP4R1 or non-targeting siRNA. 72 h 
post transfection cells were stimulated via the TCR for different time periods as indicated. 
Subsequently, mRNA levels of NF-B target genes, such as IL-2 and IL-8 (upper panel) as well as 
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A20 and IB (lower panel) were assessed by qPCR. (B) Jurkat T cells were retrovirally 
transduced with five independent shRNAs targeting PP4R1 or non-targeting control shRNA. Stably 
transduced cells were selected via antibiotic resistance and levels of endogenous PP4R1 and 
PP4c proteins were determined by SDS-PAGE of whole cell lysates and immunoblotting using 
primary antibodies as indicated. Reprobing with anti-Tubulin antibodies verified equal loading. (C-
E) shRNA-expressing Jurkat T cells were stimulated with indicated concentrations of anti-
CD3/CD28 antibodies overnight or were treated with PMA/ionomycin for 8 h. Subsequently, levels 
of secreted IL-2, IL-8, and IFN were measured by ELISA. In addition, cell numbers and viability 
were determined for normalization. 
 
time points. Moreover, no significant changes in basal transcription of NF-B target genes 
were observed. 
As yet, all functional analyses were based on transient siRNA-mediated knock-down of 
PP4R1 in Jurkat T cells. To achieve more efficient and sustained PP4R1 gene silencing 
and to further confirm the PP4R1 RNAi phenotype by an independent knock-down 
approach, Jurkat T cells were lentivirally transduced with vectors encoding for small 
hairpin RNA (shRNA) against PP4R1. Five independent shPP4R1-transduced Jurkat 
clones were obtained of which two displayed most efficient knock-down of endogenous 
protein and were selected for further analyses (Fig. 5.8 B). To corroborate and 
complement previous data, stably PP4R1-silenced cells were stimulated via the TCR with 
indicated concentrations of agonistic antibodies or were left unstimulated. In addition, a 
fraction of cells was again subjected to stimulation with PMA/ionomcyin. Subsequently, 
levels of secreted cytokines IL-2, IL-8, and IFN were measured by ELISA. Consistent 
with previous findings, stable knock-down of PP4R1 led to a substantial increase in 
cytokine secretion, both in response to TCR stimulation and treatment with 
PMA/ionomcyin (Fig. 5.8 C-E). With respect to TCR-stimulated cells, levels of secreted  
IL-2 and IL-8 were almost 3-4-fold increased compared to controls, and secretion of IFN 
was twice as high. In accordance with augmented cytokine secretion, PP4R1-silenced 
Jurkat T cells displayed enhanced TCR-dependent induction of a variety of NF-B target 
genes encoding for IL-8, TNF, the T cell activation marker CD69, or the anti-apoptotic 
Bcl2-family member Bcl2A1 (data not shown). 
In summary, these data demonstrate that NF-B hyperactivation in T cells lacking PP4R1 
expression is reflected by enhanced transcriptional upregulation and secretion of NF-B-
responsive genes and cytokines, respectively. In contrast to transient siRNA-mediated 
gene silencing, sustained deficiency for PP4R1 by shRNA transduction was shown to 
result in enhanced basal cytokine secretion. These findings provide evidence for a critical 
physiological role of PP4R1 as a negative regulator of T cell activation in vitro. 
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5.2.4 Overexpression of PP4R1 selectively attenuates TCR-induced NF-B, but not 
AP-1 activation 
The functional importance of PP4R1 in negative regulation of NF-B signaling and T cell 
activation had been systematically defined by a number of different loss-of-function 
studies. In complementation of these data, it was tested next in a reverse approach 
whether overexpression of PP4R1 hampers TCR-induced NF-B activation.  
Therefore, Jurkat T cells were transiently transfected with an expression plasmid encoding 
for haemagglutinin (HA)-tagged human PP4R1 or with empty vector for control (Mock). 
Cells were stimulated with increasing amounts of agonistic antibodies, and NF-B activity 
was determined using a co-transfected NF-B luciferase reporter system. As shown in Fig. 
5.9 A, Jurkat T cells readily expressed exogenous HA-tagged PP4R1 protein upon 
transient transfection. As expected, overexpression of PP4R1 attenuated NF-B activation 
in response to TCR stimulation (Fig. 5.9 B, left panel) or PMA/ionomycin treatment (Fig. 
5.9 B, right panel). Moreover, inhibition of TCR stimulation-dependent NF-B reporter 
activity by PP4R1 occurred in a dose-dependent manner and was already seen for low 
quantities of overexpressed exogenous protein (Fig. 5.9 C). Intriguingly, PP4R1 
overexpression specifically inhibited NF-B, but had no significant impact on TCR- or 
PMA/ionomycin-induced activity of the transcription factor AP-1, as assessed by 
analogous co-transfection of an AP-1-specific reporter system (Fig. 5.9 D). 
PP4R1-mediated inhibition of NF-B signaling was further demonstrated by analysis of 
TCR-induced surface expression of the NF-B-dependent T cell activation marker CD69. 
For this purpose, exogenous PP4R1 and GFP were co-overexpressed in Jurkat T cells, 
followed by analysis of CD69 surface expression in response to TCR stimulation using 
flow cytometry. Simultanous expression of GFP in PP4R1-overexpressing cells allowed 
for the indirect tracing of cells with different expression levels of exogenous PP4R1 
protein. Indeed, overexpression of PP4R1 reduced CD69 cell surface levels by more than 
40% compared to control-transfected cells (Fig. 5.9 E). Similarly to NF-B reporter activity, 
increasing expression levels of exogenous PP4R1, as assessed by GFP positivity, caused 
a more profound effect of inhibition. 
In concert, these data show that forced overexpression of PP4R1 attenuates TCR-
induced NF-B-activation and, therefore, corroborate preceding loss-of-function data. 
Moreover, these results provide the first hint that PP4R1 is specifically involved in 
negative regulation of NF-B signaling, but does not control AP-1 activity. 
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Figure 5.9 | Overexpression of PP4R1 in Jurkat T cells impedes T cell activation by 
specifically counteracting NF-B, but not AP-1 signaling. (A) Jurkat T cells were transiently 
transfected with an expression plasmid encoding for HA-tagged PP4R1 or empty vector (Mock) for 
control. In addition, cells were co-transfected either with a NF-B (B) or AP-1 (D) specific luciferase 
reporter system. 36 h post transfection cells were lysed and expression of exogenous PP4R1 was 
assessed by SDS-PAGE and immunoblotting. Reprobing with anti-Tubulin antibodies verified equal 
loading. (B) NF-B luciferase assay of Jurkat T cells transiently overexpressing HA:PP4R1, and 
stimulated with indicated concentrations of anti-CD3/CD28 antibodies or treated with 
PMA/ionomycin for 8 h. (C) Jurkat T cells were transfected as in (A), but with increasing 
concentrations of cDNA encoding for HA:PP4R1 or empty vector for control. NF-B-dependent 
luciferase activity was determined as in (B). NF-B activity of PP4R1-expressing cells was 
normalized to that of mock-transfected cells. SD for mock-transfected cells refers to the geometric 
mean of SDs of individual mock transfections with different cDNA concentrations. For expression 
control, whole cell lysates were subjected to SDS-PAGE followed by immunoblotting of exogenous 
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protein. Reprobing with anti-Tubulin antibodies verified equal loading. (D) AP-1 luciferase assay of 
Jurkat T cells analogous to that in (B). Mean and SD of all luciferase assays are representative of 
dublicate measurements. (E) Jurkat T cells were transiently transfected with cDNA encoding for 
PP4R1 or empty vector together with an expression vector encoding for GFP. 36 h post 
transfection, cells were stimulated via the TCR for 8 h and CD69 surface expression of GFP-
positive cells was determined by flow cytometry. Mean fluorescence intensity (MFI) was 
determined for transfected cells with low, intermediate (int.), and high GFP co-overexpression (left 
panel). MFI of PP4R1-expressing cells was normalized to that of mock-transfected cells (right 
panel). Mean and SD are representative of triplicate measurements. 
 
5.2.5 PP4R1 is upregulated in expanded primary human T cells and affects NF-B 
activity and TCR-induced cytokine secretion in vitro 
So far, the functional importance of PP4R1 had been extensively documented for the 
human T cell line Jurkat, but expression and function of PP4R1 in non-malignant primary 
human T lymphocytes remained elusive. In order to address this question, primary human 
T cells were isolated, stimulated, and expanded ex vivo over the course of 8 days in the 
presence of IL-2. To assess PP4R1 protein expression, cells were lysed before (day 0) 
and at different time points post stimulation (day 1-8). Subsequently, lysates were 
subjected to SDS-PAGE and expression of endogenous proteins was assessed by 
immunoblotting. Surprisingly, endogenous PP4R1 protein was not detectable in resting T 
cells (Fig. 5 A). At about day 2 post stimulation, PP4R1 expression became visible and 
continuously increased in the course of expansion. Compared to its rather modest 
expression at day 2, PP4R1 protein levels were induced by more than 30-fold in T cells at 
day 8 of in vitro culture (Fig. 5.10 A, right panel). In marked contrast, the catalytic subunit 
of the PP4 holoenzyme (PP4c) was already well-expressed in unstimulated T cells and its 
expression level did not significantly change over time. 
To further elucidate whether the differential expression of PP4R1 in resting vs. activated T 
cells is a generic or gene-specific phenomenon, expression profiles of two different protein 
phosphatase catalytic subunits, PP2Ac and PP1c, that do not form part of the PP4 
holoenzyme were examined. Akin to PP4c, PP1c expression remained unchanged upon T 
cell activation and expansion, whereas expression of the PP2A catalytic subunit PP2Ac 
was strongly induced upon T cell activation (Fig. 5.10 A). In contrast to PP4R1 however, 
maximal protein levels were detected earlier and thereafter remained constant. 
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Figure 5.10 | PP4R1 suppresses TCR-induced cytokine secretion and NF-B signaling in 
pre-stimulated primary human T lymphocytes in vitro. (A) Primary human T lymphocytes were 
isolated from peripheral blood, stimulated with PHA, and expanded in the presence of IL-2. Before 
and during in vitro expansion whole cell lysates of T lymphocytes were collected and subjected to 
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SDS-PAGE. Endogenous proteins were detected by immunoblotting using primary antibodies as 
indicated (left panel). PP4R1 and PP4c protein levels were quantified using -actin levels for 
normalization. Relative PP4c and PP4R1 expression is shown as fold induction relative to levels of 
day 2 of in vitro expansion (right panel). (B) Pre-stimulated peripheral blood T cells were 
transfected with indicated siRNAs at day 4 of in vitro expansion. 72 h post transfection, cells were 
lysed and PP4R1 and PP4c protein levels were determined by SDS-PAGE and immunoblotting. 
Reprobing with anti-Tubulin antibodies verified equal loading. (C-E) Transiently silenced cells were 
stimulated with indicated concentrations of anti-CD3/CD28 antibodies and secretion of IL-2, TNF, 
and IFN was measured by ELISA. (F) CD4+ primary peripheral blood T cells were isolated and 
expanded in vitro by TCR stimulation. At day 3 of in vitro expansion cells were co-transfected with 
cDNA encoding for PP4R1 or empty vector (Mock) for control together with a NF-B-specific 
luciferase reporter system. 24 h post transfection cells were stimulated as indicated and NF-B-
dependent luciferase was measured. Results are shown as fold induction relative to untreated 
control-transfected cells. Mean and SD of luciferase activity are representative of triplicate 
measurements (right panel). To confirm PP4R1 overexpression a fraction of cells was lysed, 
followed by SDS-PAGE of whole cell lysates and immunoblotting. Reprobing with anti-Tubulin 
antibodies verified equal loading. (N.D.: not detectable). 
 
The differential regulation of PP4R1 protein expression in primary human T lymphocytes 
in vitro raised the question whether, analogous to Jurkat T cells, PP4R1 plays a role as 
negative regulator of NF-B specifically in pre-activated, expanded T cells. To answer this 
question, primary human T lymphocytes were isolated and expanded in vitro as described 
before. At day 4 post stimulation cells were transfected with siRNA specific for PP4R1 or 
non-targeting control siRNA. Subsequently, cells were stimulated with increasing 
concentrations of anti-CD3/CD28 antibodies or were left unstimulated. T cell activation 
was monitored based on measurement of cytokine secretion by ELISA. Knock-down of 
endogenous PP4R1 protein by two independent siPP4R1 oligos was confirmed by SDS-
PAGE and immunoblotting (Fig. 5.10 B). As already seen for Jurkat T cells, transient 
siRNA-mediated down-regulation of PP4R1 protein in expanded primary T lymphocytes 
substantially augmented production of the NF-B-regulated cytokines IL-2, TNF, and 
IFN in response to anti-CD3/CD28 treatment (Fig. 5.10 C-E). Moreover, basal IL-2 
secretion was already markedly increased in PP4R1-silenced cells indicative of enhanced 
T cell activation and expansion even without TCR re-stimulation. As seen before, cytokine 
secretion and PP4R1 protein levels showed a tight inverse correlation. 
To directly confirm negative regulation of NF-B activity, expanded primary human T cells 
at day 3 of in vitro culture were transfected with a PP4R1 expression plasmid or empty 
vector for negative control. Subsequently, cells were stimulated by treatment with anti-
CD3/CD28 antibodies and PMA/ionomycin, respectively, or were left untreated. NF-B 
activity was measured using a co-transfected NF-B-dependent luciferase system. Pre-
stimulated expanded T lymphocytes displayed already high basal NF-B activity that was 
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further increased by up to 2-fold in response to stimulation (Fig. 5.10 F). However, 
overexpression of PP4R1 considerably inhibited basal NF-B activity compared to control-
transfected cells and almost completely prevented further luciferase upregulation upon 
TCR stimulation or PMA/ionomycin treatment. 
Collectively, these data suggest that PP4R1 counterbalances activation of pre-stimulated 
primary human T cells by negatively regulating NF-B signaling. Upregulated PP4R1 
expression in expanded pre-stimulated T lymphocytes implies a mechanism of activation-
induced negative feedback that limits NF-B signaling upon TCR re-stimulation. 
 
5.2.6 PP4R1 physically interacts with the IKK complex in a TCR stimulation-
dependent manner 
So far, genetic and functional analyses had clearly established an important role for 
PP4R1 in regulating NF-B activation in Jurkat T cells and primary human T lymphocytes. 
However, the precise molecular mechanism governing PP4R1-dependent NF-B 
modulation as well as potential effector molecules targeted by PP4R1 remained elusive. 
The fact that PP4R1 does not only impinge upon TCR-induced NF-B activity but similarly 
affects PKC-driven and TNFR-mediated NF-B signaling gave rise to the assumption that 
PP4R1 operates on a shared level within the canonical pathway downstream of PKC and 
the TNFR signaling complex (TNF-RSC) (see Fig. 5.7 E). A central point of convergence 
in canonical signaling is the IKK complex. 
To test for a potential physical interaction between PP4R1 and individual components of 
the IKK complex, HA-tagged PP4R1 was transiently overexpressed in HEK293T cells 
alone or in combination with FLAG-tagged versions of IKK, IKK, and IKK (NEMO), 
respectively. Exogenous proteins were subjected to immunoprecipitation using either anti-
FLAG antibodies (Fig. 5.11 A) or anti-HA antibodies (Fig. 5.11 B). Subsequently, immune 
complexes were resolved by SDS-PAGE, and (co-)immunoprecipitated proteins were 
detected by immunoblotting using anti-HA or anti-FLAG antibodies. Indeed, PP4R1 was 
demonstrated to be a potent interaction partner of IKK as revealed both by anti-FLAG 
and anti-HA co-immunoprecipitation experiments (Fig. 5.11 A,B). Of note, the interaction 
between exogenous PP4R1 and IKK seemed to be highly specific. PP4R1 did not 
interact with NEMO and only showed a weak interaction with IKK in anti-HA immuno-
precipitations (Fig. 5.11 B). IKK is an integral part of the heterotrimeric IKK complex, but 
also serves separate functions, e.g. by mediating non-canonical NF-B activation or by 
controlling nuclear NF-B activity (Ghosh and Hayden, 2008; Senftleben et al., 2001). 
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Therefore, it is conceivable that PP4R1 specifically interacts with IKK to be recruited to 
the endogenous IKK complex. Alternatively, the PP4R1-IKK interaction might occur 
independently of additional IKK compounds and IKK complex formation. So far, interaction 
data were based on concomitant overexpression of exogenous proteins in HEK293T cells, 
thereby limiting conclusions regarding the specificity of possible interactions under 
physiological conditions in T cells. 
To test for an endogenous interaction between PP4R1 and the IKK complex, Jurkat T 
cells (Fig. 5.11 C) as well as expanded primary human T lymphocytes at day 7 of culture 
(Fig. 5.11 D) were stimulated with anti-CD3/CD28 antibodies for various time periods. 
Cells were lysed and the IKK complex was immunoprecipitated using anti-NEMO 
antibodies. The immunoprecipitated material was then subjected to SDS-PAGE and 
endogenous proteins were detected by immunoblotting. Both in Jurkat T cells and in 
primary human T cells a small fraction of PP4R1 pre-associated with the endogenous IKK 
complex under resting conditions (Fig. 5.11 C,D). Importantly, TCR engagement led to a 
transient, but marked increase in IKK-associated PP4R1. Thereby, enhanced association 
of PP4R1 with the IKK complex became apparent at later time points and peaked at about 
45-90 minutes of stimulation. Proper assembly and pull-down of the endogenous IKK 
complex was confirmed by immunoblotting of IKK and IKK, respectively. In addition, T 
cell activation was monitored by determining levels of phospho-ERK in whole cell lysates. 
In summary, these data demonstrate a physical interaction between PP4R1 and the IKK 
complex in T cells. This association is regulated and transiently increased in a TCR 
stimulation-dependent manner and presumably involves specific binding of PP4R1 to 
IKK. Delayed recruitment of PP4R1 to the IKK complex upon TCR triggering suggests a 
role of PP4R1 in activation-induced termination of IKK activity. 
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Figure 5.11 | PP4R1 interacts with IKK and associates with the IKK complex in a TCR 
stimulation-dependent manner. (A) and (B) HA-tagged PP4R1 was overexpressed in HEK293T 
cells alone or in combination with FLAG-tagged versions of IKK, IKK, or NEMO. Cells were lysed 
and exogenous proteins were immunoprecipitated using anti-FLAG (A) or anti-HA (B) antibodies. 
Whole cell lysates and immune complexes were resolved by SDS-PAGE and (co)immuno-
precipitated proteins were detected by immunoblotting using primary antibodies as indicated. (C,D) 
Jurkat T cells (C) or primary human day 6 T lymphocytes (D) were stimulated with 1.0 µg/ml of anti-
CD3/CD28 antibodies for indicated time periods. Cells were lysed and the IKK complex was 
immunoprecipitated using anti-NEMO antibodies. A non-precipitating antibody was used to control 
for specificity. Whole cell lysates and immune complexes were resolved by SDS-PAGE followed by 
immunoblotting using primary antibodies as indicated. Reprobing with anti-phospho-ERK 
antibodies verified proper stimulation of cells. Results are representative of at least three 
independent experiments. (Filled and open arrowheads indicate specific proteins and IgGH, 
respectively). 
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5.2.7 PP4R1 and the catalytic subunit PP4c constitutively interact with each other 
and pre-associate with the IKK complex 
The stimulation-dependent interaction of PP4R1 with the IKK complex provided a first hint 
for the molecular basis of PP4R1-mediated NF-B inhibition. However, PP4R1 itself does 
not contain intrinsic enzymatic activity, rendering its precise molecular function elusive. 
Instead, several earlier reports indicated – based on proteomics approaches – that PP4R1 
forms a stable complex with the PP4 catalytic subunit PP4c and thereby might function as 
a regulatory subunit of the PP4 holoenzyme (Bennett et al., 2006; Ewing et al., 2007; 
Gingras et al., 2005; Kloeker and Wadzinski, 1999). 
To confirm the PP4R1-PP4c interaction, HEK293T cells were transiently transfected with 
expression plasmids encoding for HA-tagged PP4R1 or FLAG-tagged PP4c, either alone 
or in combination. Subsequently, overexpressed proteins were specifically pulled-down 
using anti-HA or anti-FLAG antibodies. Immune complexes were resolved by SDS-PAGE 
and (co-)immunoprecipated exogenous proteins were probed by anti-FLAG and anti-HA 
antibodies, respectively. In accordance with published observations, a strong interaction 
between exogenous PP4R1 and PP4c proteins was demonstrated both by anti-FLAG 
immunoprecipitations and, vice versa, anti-HA pull-down (Fig. 5.12 A). 
To confirm an association of endogenous proteins and to further test whether this 
interaction is subject to regulation by TCR-stimulation, Jurkat T cells (Fig. 5.12 B) as well 
as primary human T cells at day 6 of in vitro culture (Fig. 5.12 C) were stimulated with 
anti-CD3/CD28 antibodies for different time points, followed by cell lysis and 
immunoprecipitation of endogenous PP4R1 protein using anti-PP4R1 antibodies. 
Endogenous proteins were detected by immunoblotting. PP4R1 and PP4c were shown to 
constitutively interact with each other irrespective of TCR stimulation (Fig. 5.12 B,C). In 
contrast to binding of PP4R1 to the IKK complex, there was a strong pre-association of 
both proteins that was maintained in stimulated cells. Of note, the PP4R1-PP4c 
interaction seemed to be highly specific since PP2Ac, a structurally related catalytic 
subunit of the PP2A holoenzyme (Bennett et al., 2006), did not co-purify with endogenous 
PP4R1 protein in Jurkat T cells, neither before nor post TCR stimulation (Fig. 5.12 C). 
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Figure 5.12 | PP4R1 and PP4c form a stable complex in T lymphocytes that pre-associates 
with the IKK complex in T lymphocytes. (A) HA-tagged PP4R1 and PP4c were overexpressed 
in HEK293T cells alone or in combination. Exogenous proteins were pulled-down either by anti-
FLAG or by anti-HA antibodies. Whole cell lysates and immune complexes were resolved by SDS-
PAGE and (co-)immunoprecipitated proteins were detected by immunoblotting using primary 
antibodies as indicated. (B,C) Primary human day 6 T cells (B) or Jurkat T cells (C) were 
stimulated with 1.0 µg/ml of anti-CD3/CD28 antibodies and endogenous PP4R1 was 
immunoprecipitated using anti-PP4R1 antibodies. A non-precipitating antibody was used to control 
for specificity. Whole cell lysates and immune complexes were resolved by SDS-PAGE and       
(co-)immunoprecipitated proteins were detected by immunoblotting using primary antibodies as 
indicated. Reprobing with anti-phospho-ERK antibodies confirmed T cell stimulation. (D) Resting 
Jurkat T cells were lysed and the IKK complex was immunoprecipitated by anti-NEMO antibodies. 
A non-precipitating antibody was used to control for specificity. (Co)immunoprecipitated proteins 
were detected by SDS-PAGE and immunoblotting using primary antibodies as indicated. Whole 
cell lysates were included to confirm equal input. (E) Schematic representation of PP4R1 domain 
structure and HA-tagged deletion mutants. Light grey boxes indicate regions with homology to the 
A subunit of PP2A. Dark grey boxes represent in silico predicted “heat” repeats (upper panel). Full 
length HA-tagged PP4R1 (wt) or different PP4R1 deletion mutants were overexpressed in 
HEK293T cells. In addition, HA-tagged PP4c was overexpressed. Exogenous proteins were 
immunoprecipitated by anti-HA antibodies from whole cell lysates. Immune complexes and lysates 
were subjected to SDS-PAGE followed by immunoblotting using primary antibodies as indicated. 
(F) HA-tagged PP4R1 and FLAG-tagged versions of IKK, IKK, and PP4c, respectively, were in 
vitro translated in the presence of radioactively labeled 35S-methionine. In vitro translated 
HA:PP4R1 protein was recombined with anti-FLAG in vitro translates followed by anti-FLAG 
immunoprecipitations. (Co-)immunoprecipitated recombinant proteins were detected by autoradio-
graphy. In addition, equal input of in vitro translated proteins was confirmed. (Filled and open 
arrowheads indicate specific proteins and IgGH, or IgGL respectively. For anti-PP4c immunoblotting 
open arrowheads indicate endogenous protein). 
 
Given the strong complex formation between PP4R1 and PP4c it was next examined 
whether PP4c, analogously to PP4R1, associates with the IKK complex in T cells. To this 
end, the IKK complex was again immunoprecipitated from lysates of resting Jurkat T cells 
using anti-NEMO antibodies. Immune complexes were resolved by SDS-PAGE and the 
presence of purified proteins was analyzed by immunoblotting. Indeed, PP4c was found to 
pre-associate with the IKK complex in T cells prior to stimulation, as observed for PP4R1 
(Fig. 5.12 D). Consistent with this finding, PP4c was shown to interact with IKK upon 
overexpression in HEK293T cells (data not shown). 
PP4R1 harbours two N-terminal and C-terminal regions, respectively, that display 
homology to the A subunit of PP2A (Chen et al., 2008; Kloeker and Wadzinski, 1999). In 
addition, the N-terminal domain was predicted in silico to contain two so-called “heat” 
repeats – specific motifs that have been proven to be involved in protein protein 
interactions (Andrade and Bork, 1995; Groves et al., 1999) (Fig. 5.12 E). To test for 
minimal structural requirements underlying PP4R1-PP4c complex formation, a series of 
HA-tagged PP4R1 deletion mutants was cloned and overexpressed in HEK293T cells. In 
addition, full-length HA:PP4R1 was overexpressed for positive control. Exogenous 
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proteins were pulled-down by anti-HA immunoprecipitation and co-association of 
endogenous PP4c was analyzed by SDS-PAGE and anti-PP4c immunoblotting. To control 
for specificity, HEK293T lysates containing overexpressed HA-tagged PP4c were included. 
Surprisingly, none of the PP4R1 deletion mutants showed interaction with PP4c, while the 
full-length protein mediated again strong co-pull-down of endogenous PP4c (Fig. 5.12 E). 
This result indicated that separated or already partially disrupted PP2A homology regions 
within PP4R1 are insufficient for PP4c association implying the involvement of multiple 
PP4R1 domains in PP4c binding. 
To test whether the dual interactions of PP4R1 with IKK on the one hand, and with PP4c 
on the other hand occur in a direct manner, HA-tagged PP4R1 as well as FLAG-tagged 
versions of IKK, IKK, or PP4c were recombinantly expressed and radioactively labeled 
using an in vitro translation system in the presence of 35S-methionine. Subsequently, 
recombinant HA-tagged PP4R1 was immunoprecipitated from in vitro translates 
containing either PP4R1 alone or in combination with individual and separately expressed 
FLAG-tagged proteins. Immunoprecipitation of proteins was detected by autoradiography. 
Again, PP4R1 specifically interacted with FLAG-IKK, but not with FLAG-IKK(Fig. 5.12 
F). Furthermore, PP4R1 was confirmed as a ligand of recombinant PP4c in vitro. 
In conclusion, these data reveal stable and TCR stimulation-independent complex 
formation between PP4R1 and PP4c. Most likely, PP4c is co-recruited to the IKK complex 
via binding to PP4R1, probably involving direct interactions between PP4R1 and IKK and 
PP4c, respectively. 
 
5.2.8 PP4R1 negatively regulates TCR-induced IKK signaling and kinase activity 
The observation that TCR stimulation is followed by a transient increase in IKK-associated 
PP4R1 suggested that PP4R1 directly impedes IKK activation and thereby negatively 
regulates NF-B signaling in T lymphocytes. To test this hypothesis and to further analyze 
at which stage PP4R1 interferes with the NF-B signaling cascade, the impact of PP4R1 
deficiency or overexpression on IKK signaling was elucidated in detail. 
First, Jurkat T cells were transiently transfected with siRNA specific for PP4R1 or control 
siRNA. 72 h post transfection cells were stimulated by treatment with PMA/ionomycin for 
various time periods and the IKK complex was immunoprecipitated from whole cell lysates 
using anti-NEMO antibodies. To directly measure IKK activity, a fraction of anti-NEMO 
immunoprecipitates was subjected to an in vitro kinase assay using recombinant 
GST:IB as a substrate. In addition, an equivalent portion of the immunoprecipitated 
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material was subjected to SDS-PAGE and proper co-purification as well as the 
phosphorylation status of IKK and IKK was determined by immunoblotting. As seen in 
Fig. 5.13 A, siRNA-mediated knock-down of PP4R1 caused a marked increase in 
stimulation-dependent IKK activity as visualized by IB and IKK autoradiography. 
Thereby, IKK activation occurred more rapidly, with a considerably higher peak of kinase 
activity after 25 minutes of stimulation and seemed to be more sustained. No changes in 
basal IKK activity were observed. Interestingly, T loop phosphorylation of IKKs, as 
assessed by immunoblotting with phospho-specific antibodies, was already heavily 
increased in unstimulated PP4R1-deficient cells compared to control-transfected cells. 
Constitutive IKK phosphorylation did not change substantially in response to stimulation 
but was highly sustained – in marked contrast to transient IKK phosphorylation observed 
in control-transfected cells. PP4R1 knock-down did not alter PMA/ionomcyin-induced 
PKC phoshorylation and kinase activity (data not shown) indicating that PP4R1 directly 
inhibits the IKK complex. Accordingly and further supporting its IKK-specific function, 
transient or stable knock-down of PP4R1 did not alter ERK phosphorylation (Fig. 5.13 A 
and data not shown). 
In a reverse experiment, the impact of PP4R1 overexpression on TCR-induced IKK 
activity was determined. To this end, exogenous FLAG:IKK was transiently 
overexpressed in Jurkat T cells with or without HA-tagged PP4R1. Cells were stimulated 
via the TCR with agonistic antibodies and exogenous IKK was immunoprecipitated from 
whole cell lysates. Subsequently, FLAG:IKK kinase activity was analyzed in an in vitro 
kinase assay as described before. Conversely to PP4R1 silencing, ectopic PP4R1 
completely blunted TCR-induced IKK activation (Fig. 5.13 B). Whereas in control-
transfected cells maximal IKK and IB phosphorylation were detected at 20 minutes post 
stimulation, PP4R1-overexpressing cells exhibited almost no induction of IKK activity. 
Overexpression of HA-tagged PP4R1 and equivalent pull-down of IKK were confirmed 
by anti-HA and anti-IKK immunoblotting, respectively. 
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Figure 5.13 | PP4R1 negatively regulates IKK activation in resting and stimulated T cells. 
Jurkat T cells were transiently transfected with PP4R1-specific siRNA or control siRNA. 72 h post 
transfection cells were stimulated with PMA/ionomcyin for indicated time periods and the IKK 
complex was immunoprecipitated by anti-NEMO antibodies. A non-precipitating antibody was used 
to control for specificity. A fraction of immunoprecipitates was subjected to an in vitro kinase assay 
(KA) in the presence of radioactively labeled [-32P]ATP and GST:IB as a substrate. Remaining 
immunoprecipitates together with whole cell lysates were subjected to SDS-PAGE followed by 
immunoblotting using primary antibodies as indicated. Reprobing with anti-PP4R1 and anti-Tubulin 
antibodies verified efficient knock-down and equal loading, respectively. (B) Jurkat T cells were 
transfected with cDNA encoding for FLAG:IKK together with an expression vector for HA:PP4R1 
or empty vector (Mock). 48 h post transfection exogenous IKK was pulled-down by anti-FLAG 
immunoprecipitation. A non-precipitating antibody was used to control for specificity. Immuno-
precipitates were subjected to an in vitro kinase assay or, in parallel, to SDS-PAGE and anti-IKK 
immunoblotting. Overexpression of HA:PP4R1 was confirmed by SDS-PAGE and anti-HA immuno-
blotting of whole cell lysates. (C) Jurkat cells stably expressing PP4R1-specific shRNA 
(shPP4R1#3) or control shRNA were stimulated with PMA/ionomcyin for different time periods. 
Cells were lysed and the IKK complex was immunoprecipitated by anti-NEMO antibodies. Immune 
complexes and whole cell lysates were subjected to SDS-PAGE followed by immunoblotting using 
primary antibodies as indicated. Reprobing with anti-PP4R1 and anti-Tubulin antibodies verified 
efficient knock-down and equal loading, respectively (upper panel). IB phosphorylation was 
quantified as fold induction compared to unstimulated control-transduced cells (lower panel). 
(Asterisks indicate non-specific bands, filled and open arrowheads specific proteins and IgGH, 
respectively). (D) Increasing amounts of HA:PP4R1 were overexpressed in HEK293T cells either 
alone or together with a dominant-active kinase mutant of FLAG:IKK (FLAG:IKK SS/EE). 48 h 
post transfection cells were lysed and NF-B activity was measured by use of a co-transfected    
NF-B-specific luciferase reporter system. Overexpression was confirmed by SDS-PAGE and 
immunoblotting. Mean and SD of luciferase activity are representative of dublicate measurements. 
 
To further confirm and analyze the role of PP4R1 in negative regulation of IKK signaling, 
stably PP4R1-silenced Jurkat T cells were stimulated with PMA/ionomycin and IKK 
phosphorylation was assessed as described before. In parallel, the phosphorylation status 
and expression levels of IB were analyzed by immunoblotting. In accordance with 
transient PP4R1 silencing, stable shRNA-mediated knock-down of PP4R1 caused again a 
dramatic increase in basal IKK phosphorylation compared to control-transduced cells 
(Fig. 5.13 C upper panel). Furthermore, IKK phosphorylation seemed to be constitutive 
and sustained in PP4R1-deficient cells and did not change significantly upon stimulation. 
In contrast, phosphorylation of IKK peaked at about 25 minutes post stimulation, but was 
markedly increased in cells lacking PP4R1 expression. Constitutive IKK phosphorylation 
correlated well with significantly less IB protein in resting PP4R1-deficient Jurkat T cells. 
Moreover, residual IB protein was rapidly degraded upon stimulation, while in control 
cells IB protein levels decreased later after about 25 minutes of stimulation. Despite low 
IB protein expression, relative phosphorylation of IB was much higher in PP4R1-
deficient cells and precisely paralleled IB degradation (Fig. 5.13 C lower panel). 
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To determine whether PP4R1 affects signaling events downstream of IKK activation, HA-
tagged PP4R1 was overexpressed in HEK293T cells, alone or in combination with a 
constitutively active mutant of FLAG-tagged IKK, IKK S177E/S181E (IKK SS/EE) 
(Mercurio et al., 1997). NF-B activity was measured by means of a co-transfected       
NF-B-specific luciferase reporter system. As seen in Fig. 5.13 D, forced overexpression 
of HA:PP4R1 inhibited basal NF-B activity in a dose-dependent manner, but had no 
impact on IKK SS/EE-dependent NF-B signaling. Thus, constitutive kinase activity that 
is uncoupled from inducible phosphorylation of T loop serines within IKK was sufficient to 
bypass PP4R1-mediated NF-B inhibition. 
Collectively, the combined data demonstrate that PP4R1 negatively regulates IKK 
phosphorylation and kinase activity. Increased levels of phospho-IKK in PP4R1-silenced 
cells correlated well with enhanced in vitro kinase activity and IB phosphorylation and 
degradation upon stimulation. Constitutive IKK phosphorylation was reflected by 
significantly decreased IB protein levels in resting PP4R1-deficient cells, although no 
changes in basal IKK activity were observed in an in vitro kinase assay. Importantly, 
PP4R1 deficiency did not cause any alterations in stimulation-dependent ERK 
phosphorylation. The specificity of PP4R1 on IKK phosphorylation and activation was 
further substantiated by epistasis analysis on the basis of overexpression of a 
constitutively active version of IKK. 
 
5.2.9 The PP4R1/PP4c module exerts TCR stimulation-dependent phosphatase 
activity and mediates dephosphorylation of IKK proteins in vitro 
Functional and biochemical analyses had clearly established PP4R1 as a negative and 
most likely direct regulator of the IKK complex in T lymphocytes. Since PP4R1 and the 
catalytic subunit PP4c form part of a stable holoenzyme and similarly associate with the 
IKK complex, it is conceivable that PP4R1 regulates and directs PP4c phosphatase 
activity towards dephosphorylation of IKK proteins, thereby limiting and terminating kinase 
activation. 
First, the question was addressed whether PP4R1 functions as a co-regulator of PP4c 
enzymatic activity. Therefore, HA-tagged versions of PP4R1 and PP4c, respectively, were 
overexpressed in HEK293T cells, either alone or in combination. Subsequently, 
exogenous proteins were pulled-down from whole cell lysates using anti-HA antibodies.  
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Figure 5.14 | The PP4R1/PP4c module exerts TCR stimulation-dependent phospholytic 
activity and dephosphorylates IKKs in vitro. (A) HA-tagged versions of PP4R1 and PP4c were 
overexpressed in HEK293T cells alone or in combination. Exogenous proteins were pulled-down 
by anti-HA antibodies and subjected to a colorimetric phosphatase activity assay. Mean and SD of 
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relative phosphatase activities are representative of triplicate measurements. (B,C) Jurkat T cells 
(B) or primary human day 6 T cells (C) were stimulated by treatment with PMA/ionomycin or anti-
CD3/CD28 antibodies for various time periods as indicated. Cells were lysed and endogenous 
PP4R1 was immunoprecipitated. A non-precipitating antibody was used to control for specificity. 
Immunoprecipitates were subjected to an in vitro phosphatase activity assay as described in (A). In 
parallel, to control equal input, a fraction of immunoprecipitates was subjected to SDS-PAGE and 
immunoblotting using primary antibodies as indicated. (D) FLAG:IKK together with increasing 
amounts of HA:PP4R1 and/or HA:PP4c was overexpressed in HEK293T cells. 48 h post 
transfection FLAG:IKK was pulled-down from whole cell lysates by anti-FLAG immuno-
precipitation. Immune complexes were resolved by SDS-PAGE followed by immunoblotting using 
primary antibodies as indicated. In addition, expression of HA-tagged proteins in whole cell lysates 
was confirmed by SDS-PAGE and anti-HA immunoblotting. (E) To generate phospho-substrates for 
a reconstituted in vitro phosphatase assay, FLAG-tagged versions of IKK or IKK were 
overexpressed in HEK293T cells. Following PMA/ionomycin stimulation for 15 min cells were lysed 
and FLAG:IKKs were pulled down by anti-FLAG immunoprecipitation. In parallel, HA:PP4R1 and 
HA:PP4c were separately overexpressed in HEK293T cells and exogenous proteins were 
immunoprecipitated by anti-HA antibodies. Subsequently, anti-HA immunoprecipitates and 
FLAG:IKKs were recombined in a phosphatase reaction for 1 h. Dephosphorylation of IKKs was 
monitored by SDS-PAGE of immunoprecipitates followed by immunoblotting using phospho-IKK/ 
(ser180/ser181)-specific antibodies. Reprobing with anti-FLAG, anti-HA, and anti-PP4c antibodies 
confirmed equal input and proper expression of FLAG:IKKs and HA-tagged proteins, respectively. 
(F) The endogenous IKK complex was pulled-down from resting or PMA/ionomycin-stimulated 
Jurkat T cells using anti-NEMO antibodies. The immunoprecipitated material was then subjected to 
an in vitro phosphatase reaction as described in (E). (Filled and open arrowheads indicate specific 
proteins and IgGH, respectively. For anti-PP4c immunoblotting open arrowheads indicate 
endogenous protein). 
 
To determine phospholytic activity, anti-HA immune complexes were subjected to an in 
vitro phosphatase activity assay. In parallel, to confirm proper expression and pull-down of 
HA-tagged proteins, equivalent fractions of anti-HA immunoprecipitates were subjected to 
SDS-PAGE followed by immunoblotting. As seen in Fig. 5.14 A, concomitant expression 
of PP4R1 and PP4c caused a synergistic increase in phosphatase activity compared to 
separate expression of either protein. Of note, modest PP4R1-associated phosphatase 
activity in the absence of co-overexpressed PP4c was most likely due to an interaction 
between exogenous HA-tagged PP4R1 and endogenously expressed PP4c as assessed 
by anti-PP4c immunoblotting. 
The observation that TCR triggering transiently increased binding of PP4R1 to the IKK 
complex gave further rise to the question whether the PP4R1/PP4c module exerts 
phosphatase activity in a TCR stimulation-dependent manner. To test this hypothesis, 
Jurkat T cells or primary human T cells at day 6 of in vitro expansion were stimulated for 
different time periods by treatment with PMA/ionomycin and anti-CD3/CD28 antibodies, 
respectively. Subsequently, the PP4R1-PP4c complex was immunoprecipitated from 
whole cell lysates using anti-PP4R1 antibodies. To measure phosphatase activity, a 
fraction of the immunoprecipitated material was subjected to an in vitro phosphatase 
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assay as described before. In parallel, proper pull-down of endogenous PP4R1 and PP4c 
proteins was assessed by SDS-PAGE of immune complexes and immunoblotting. Indeed, 
TCR stimulation led to a strong and transient rise in PP4R1-associated phosphatase 
activity that reached its maximum at about 25 minutes post stimulation indicating that the 
PP4R1/PP4c module is itself subject to regulation by TCR triggering (Fig. 5.14 B,C). 
PP4R1 physically interacts with the IKK complex while PP4c forms the catalytically active 
subunit of the PP4 holoenzyme. Moreover, activating mutations of IKK T loop serine 
residues to phosphomimetic glutamate prevented NF-B inhibition by PP4R1 (Fig. 5.13 D). 
To examine whether PP4R1 and PP4c cooperate to catalyze dephosphorylation of IKK T 
loop serines in vitro, HEK293T cells were transfected with expression plasmids encoding 
for FLAG:IKK either alone or in combination with increasing cDNA concentrations of HA-
tagged PP4R1 and/or expression plasmids encoding for HA-tagged PP4c. 
Overexpression of exogenous IKKs is known to cause kinase transautophosphorylation 
and activation by induced-proximity. To monitor IKK phosphorylation, cells were lysed 
and exogenous IKK was pulled-down by anti-FLAG immunoprecipitation followed by 
immunoblotting with phospho-specific antibodies. As seen in Fig. 5.14 D, the presence of 
either ectopic PP4R1 or PP4c was already sufficient to mediate a slight reduction in IKK 
phosphorylation. However, combined PP4R1 and PP4c overexpression completely 
blunted IKK phosphorylation. Overexpression of HA-tagged versions of PP4R1 and 
PP4c was confirmed by immunoblotting. 
To test whether IKK and IKK are similarly targeted and dephosphorylated by the 
PP4R1/PP4c holoenzyme, a reconstituted in vitro phosphatase assay was established. 
For this, FLAG-tagged forms of IKK or IKK were separately overexpressed in HEK293T 
cells. IKK-overexpressing cells were then stimulated with PMA/ionomycin and IKKs were 
immunoprecipitated from whole cell lysates by anti-FLAG immunoprecipitation. 
Phosphorylated exogenous IKK proteins were recombined and served as substrates in a 
subsequent phosphatase reaction. For this purpose, HA:PP4R1 or HA:PP4c were 
separately expressed in HEK293T cells and purified by anti-HA immunoprecipitation. Anti-
HA immunoprecipitates were then co-incubated with equivalent portions of FLAG-tagged 
IKK substrates. Subsequently, combined immune complexes were resolved by SDS-
PAGE and IKK phosphorylation was analyzed by immunoblotting. As seen in Fig. 5.14 E, 
purified PP4R1 and PP4c proteins were equally sufficient to mediate dephosphorylation of 
both recombinant phospho-IKK and phospho-IKK. Of note, exogenous PP4R1 was 
associated with endogenous PP4c which most likely conferred catalytic activity. 
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In a similar experiment, it was examined whether PP4R1 and PP4c mediate 
dephosphorylation of the endogenous activated IKK complex in vitro. Therefore, the 
phosphorylated IKK complex was immunoprecipitated by anti-NEMO antibodies from 
whole cell lysates of Jurkat T cells that had been stimulated by treatment with 
PMA/ionomycin. Purified endogenous phospho-IKK proteins were then subjected to a 
reconstituted in vitro phosphatase activity assay as described before. Again, 
immunoprecipitated PP4R1 and PP4c proteins mediated complete dephosphorylation of 
IKK/ and reversed the phospho-IKK signal to basal levels (Fig. 5.14 F). 
In summary, these data demonstrate that (i) PP4R1 regulates and potentiates PP4c 
phosphatase activity, (ii) that phospholytic activity exerted by the endogenous 
PP4R1/PP4c complex is transiently increased by TCR stimulation, and (iii) that PP4R1 
synergizes with PP4c to catalyze dephosphorylation of IKK proteins in vitro. 
 
 
5.3 Expression and function of PP4R1 in Sézary T cells 
The Sézary syndrome is an aggressive version of CTCL that is characterized by the 
presence of highly proliferating malignant T cells in the blood of Sézary patients (Klemke 
et al., 2005). Recent studies provided evidence for constitutive NF-B activation in Sézary 
T cells that is crucial for CTCL survival (Izban et al., 2000; Kiessling et al., 2009; Sors et 
al., 2006). Hence, deregulation of NF-B is most likely a central event that is required for 
the maintenance of the malignant phenotype of Sézary T cells. However, the molecular 
aetiology and genetic aberrations underlying constitutive NF-B signaling in this subtype 
of CTCL remain largely enigmatic. The present study identified PP4R1 as an important 
negative regulator of NF-B signaling in T lymphocytes. Therefore, the following analyses 
were conducted with the goal to elucidate a potential role of PP4R1 in the molecular 
pathogenesis of the Sézary syndrome. 
 
5.3.1 Diminished expression of PP4R1 in a fraction of Sézary T cells 
Forced RNAi-mediated PP4R1 deficiency in Jurkat T cells as well as in primary human T 
lymphocytes had been demonstrated to cause constitutive IKK phosphorylation and 
hyperactivation as well as enhanced IB degradation. Therefore, it was tempting to 
speculate whether chronic NF-B signaling in Sézary T cells, at least for a subgroup of 
cells, occurs as a result of diminished PP4R1 expression. 
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To test this hypothesis, whole cell lysates of four different CTCL cell lines, SeAx, MyLa, 
Hut78, and HH, as well as lysates derived from the leukemic and non-CTCL T cell lines 
Jurkat, or CEM, or from non-malignant in vitro expanded primary human T cells were 
subjected to SDS-PAGE and endogenous protein levels were determined by 
immunoblotting using primary antibodies as indicated. As seen in Fig. 5.15 A, two different 
Sézary T cell lines showed significantly diminished PP4R1 protein levels compared to 
Jurkat T cells. PP4R1 expression in Hut78 cells was reduced by about 50% and HH cells 
completely lacked PP4R1 protein expression (Fig. 5.15 A right panel). By contrast, SeAx 
and MyLa cells expressed PP4R1 similar to Jurkat, CEM and primary T cells. Interestingly, 
PP4c and the related phosphatase subunit PP2Ac as well as other T cell signaling 
components were equally abundant in all tested cell lines, indicating specific dysregulation 
of PP4R1 protein expression in a subset of CTCL cell lines. Solely, IKK expression levels 
seemed to be elevated in PP4R1-deficient HH cells. 
Decreased or absent PP4R1 protein expression in Hut78 and HH cells, respectively, was 
reflected by diminished PP4R1 mRNA levels as determined by qPCR (Fig. 5.15 B). Hut78 
cells displayed about 40% of PP4R1 mRNA expression relative to Jurkat T cells, and HH 
cells virtually lacked PP4R1-specific transcripts. Again, SeAx and MyLa cells exhibited a 
similar expression pattern compared to Jurkat cells. Moreover, defective mRNA 
expression was specifically assigned to PP4R1, since expression of PP2Ac was largely 
unaffected. 
To investigate PP4R1 expression in primary Sézary cells, T lymphocytes were isolated 
from peripheral blood of a number of patients suffering from Sézary syndrome and PP4R1 
mRNA levels were analyzed by qPCR. For transcriptional profiling only those samples 
were included that showed tumor loads of generally at least 60% as determined by 
microscopical evaluation of blood smears. At large, the percentage of Sézary T cells 
relative to whole lymphocytes in peripheral blood samples was about 70% with CD4+ to 
CD8+ T cell ratios between 11 and 99 as evaluated by flow cytometry (Klemke et al., 
2008). Indeed, compared to peripheral T cells from normal healthy donors, peripheral 
blood T cells of Sézary patients exhibited a reduced expression of PP4R1 mRNA (Fig. 
5.15 C). Overall, median expression of PP4R1 was reduced by more than 50% in patient 
samples relative to control samples. 
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Figure 5.15 | Subgroups of Sézary cell lines and primary Sézary cells display diminished 
PP4R1 protein and mRNA expression. (A) Whole cell lysates derived from expanded day 6 
primary human T lymphocytes (two independent donors), Jurkat, CEM or different CTCL cell lines 
were subjected to SDS-PAGE followed by immunoblotting using primary antibodies as indicated. 
For anti-PP4R1 immunoblotting two different PP4R1-specific antibodies, either recognizing N-
terminal or C-terminal epitopes, were used. (Filled arrowhead indicates PP4R1). Reprobing with 
anti-Tubulin antibodies verified equal loading (left panel). Endogenous PP4c and PP4R1 
expression was normalized to Tubulin levels and quantified as fold levels relative to Jurkat cells 
(right panel). (B) mRNA levels of PP2Ac and PP4R1 in CTCL cell lines were determined by qPCR. 
Levels are shown as fold change relative to Jurkat cells. (N.D.: not detectable). (C) Similar to (B) 
mRNA levels of peripheral blood T cells derived from normal healthy controls (10 donors) or Sézary 
patients (12 donors) were quantified by qPCR. Bars indicate median values. Expression was 
calculated as fold change to median expression of controls (Student’s t-test, p=0.01699). (D,E) 
Analogous to (A) whole cell lysates of different human B cell lines (D) or epithelial cell lines in 
addition to lysates of CEM and Jurkat cells (E) were subjected to SDS-PAGE. Expression of 
PP4R1 and PP4c proteins was assessed by immunoblotting. Reprobing with anti-Tubulin 
antibodies verified equal loading. 
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Similarly to Sézary T cells, aberrant NF-B activity has been reported for a number of 
clinically distinct B cell lymphomas among which the DLBCL plays a prominent role 
(Alizadeh et al., 2000; Ngo et al., 2006; Rosenwald et al., 2002). Whereas the ABC-
DLBCL subtype critically relies on constitutive NF-B signaling for lymphoma survival, the 
GCB-DLBCL subtype does not (Davis et al., 2001). To examine the expression of PP4R1 
in different NF-B-dependent or independent B cell lines, whole cell lysates from ABC-
DLBCL (OCI-Ly3, SUDHL-5) and GCB-DLBCL (BJAB, SUDHL-6) cell lines, respectively, 
as well as lysates from the diffused mixed lymphoma line HT or the Burkitt lymphoma cell 
line Raji were subjected to SDS-PAGE and PP4R1 and PP4c expression were assessed 
by immunoblotting. Although expression of both PP4 phosphatase subunits differed 
slightly among the different cell lines, no specific reduction in expression of either 
phosphatase protein was observed for NF-B-dependent ABC-DLBCL cells (Fig. 5.15 D). 
Moreover, expression of PP4R1 and PP4c was further investigated in a number of non-
lymphoid epithelial cell lines. Interestingly, the human cell lines HeLa and HEK293T 
displayed low PP4R1 protein levels, while PP4R1 was similarly abundant in the hepatic 
cell line Hep3B compared to CEM or Jurkat T cells (Fig. 5.15 E). 
In summary, it was demonstrated that a fraction of Sézary T cells derived from Sézary 
patients as well as a subgroup of CTCL cell lines exhibit defective or completely lack 
endogenous PP4R1 expression. Abrogration of PP4R1 expression was observed both on 
protein and mRNA levels and was highly gene-specific, since expression of PP2Ac was 
almost not altered. 
 
5.3.2 Overexpression of PP4R1 reverses constitutive IKK activity and limits 
survival of PP4R1-deficient Sézary T cells 
To confirm and examine on a genetic level whether CTCL Sézary T cells display 
enhanced basal NF-B signaling, the transcription profile of a variety of different NF-B 
target genes was determined. For this, basal mRNA levels of selected target genes in 
different Sézary cell lines, such as SeAx, Hut78, and HH, were quantified using a qPCR 
expression array. As a control, mRNA expression in Jurkat T cells, a non-CTCL leukemic 
T cell line, was determined. In accordance with published observations (Izban et al., 2000; 
Sors et al., 2006), Sézary cells showed a specific NF-B target gene expression signature 
that was most pronounced for Hut78 and HH cells (Fig. 5.16 A). Interestingly, HH cells 
lacked expression of anti-apoptotic Bcl2 family members Bcl2A1 and Bcl2L11, but showed 
strongly upregulated expression of c-IAP1 (BIRC2) and c-IAP2 (BIRC3). Even more 
 Results 127 
strikingly, expression of the bona fide NF-B target genes IB (NFKBIA) and A20 
(TNFAIP3) was increased by more than 10-fold in HH cells compared to Jurkat T cells. 
Moreover, Hut78, HH, and to a lesser extend SeAx cells exhibited significantly increased 
expression of NFKB1, NFKB2, and RELB. Remarkably, expression of STAT5A was 
uniformly increased in all Sézary cell lines by up to 70-fold. 
Consistent with constitutive NF-B signaling inhibition of the NF-B pathway in Sézary T 
cells, either derived from cell lines or primary patient material, had been recently shown to 
cause spontaneous cell death in vitro (Kiessling et al., 2009). However, for most Sézary 
cell lines it has not been clarified yet at what stage within the TCR or NF-B signaling 
cascade constitutive signaling activity is exerted. To examine IKK activity in Jurkat T cells 
and Sézary T cells under resting conditions, the IKK complex was immunoprecipitated by 
anti-NEMO antibodies from whole cell lysates of unstimulated cells. Subsequently, kinase 
activity and phosphorylation were measured by autoradiography. As seen in Fig. 5.16 B, 
Jurkat T cells as well as SeAx and MyLa cells exhibited weak IKK phosphorylation in the 
absence of stimulation. By contrast, increased basal IKK phosphorylation was observed 
for Hut78 cells and was even more striking for PP4R1-deficient HH cells. 
So far, inverse correlation between PP4R1 expression and enhanced basal IKK activity 
implied but did not formally prove a causative role of PP4R1 deficiency in constitutive IKK 
signaling in Sézary T cells. To directly address this question, it was tested whether 
aberrant IKK activity was rescued by reconstitution of PP4R1 expression in PP4R1-
deficient HH cells. To this end, FLAG-tagged IKK was transiently overexpressed with or 
without exogenous HA-tagged PP4R1, and IKK phosphorylation was monitored by anti-
FLAG immunoprecipitation and autoradiography. Intriguingly, overexpressed exogenous 
IKK in HH cells was highly phosphorylated, consistent with constitutive activation of the 
endogenous IKK complex in this cell line (Fig. 5.16 C). However, co-overexpression of 
PP4R1 completely prevented IKK activation, demonstrating that re-expression of PP4R1 
is sufficient to reverse the phenotype of IKK hyperactivation in HH cells. In line with these 
results, basal NF-B luciferase reporter activity in PP4R1-deficient HH cells was 
substantially elevated compared to PP4R1-sufficient Jurkat T cells, and this NF-B 
phenotype was again reversed by re-expression of exogenous PP4R1 (Fig. 5.16 D). 
Preceding experiments had uncovered PP4R1 as a potent negative regulator of the      
NF-B pathway in T lymphocytes. Moreover, PP4R1 expression is reduced in a subset of 
primary Sézary cells and CTCL cell lines that exhibit and rely on chronic NF-B signaling 
for survival. 
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Figure 5.16 | PP4R1 overexpression reverses constitutive IKK activity and causes 
spontaneous cell death specifically in PP4R1-deficient Sézary cells. (A) Basal mRNA 
expression levels of various NF-B target genes were examined in Sézary cell lines using a qPCR 
gene expression array. In addition, PP4R1 mRNA levels were determined. Relative expression is 
shown as fold change compared to Jurkat cells. Decreased and increased relative expression 
levels are shown in green and red, respectively, according to the colour scale shown. (B) The IKK 
complex was immunoprecipitated from whole cell lysates of unstimulated cells by anti-NEMO 
antibodies as indicated. In addition, immunoprecipitation of Jurkat lysates by a non-precipitating 
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antibody was included to control for specificity. Immune complexes were divided and subjected 
either to an in vitro kinase assay using radioactively labeled [-32P]ATP or to SDS-PAGE followed 
by anti-IKK immunoblotting. (C) HA:PP4R1 was transiently overexpressed in HH cells, alone or 
together with FLAG:IKK. 24 h post transfection cells were lysed, followed by anti-FLAG 
immunoprecipitation of whole cell lysates. Immunoprecipitates were subjected to an in vitro kinase 
assay as described in (B) or subjected to SDS-PAGE and immunoblotting. Overexpression of 
HA:PP4R1 was assessed by SDS-PAGE and anti-HA immunoblotting of whole cell lysates. (D) 
PP4R1 was transiently overexpressed in Jurkat and HH cells. NF-B activity in resting cells was 
measured using a co-transfected NF-B-specific reporter luciferase system. Fold activity is shown 
relative to that of control-transfected Jurkat cells. Mean and SD of luciferase activity are 
representative of dublicate measurements. (E) Indicated CTCL cell lines were retrovirally 
transduced with overexpression vectors encoding for PP4R1, PP4c, and PP2Ac, respectively. 
Frequency of transduced cells was monitored over time by flow cytometry based on IRES-driven 
co-expression of GFP. Percentage of GFP-positive cells was normalized to that of control-
transduced cells. 
 
Therefore, it was tested next whether PP4R1-mediated IKK inhibition is sufficient to 
induce spontaneous cell death of Sézary T cells in vitro. To this end, cDNA encoding for 
HA-tagged PP4R1 was cloned into a GFP-expressing retroviral vector and four different 
Sézary cell lines were retrovirally transduced. In addition, empty vector and retroviral 
vectors for overexpression of PP2Ac or PP4c were included. Co-overexpression of GFP 
by means of an internal ribosome entry site (IRES) sequence allowed for the tracing of 
retrovirally transduced cells by flow cytometry. Indeed, re-expression of PP4R1 reduced 
the frequency of GFP-positive PP4R1-expressing Hut78 and HH cells relative to control-
infected cells over time (Fig. 5.16 E lower panels). Remarkably, HH cells that completely 
lack endogenous PP4R1 were highly sensitive towards PP4R1 overexpression, whereas 
the frequency of PP4R1-expressing Hut78 cells declined continuously, but less rapidly. By 
contrast, PP4R1-sufficient MyLa and SeAx Sézary cells were completely refractory to 
PP4R1 overexpression (Fig. 5.16 E upper panels). Intriguingly, lethality of PP4R1 
overexpression was highly specific in HH cells since ectopic PP4c had almost no impact 
on cell survival. Moreover, there was no toxicity of forced PP2Ac expression in all tested 
cell lines. 
Taken together, these data demonstrate that PP4R1 deficiency in a subset of Sézary cell 
lines is causative for constitutive IKK phosphorylation and activation. Consistently, PP4R1 
re-expression was highly toxic for PP4R1-deficient Sézary cells while PP4R1-sufficient 
cells were largely resistant to forced overexpression of exogenous PP4R1. These results 
establish PP4R1 not only as a gatekeeper of IKK activity but also as physiological 
suppressor of T cell activation and lymphomagenesis. 
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6. Discussion 
The transcription factor NF-B plays a key role in the immune system by governing 
lymphocyte activation, proliferation, and survival (Vallabhapurapu and Karin, 2009). 
Physiological NF-B activity requires precise control by positive and negative regulatory 
mechanisms. Whereas disruption of NF-B signaling is known to cause severe immune 
defects, constitutive NF-B activity has been implicated in several lymphoid malignancies 
and autoimmune diseases (Li and Verma, 2002; Staudt, 2010). 
Signal transduction to NF-B from engaged cell surface receptors, such as the TCR or 
TNFR1, proceeds rapidly and involves multiple well-characterized phosphorylation events 
(Mayya et al., 2009; Viatour et al., 2005). A large body of literature has described a 
plethora of kinases and phosphorylated target proteins as being indispensable for TCR-
induced NF-B activation, ranging from upstream signaling platforms to the IKK complex 
and NF-B subunits themselves (Hacker and Karin, 2006; Hayden and Ghosh, 2008). In 
marked contrast, a detailed understanding of mechanisms controlling NF-B signal 
termination is only starting to emerge. In this context, recent progress has been made with 
the identification of Ub-editing enzymes, such as A20 and CYLD, that counterbalance the 
activity of proximal signaling complexes downstream of several pro-inflammatory 
receptors (Brummelkamp et al., 2003; Lee et al., 2000). However, negative regulation of 
phosphorylation in NF-B signaling is only partially understood – despite the abundance 
and critical role of the NF-B-activating phospho-proteome. 
In few cases, phosphorylation has been shown to mediate protein degradation, thereby 
promoting signal interception and termination in a negative feedback fashion (Bidere et al., 
2008; Lobry et al., 2007; Moreno-Garcia et al., 2010; Wegener et al., 2006). Nonetheless, 
most stimulation-dependent phosphorylation events are transient and reversible, implying 
the opposing action of kinases and phosphatases in controlling the phosphorylation state 
of NF-B signaling components. In support of the concept of reversible and site-specific 
protein (de)phosphorylation, several phosphatases have been already implicated in 
negative regulation of a number of distinct phosphorylation-dependent signaling pathways, 
such as in signal transducer and activator of transcription (STAT) signaling (Nakahira et 
al., 2007), JNK signaling (Eichhorn et al., 2007), or in the MAPK cascade (Liu et al., 2007). 
The role of individual phosphatases in NF-B signaling is less well defined. Most studies 
were based on phosphatase inhibitors and overexpressed proteins, limiting conclusions 
regarding specificity and functional importance of endogenous proteins under 
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physiological conditions (see 1.4.3). Only few genetic studies demonstrated the selective 
involvement of different phosphatase entities in NF-B inhibition and dephosphorylation of 
specific phosho-substrates (Chew et al., 2009; Li et al., 2008; Li et al., 2006b). However, 
the results of these studies do not allow for a generalized and comprehensive picture of 
NF-B-modulating phosphatases, especially with regard to different receptor systems and 
cellular contexts (e.g. T lymphocytes). (i) Most studies were conducted on the basis of 
TNF-induced NF-B signaling and thereby did not address phosphatases specifically 
targeting signaling proteins of the TCR-induced NF-B pathway. (ii) So far, genetic 
screens and functional analyses of phosphatase activity were uniformly performed using 
non-lymphoid cellular systems, such as human epithelial cell lines. Contradictory results 
among different approaches already suggested species and cell type-specific patterns of 
expression and/or activity of individual phosphatase components. Therefore, a systematic 
examination of NF-B-modulating phosphatases in T lymphocytes is still elusive. 
The current study has been conducted with the aim to functionally define phosphatases 
that are involved in TCR-induced NF-B signaling. Using a novel NF-B reporter system a 
large-scale RNAi-based loss-of-function screen in T cells has been adopted. Several 
novel phosphatases were uncovered as negative regulators of TCR-dependent NF-B 
signaling. Subsequent experiments were performed to confirm candidate genes and to 
gain a more detailed understanding of the functional roles of individual phosphatases in 
lymphocyte biology. 
 
 
6.1 Analysis and evaluation of the phosphatase RNAi screen: 
 technical aspects and genetic understanding 
6.1.1 RNAi screening in mammalian systems: strategies and restrictions 
RNAi has emerged as a powerful technique of reverse genetics and has opened up new 
avenues for large-scale genetic screens aiming at identifying genetic components 
underlying specific cellular processes or signaling pathways (Boutros and Ahringer, 2008; 
Moffat and Sabatini, 2006). For mammalian systems, genome-scale RNAi screens have 
been largely hampered by lack of suitable tools for efficient gene silencing under HTS 
conditions. To date a number of subgenome-wide RNAi screens in human cells have 
been reported. Most of these screening approaches were based on morphology or 
viability phenotypes that are likely to integrate various signaling pathways. Examples 
include RNAi screens for genes regulating apoptosis sensitization (za-Blanc et al., 2003), 
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cell survival (Barbie et al., 2009; Luo et al., 2009a; MacKeigan et al., 2005), proliferation 
(Berns et al., 2004), and transformation (Kolfschoten et al., 2005) (for review see Boutros 
and Ahringer, 2008; Moffat and Sabatini, 2006). However, screening approaches in 
human cells that are based on directed transcriptional reporter assays and therefore allow 
for the systematic dissection of specific signaling pathways are technically challenging. 
Only few examples of reporter-based screens in human epithelial cell lines have been 
reported (Brummelkamp et al., 2003; Chew et al., 2009; Major et al., 2008). 
RNAi-based loss-of-function screens in immune cells turned out to be even more difficult 
and require sophisticated strategies for efficient gene silencing. Lymphocytes are largely 
refractory to transient siRNA transfection. Usually, conventional electroporation of T 
lymphocytes requires high concentrations of siRNA and is further complicated by 
decreased cell viability (Sharma and Rao, 2009). Therefore, most screens were 
conducted on the basis of shRNA libraries delivered by viral transduction and selection of 
stable integrants (Root et al., 2006). Using this method several molecular targets required 
for proliferation and survival of B cell lymphoma cells have been successfully identified 
(Davis et al., 2010; Lenz et al., 2008). Recently, a shRNAi screen in T cells led to the 
discovery of a specific splicing factor involved in CD45 alternative splicing (Oberdoerffer et 
al., 2008). To date, only one shRNA library-based screen has been reported for primary T 
lymphocytes that revealed regulators of IL-10 secretion (Astier et al., 2010). 
Design and implementation of systematic RNAi screens in mammalian systems require 
the optimization of several experimental conditions and involve a multi-step protocol that 
can be generalized as follows (Falschlehner et al., 2010; Moffat and Sabatini, 2006): 
 
(i) screen preparation (development of appropriate cell-based reporter assays, 
optimization of transfection conditions, and library design) 
(ii) screen performance (screen protocol under HTS conditions) 
(iii) screen and post-screen analysis (data pre-processing, normalization, statistical 
analysis, as well as candidate selection, validation, and characterization) 
 
The adaptation of these parameters provided the basis of the present RNAi screening 
strategy that led to the identification of several phosphatases regulating TCR-induced   
NF-B activity. Major technical and biological aspects of the RNAi screen will be 
discussed in the following sections. 
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6.1.2 Gluc-J16 reporter cells: a novel NF-B screening system in T cells 
The development of an appropriate and validated phenotypic assay is the core element of 
a successful RNAi screening strategy. In order to measure transcriptional activity of a 
signal transduction pathway of interest, a primary assay system is needed that has to be 
robust, sensitive, and specific with respect to signal manipulation, as well as adoptable to 
HTS conditions. Luciferase-based transcriptional reporters are especially amenable to 
screening experiments since they allow for the rapid quantification of signaling activity on 
a large scale (Boutros and Ahringer 2008; Moffat and Sabatini, 2006). 
In the present study a novel NF-B dependent screening system based on expression of 
secreted luciferase in T lymphocytes has been generated. To this end, Jurkat-derived 
J16-145 T cells (Gulow et al., 2005) were engineered with stable genomic integration of a 
NF-B-dependent Gaussia luciferase cassette (Gluc-J16 cells) (Fig. 5.1 and 5.2). The 
reporter system was highly sensitive towards TCR or TNFR stimulation and responded 
synergistically towards TCR and CD28 co-stimulation (Fig. 5.2). 
RNAi-based gene silencing in reporter cells was based on transient siRNA delivery 
according to a novel nucleofection protocol that is suitable for siRNA transfections under 
HTS conditions (see 4.3.3 and 4.3.4). In pre-experiments transfection and stimulation 
conditions were optimized and established Gluc-J16 cells as a valuable tool for large-
scale RNAi screening experiments (Fig. 5.3-5.5). As expected and in accordance with 
published observations, siRNA-mediated knock-down of bona fide positive or negative 
regulators of the TCR and/or TNFR1-induced NF-B signaling pathway resulted in 
significant reduction and enhancement of luciferase secretion, respectively (Fig. 5.3 and 
5.4, Frey, 2009). The fact that reporter cells similarly respond to TCR or TNFR1 
stimulation was exploited by a dual screening strategy that enabled the synoptic analysis 
of phosphatases modulating TCR and/or TNFR-induced NF-B activity (see section 5.1.5 
and Frey, 2009). In addition to signal manipulation by RNAi, the reporter system was 
shown to be sensitive to NF-B inhibition by chemical compounds (Fig. 5.4 and data not 
shown). Future applications of the Gluc-J16 NF-B screening system might therefore not 
only comprise further subgenome-wide RNAi screens (e.g. targeting kinases or Ub-editing 
enzymes), but also small-molecule screens to identify (pathway-specific) pharmacological 
inhibitors of NF-B (Fig. 6.1). 
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Fig. 6.1 | Possible screening applications of the Gluc-J16 NF-B reporter system. The RNAi 
screening protocol that was designed for the Gluc-J16 reporter system may be suitable for further 
screening approaches based on siRNA libraries targeting specific classes of signaling modifiers, 
such as kinases, E3 ligases, or deubiquitinating enzymes (DUBs). Moreover, the application of 
large-scale small-compound libraries may enable drug screening to identify novel (pathway-
specific) pharmacological inhibitors of the NF-B pathway. Compound screening based on known 
chemical inhibitors of effector enzymes (e.g. kinase or phosphatase inhibitors) can complement 
RNAi screening strategies to confirm and validate candidate genes on a large scale. 
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6.1.3 Post-screen analysis of primary RNAi phosphatase screening 
(i) Screen robustness and sensitivity: positive controls and hit selection 
For identification of candidate phoshatase genes (hits) RNAi phenotypes – based on 
mean values of normalized NF-B activity – were scored for statistical significance. To this 
end, normalized measurements were transformed into the statistical z score (Boutros et 
al., 2006). Data transformation allows for the analysis of statistical normality which is 
instrumental in defining appropriate thresholds for hit selection. Using a quantile-quantile 
(QQ) plot analysis (Ramadan et. al., 2007) (Fig. 5.5 A) z score deviations from normally 
(randomly)-distributed values indicated statistically significant RNAi phenotypes. For the 
present screen z scores > +1.5 and < -1.5 were defined as cut-offs values (Fig. 5.5 A,B). 
To facilitate secondary screening and to minimize the numbers of false-positives, only 
those phosphatase genes were categorized as tentative candidates that scored with at 
least two independent siRNAs beyond given z score thresholds (Table 5.1). Definition of 
cut-offs for hit selection depends on the individual screening system and is recommended 
to be adapted empirically to ensure a proper balance between sensitivity and specificity 
(Ramadan et. al., 2007). Too stringent definitions might lead to a high rate of false-
negatives, whereas more permissive criteria might enrich for false-positive candidates 
(Echeverri et al., 2006). 
A first step in assessing sensitivity of RNAi screening and statistical analysis involves the 
inspection of positive controls (Ramadan et. al., 2007). Remarkably, almost all positive 
control siRNAs were identified as statistically significant hits (Fig. 5.5 B). Knock-down of 
Carma1 and RelA, respectively, translated into robust and distinct RNAi phenotypes with 
low variability across individual plates. Similarly, siRNA-mediated silencing of CYLD led to 
significant NF-B phenotypes. In general, CYLD-specific siRNAs uniformly scored with z 
scores above +1.5. The relative strength of RNAi phenotypes varied among positive 
controls. siRNAs targeting positive regulators conferred highly stable and significant 
phenotypes with Z scores < -10.0, whereas CYLD knock-down yielded less strong 
z scores in the range of +1.0 to +4.3. Robust phenotypes of positive controls were 
reflected by highly efficient silencing of control genes on mRNA and protein levels, further 
underscoring the validity of the HTS protocol (Fig. 5.5 C,D). Interestingly, non-targeting 
control siRNAs seemed to be biased towards negative z scores. Thus, the threshold for 
identification of positive regulators might be further decreased to minimize numbers of 
false-positive candidates. 
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In summary, the distributions of negative and positive control values showed significant 
and sufficient separation. Importantly, the dynamic range of phenotypes enabled 
bidirectional screening for positive and negative regulators of NF-B. QQ plot-based 
statistical criteria for hit selection allowed for high screening sensitivity as reflected by 
scoring of almost all positive control siRNAs. 
 
(ii) False-positive and false-negative candidate phosphatases 
Another measure of screening sensitivity refers to the number of confirmed genes that 
were expected a priori to be identified as candidate modifiers (Ramadan et. al., 2007). 
The present screen identified six phosphatases as suppressors and six phosphatases as 
activators of TCR-induced NF-B activity (Table 5.1). 
Among NF-B-activating candidate genes, two phosphatases, PTPN9 (MEG2) and 
PTPRN, were previously implicated in TCR and NF-B signaling, respectively. Using a 
similar RNAi screening approach in murine astrocytes, Li et al. identified PTPRN as a   
NF-B-activating phosphatase regulating both basal and TNF-induced NF-B activity (Li 
et al., 2006b). Interestingly, PTPN9 has not been specifically associated with NF-B 
signaling before, but is required for lymphocyte activation by inducing secretory vesicle 
fusion (Huynh et al., 2003; Huynh et al., 2004; Wang et al., 2005). PTPN9-deficient 
T lymphocytes almost completely lack mature secretory vesicles and display impaired IL-2 
secretion (Wang et al., 2005). The unexpected identification of a vesicle-modulating 
phosphatase was due to the primary assay system that relies on the ER-dependent 
secretion of the Gaussia luciferase reporter. Indeed, a Gluc secretion assay was recently 
reported as a highly sensitive HTS technique to monitor secretory pathway activity and ER 
stress (Badr et al., 2007). 
Surprisingly, negative regulatory candidates did not include any known phosphatases that 
were previously implicated in NF-B signaling. Solely, the tyrosine phosphatase PTPRA – 
that had been reported to serve CD45-like functions in T cells (Maksumova et al., 2005; 
Maksumova et al., 2007) – was identified as an inhibitor of TCR-induced NF-B activation. 
Both PTPN6 (SHP1) and PTPN22 did not match the criteria for hit selection although two 
PTPN22-specific siRNAs yielded z scores that were only marginally below the selection 
threshold (Table 5.1, reference phosphatases). PP2Ac, the catalytic subunit  isoform of 
the PP2A holoenzyme, has been associated with negative regulation of NF-B by several 
independent laboratories based on genetic approaches, expression of recombinant 
protein, and the use of PP2A inhibitors (see 1.4.3). However, primary screening failed to 
Discussion 137
confirm PP2Ac as a NF-B-suppressing phosphatase. Strikingly, only one PP2Ac-specific 
siRNA significantly enhanced TCR-induced reporter activity, whereas PP2Ac showed 
highest scores and was amongst the top candidates of the TNFR1-specific subscreen 
(Frey, 2009). These apparently contradictory findings prompted closer reinvestigation of 
the effect of PP2Ac gene silencing on TCR-induced NF-B activity. Indeed, PP2Ac knock-
down by several independent siRNA oligos led to an enhancement of NF-B reporter 
activity, TCR-induced upregulation of NF-B-dependent gene expression, and cytokine 
secretion. Thereby, PP2Ac-specific siRNAs largely mediated efficient gene silencing. 
Consistent with these genetic data, treatment of Jurkat T cells with the PP2A inhibitor 
okadaic acid amplified NF-B reporter activity in response to PMA/ionomcyin and TNF 
treatment (data not shown), further proving an involvement of PP2Ac in negative 
regulation of TCR- and TNFR1-induced NF-B signaling. 
Collectively, these results suggest that several false-negative phosphatases were not 
identified by primary screening. Overall, the percentage of false-negatives is difficult to 
assess. In general, error rates of about 15% in genome-wide screens have been 
suggested (Ramadan et. al., 2007), but certainly depend on the individual screening 
design. Experimental factors affecting screening sensitivity might include (i) limitations of 
the phenotypic assay system, (ii) loss of biological information by stringent B score 
normalization of raw data, (iii) thresholds of NF-B activity and rigid criteria for candidate 
selection, and (iv) poor knock-down efficacies by non-functional siRNAs. 
 
6.1.4 The NF-B-modulating phosphatasome: How much phosphatases do we 
need? 
A brief survey of the current literature reveals more than 20 phosphatases that were 
previously suggested or proven to be involved in either negative or positive modulation of 
NF-B. The complexity of the NF-B-modulating phosphatasome was further increased by 
the present screen which identified several novel phosphatases associated with TCR-
dependent NF-B activation (Table 5.1). Certainly, caution is warranted with respect to the 
in vivo relevance and substrate specificity of endogenous proteins unless detailed genetic, 
functional, and biochemical analysis is provided. Nonetheless, several questions may 
arise: How many phosphatases can one expect to participate in NF-B signaling? How 
can one explain the apparently high number of phosphatase genes associated with      
NF-B? What are the implications for specificity, redundancy, and robustness in NF-B 
signaling? 
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A first aspect lies in the species, cell type, and pathway-specific expression and/or activity 
of individual phosphatase components (see also 1.4.3). For instance, Li et al. uncovered 
PTPRN as a NF-B-activating phosphatase in murine astrocytes, but could not confirm 
gene activity in mouse fibroblasts (Li et al., 2006b). The same authors reported several 
PP2A regulatory and catalytic subunits to be involved in negative regulation of TNF-
induced NF-B signaling. In marked contrast, a recent study reported a crucial role of PP1 
in negative regulation of IKK activity upon TNF stimulation in murine macrophages as 
well as in human HeLa and HEK293T cells, but failed to confirm PP2A-mediated inhibition 
of IKK phosphorylation and activation (Li et al., 2008). The discrepancy in the function of 
PP1 vs. PP2A with respect to IKK inactivation was explained by tissue and cell type 
specificity of phosphatase activity. Moreover, PP2A regulatory subunits were shown to 
specifically impinge upon TNFR-induced, but not IL-1R-dependent NF-B signaling (Li et 
al., 2006b). The TNF-RSC employs the TRAF2 adapter, whereas the IL-1R complex relies 
on TRAF6. The regulatory subunit PP2R5C was reported to specifically confer PP2A-
dependent dephosphorylation of TRAF2, and consequently, PP2R5C silencing by RNAi 
enhanced TNF-dependent, but not IL-1-stimulated NF-B signaling. Indeed, evidence for 
pathway-specific phosphatase activity was also obtained by the present TCR/TNFR1-
specific subcreening strategy. Several phosphatases were identified as specific 
modulators of either TCR- or TNFR-dependent NF-B signaling although the overlap 
between both screens was still remarkable (see also Frey, 2009). 
Substrate-specific phosphatase activity does not only confer pathway specificity, but also 
allows for the differential regulation of distinct signaling steps within a single signal 
transduction cascade. For instance, Li et al. provided evidence for distinct functions of 
PP2A modules in the NF-B pathway, including dephosphorylation of TRAF2, IKK, and 
NF-B proteins (Li et al., 2006b). Consistently, PP2A complexes were shown before to 
modulate both IKK activity (DiDonato et al., 1997; Fu et al., 2003) and p65 
dephosphorylation (Yang et al., 2001b). Moreover, a recent report assigned PP2A-
mediated inhibition of NF-B signaling to dephosphorylation of the IKK-K MEKK3 (Sun et 
al., 2010), while PPM1 phosphatases were implicated in the direct dephosphorylation of 
IKK proteins (Prajapati et al., 2004; Sun et al., 2009). 
Intriguingly, phosphatase specificity does not only refer to protein recognition, but also 
involves site-specific discrimination of single phospho-residues within a given phospho-
substrate. The WIP1 phosphatase, for example, mediates specific dephosphorylation of 
serine 536 of p65, but does not affect the phosphorylation of adjacent phospho-acceptor 
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sites (Chew et al., 2009). Conversely, site-specific and non-redundant phosphorylation 
has been described for multiple TCR proximal and NF-B signaling components and 
involves an increasing number of kinases. For instance, Carma1 contains 142 putative 
phospho-acceptor sides, and selective phosphorylation of Carma1 by PKC (Matsumoto 
et al., 2005), HPK1 (Brenner et al., 2009), and CK1 (Bidere et al., 2008; Moreno-Garcia 
et al., 2009) has been suggested to differentially contribute to Carma1 signaling. It is 
tempting to speculate that with the phylogenetic implementation and diversification of 
kinases and phospho-proteins phosphatase activity adaptively co-evolved to ensure 
precise control of phospho-signaling circuits in multicellular organisms (Breitkreutz et al., 
2010; Tan et al., 2009). From a theoretical perspective however, it is reasonable to 
assume that the sensitivity of signaling systems to dephosphorylation depends (i) on the 
signaling activity and (ii) on the half life of targeted signaling compounds. Control of the 
phosphorylation status of central signaling hubs with high and sustained activity and high 
protein stability certainly provides a more efficient mechanism of signal termination than 
dephosphorylation of auxiliary signaling proteins with eventually redundant functions. 
Another aspect of the present RNAi screen is the large number of regulatory relative to 
catalytic PSP subunits that were identified as regulators of TCR-induced NF-B signaling 
(Table 5.1; see also Frey, 2009). Most likely, this dichotomy reflects the combinatorial 
complexity of PSP holoenzymes through which non-catalytic subunits modify catalytic 
core components by conferring and/or increasing enzymatic activity as well as substrate 
specificity (Bennett et al., 2006). Probably, pleiotropic functions of almost all catalytic 
subunits in diverse cellular processes masked or interfered with potential NF-B-specific 
loss-of-function phenotypes. However, it cannot be formerly excluded that NF-B 
modulation by regulatory PSP subunits occurs independently of phosphatase activity, but 
involves additional and unknown effector functions. 
Given the cellular and molecular complexity of phospho-substrates and phosphorylation 
events in NF-B signaling it is not surprising that the present RNAi screen identified 
several novel phoshatases as regulators of NF-B activity in T lymphocytes. The 
possibility of false-negative candidates as well as redundant or compensatory functions 
among related phosphatase components might even cause additional underestimates of 
the numbers of NF-B-regulating phosphatases in T lymphocytes. 
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6.2 PP4R1 as a novel negative regulator of NF-B in T 
lymphocytes 
Primary RNAi screening as well as subsequent validation experiments revealed PP4R1 as 
a potent negative regulator of NF-B activity in T lymphocytes. PP4R1 silencing in Jurkat 
T cells caused enhanced NF-B reporter activity, upregulation of NF-B-dependent gene 
expression, as well as cytokine secretion in response to TCR stimulation or 
PMA/ionomcyin treatment. Similarly, siRNA-mediated knock-down of PP4R1 in expanded 
primary human T lymphocytes amplified stimulation-dependent cytokine secretion, 
whereas ectopic PP4R1 almost completely blunted basal and induced NF-B activity (Fig. 
5.6-5.10). These findings prompted closer investigation of the biochemical mechanism 
through which PP4R1 regulates NF-B signaling in T lymphocytes. 
6.2.1 Molecular mechanism of PP4R1-mediated NF-B inhibition: 
 experimental evidence and remaining questions 
(i) Direct inhibition of IKK signaling by PP4R1 
The IKK complex forms a central signaling hub in canonical NF-B signaling that couples 
and integrates various receptor signals to NF-B transcriptional activity (Hayden and 
Ghosh, 2008). Several lines of evidence suggest a role of PP4R1 in directly counteracting 
IKK phosphorylation and activation (Fig. 6.2). 
 
(1) PP4R1 was shown to physically interact with the native IKK complex in T 
lymphocytes. PP4R1 pre-associated with IKK components in resting cells, and this 
association was transiently increased upon stimulation. Thereby, the PP4R1-IKK 
interaction profile closely followed the kinetics of IKK activation (Fig. 5.11).  
 
(2) Knock-down of PP4R1 in Jurkat cells dramatically enhanced IKK activation upon 
stimulation, whereas ectopic PP4R1 largely abrogated IKK kinase activity. 
Congruently, PP4R1-silenced Jurkat cells displayed constitutive IKK and 
increased IKK phosphorylation, reduced basal levels of IB protein, as well as 
accelerated IB phosphorylation and degradation following stimulation. 
Enhanced basal and induced NF-B activity as well as IKK hyperactivation in 
PP4R1-silenced Jurkat cells and PP4R1-deficient HH cells, respectively, was 
rescued by overexpression of ectopic PP4R1 (Fig. 5.13, 5.16 and data not shown). 
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(3) PP4R1 associates with the catalytic PP4 subunit PP4C (see 6.2.2) thereby 
confering IKK-specific phosphatase activity (Fig. 5.12). PP4R1 and PP4C 
synergized to catalyze dephosphorylation of T loop serine residues within IKK 
and IKK in vitro, and PP4R1-associated phosphatase activity was increased upon 
TCR stimulation. As for IKK association, maximal PP4R1-associated phosphatase 
sharply followed the peak of IKK activity (Fig. 5.14). Moreover, PP4C associated 
with the IKK complex in Jurkat cells in a PP4R1-dependent manner (data not 
shown). 
 
(4)  Constitutively active IKK (IKK SS/EE) was sufficient to bypass PP4R1-mediated 
NF-B inhibition (Fig. 5.13 D), and PP4R1 deficiency had no effect on PKC 
phosphorylation and activation (data not shown). 
 
Collectively, these results support a role of PP4R1 as a gatekeeper of IKK activity in T 
lymphocytes counterbalancing the strength and duration of IKK/NF-B signaling. However, 
several aspects still remain to be addressed in detail. 
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Figure 6.2 | Proposed mechanism of PP4R1-mediated IKK inhibition. TCR or TNFR1 
engagement triggers phosphorylation and activation of the canonical IKK complex by upstream 
kinases and effector molecules. A phosphatase complex composed of PP4R1 and PP4c limits and 
terminates IKK activation through direct dephosphorylation of T loop ser residues within IKK and 
IKK and most likely also inhibits spontaneous IKK (auto-)phosphorylation under resting conditions. 
Binding of the PP4R1/PP4c complex to the IKK complex involves most likely a direct interaction 
between IKK and PP4R1 which act as adapter molecules to recruit the catalytically active PP4c 
subunit to its major substrate IKK (right side). Loss of PP4R1 expression results in deregulated 
IKK phosphorylation causing enhanced NF-B dependent expression of target genes (left side). 
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(ii) Control of basal IKK phosphorylation and activity by PP4R1? 
It is not yet precisely understood whether PP4R1 – in addition to inhibition of stimulation-
dependent IKK activation – controls steady-state IKK activity. In transiently siRNA-
transfected T cells no changes in basal NF-B signaling were observed, neither with 
regard to NF-B reporter activity, NF-B-dependent gene expression or cytokine secretion, 
nor with respect to IKK kinase activity (Fig. 5.7, 5.8, 5.13 A). In contrast, stably silenced, 
shPP4R1-expressing Jurkat cells displayed constitutive IKK phosphorylation as well as 
reduced basal IB protein levels (Fig. 5.13 B). Moreover, PP4R1-deficient HH cells 
exhibited increased basal IKK and NF-B activity which was reversed by PP4R1 re-
expression (Fig. 5.16). However, basal IB phosphorylation did not seem to be 
increased, but was heavily triggered upon stimulation. Moreover, IKK phosphorylation 
was not altered in unstimulated PP4R1-silenced cells, but was enhanced in response to 
PMA/ionomycin treatment. However, IKK was constitutively phosphorylated both in 
siRNA-transfected and shRNA-transduced Jurkat cells (Fig. 5.13 B). The discrepancy in 
IKK vs. IKK phosphorylation may be explained by differential IKK substrate affinities of 
the PP4R1/PP4c complex. In addition, IKK is the dominant IKK component and its higher 
kinase activity may require tight control in activated and unstimulated cells. Furthermore, 
the observed experimental discrepancies might be due to differences in the efficacy of 
PP4R1 gene silencing. Residual PP4R1 protein upon transient siRNA-mediated silencing 
might be still sufficient to control basal IKK activity whereas stimulation-induced IKK 
activity is already markedly enhanced. 
Moreover, it has been hypothesized that structural changes within the IKK complex – 
induced by NEMO serine 68 and IKK phosphorylation – may provide access for 
phosphatases to mediate IKK T loop desphosphorylation and inactivation (Palkowitsch et 
al., 2008). Stimulation-induced IKK-specific phosphatase activity is an attractive model of 
negative feedback regulation and may explain increased binding of PP4R1 to the IKK 
complex upon stimulation. However, it is likely that additional mechanisms exist to limit 
and prevent spontaneous IKK phosphorylation and activation under resting conditions. 
 
(iii) Phospho-residue and pathway specificity of PP4R1? 
Induction of IKK activity critically relies on phosphorylation of T loop serines of at least one 
IKK subunit. Activation of IKK involves phosphorylation of serine 177 and serine 181 
within the activation T loop of the kinase domain, whereas in IKK serine 176 and serine 
180 need to be phosphorylated (Delhase et al., 1999; DiDonato et al., 1997). 
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Phosphorylation of these distinct residues is thought to impose conformational changes 
within IKKs thereby unleashing enzymatic activity (Hayden and Ghosh, 2008). 
In the present study, enhanced phosphorylation of serine 180/181 of IKK/ was 
observed as a result of PP4R1 deficiency (Fig. 5.13, 5.14). Whether PP4R1 analogously 
prevents or reverses serine 176/177 phosphorylation needs to be addressed by means of 
phospho-specific antibodies. The fact that PP4R1 silencing enhances overall IKK kinase 
activity, however (Fig. 5.13 A), makes it likely that phosphorylation of both IKK phospho-
acceptor sides is negatively controlled by PP4R1. This assumption is further substantiated 
by the finding that dominant active IKK, in which serine 177 and serine 181 have been 
replaced by phospho-mimetic glumate residues (Mercurio et al., 1997), is uncoupled from 
PP4R1-mediated kinase inhibition (Fig. 5.13 D). 
In contrast to T loop phosphorylation, several additional phospho-acceptor sides within 
IKK components have been described to mediate IKK inhibition. IKK contains several 
negative regulatory serine residues within a C-terminal autophosphorylation cluster, 
whose replacement by alanine residues confers increased basal and TNF-induced IKK 
activity (Delhase et al., 1999). Moreover, phosphorylation of the IKK NBD serine residue 
740 inhibits IKK activity by interfering with NEMO heterodimerization (May et al., 2002; 
Schomer-Miller et al., 2006). Autophosphorylation of these IKK serine residues is thought 
to provide an IKK intrinsic negative feedback mechanism (Hayden and Ghosh, 2008). 
Although PP4R1-associated phosphatase activity has been shown to counteract T loop 
phosphorylation and kinase activation it cannot be formerly ruled out that, in addition, 
PP4R1 interferes with phosphorylation of inhibitory serine residues within the IKK complex. 
Indeed, bifunctional IKK phosphatase activity has been already demonstrated for PP2A 
enzymes. Whereas PP2A has been shown to inhibit IKK phosphorylation and activation 
(DiDonato et al., 1997; Li et al., 2006b), PP2A inhibition following stimulation attenuated 
IKK activity, probably by interfering with removal of inhibitory phosphate groups (Kray et 
al., 2005). 
PP4R1 silencing similarly enhanced NF-B activity upon TCR stimulation or 
PMA/ionomycin and TNF treatment, respectively (Fig. 5.7). Consistently, PP4R1 was 
shown to negatively regulate IKK activity which is a central point of convergence in 
canonical NF-B signaling. However, it cannot be excluded that PP4R1 additionally acts 
at the level or downstream of PKC. For instance, the TAK1/TAB module is a shared 
positive regulator in TCR and TNFR1 signaling and is phosphorylated upon stimulation. 
Although it is unlikely that PP4R1 impedes TAK1 phosphorylation and activation because 
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AP-1 signaling was unaffected (Fig. 5.9, 5.13), this issue could be directly addressed by 
means of phospho-specific antibodies and TAK1 kinase activity assays. Moreover, 
investigation of Carma1 phosphorylation as well as Bcl10, MALT1, and NEMO 
ubiquitination could further confirm and extend epistasis analysis. 
Given the fact that PP4R1 specifically interacts with IKK and thereby associates with the 
canonical IKK complex it is conceivable that PP4R1 similarly interacts with IKK 
homodimers to mediate negative regulation of NIK-induced phosphorylation and non-
canonical IKK activation. Investigation of the effect of PP4R1 knock-down in B cells on 
IKK phosphorylation and non-canonical NF-B activation in response to CD40,   BAFF-R, 
or LTR triggering might be a suitable approach to address this question in the future. 
 
(iv) Redundancy and robustness in the control of IKK activity 
Activation of IKK signaling is a transient event and is subject to several post-inductive 
negative feedback mechanisms (Hayden and Ghosh, 2008). These include 
deubiquitination and inactivation of proximal signal compounds by the negative regulators 
A20 and CYLD as well as the activity of several IKK-specific phosphatases (see 1.4.3 and 
1.4.4). Given multiple layers of negative regulation it is surprising that targeted inactivation 
of single regulatory components is already sufficient to cause profound IKK phenotypes. 
Obviously, negative regulation of IKK activity involves an intricate network of signaling 
inhibitors that serve, at least in part, non-redundant functions and/or require co-
suppression by additional factors to mediate complete and stable IKK inhibition. 
Combined knock-down of PP4R1 and A20, CYLD, PP2Ac, or other phosphatase 
components could address the question whether these inhibitors cooperate in 
suppressing IKK activity or whether they serve redundant or additive functions. 
Interestingly, PP4R1 is not expressed in resting T cells, but its expression is heavily 
upregulated upon primary activation and expansion, implying a physiological mechanism 
of activation-induced feedback inhibition limiting NF-B signaling upon TCR re-stimulation. 
However, the fact that resting T cells lack PP4R1 expression already suggests alternative 
mechanisms of IKK control in T lymphocytes. It will be interesting to analyze phosphatase 
expression in resting vs. pre-stimulated T cells and to investigate whether in resting cells 
distinct phosphatase entities are present that serve PP4R1-like functions. Nonetheless, it 
is tempting to speculate that – through differential expression of phosphatases – resting 
vs. pre-activated T lymphocytes differ in the kinetics and strength of IKK phosphorylation 
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and kinase activation and therefore exhibit differential sensitivities towards TCR 
stimulation. 
 
6.2.2 The PP4 holoenzyme and the NF-B-specific PP4c/PP4R1 module 
(i) The PP4c interactome 
Based on co-purification strategies PP4R1 was the first non-catalytic, regulatory 
phosphatase subunit to be identified as stable interactor of the catalytically active subunit 
PP4c (Kloeker and Wadzinski, 1999; Wada et al., 2001). Stable complex formation 
between PP4R1 and PP4c was confirmed by independent proteomic screening 
approaches (Chen et al., 2008; Gingras et al., 2005). Accordingly, the present study 
provided further evidence for a specific interaction between PP4R1 and PP4c in human T 
lymphocytes (Fig. 5.12). 
PP4c (formerly known as PPX) is a highly conserved and ubiquitously expressed 
phosphatase that shares about 65% amino acid identity with PP2A catalytic subunits and 
therefore belongs, along with PP2Ac and PP6c, to the PP2A-type phosphatases (Brewis 
and Cohen, 1992; Brewis et al., 1993; Cohen et al., 2005; da Cruz e Silva OB et al., 1988). 
Given the large structural homology to PP2Ac it has been hypothesized that PP4c exists 
in distinct multimeric complexes with different subunit compositions and molecular 
functions. Indeed, to date several PP4c-interacting proteins have been reported, including 
PP4R1, PP4R2, PP4R3, PP4R3, PP4R4, and 4/IGBP1 (Carnegie et al., 2003; Chen 
et al., 2008; Gingras et al., 2005; Hastie et al., 2000) (see also Fig. 6.3). Whereas, PP4R1, 
PP4R2, and PP4R4 are likely to interact with PP4c in a direct manner and independently 
of other subunits (Fig. 5.12 F), PP4R3 isoforms depend on PP4R2 for association with 
PP4c (Chen et al., 2008; Chowdhury et al., 2008). 
Both PP4R1 and PP4R4 are HEAT repeat-containing proteins with some homology to the 
A subunit of PP2A. PP2A A contains 15 repeat motifs, whereas PP4R1 and PP4R4 
contain 14 and 3 canonical HEAT repeats, respectively (Chen et al., 2008; Kloeker and 
Wadzinski, 1999). HEAT repeats are structural elements that have been shown to 
mediate interactions between the PP2A A subunit and catalytic and regulatory B subunits 
of PP2A. Consistently, mutations or deletions of HEAT repeats within PP4R1 have been 
shown to impair or prevent binding to PP4c (Chen et al., 2008) (Fig. 5.12 E). Although 
PP4R1 and PP4R4 were suggested to display similar PP4c binding interfaces, related to 
the PP2Ac-PP2A A interaction, they seems to require different structural determinants of 
PP4c association (Chen et al., 2008). In contrast to the 4 subunit, PP4R1 and other PP4 
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regulatory subunits specifically bind to PP4c, but not to the structurally related 
phosphatase PP2Ac (Chen et al., 2008; Chowdhury et al., 2008) (Fig. 5.12 B). PP4c 
interactions, however, are specific for PP4 regulatory subunits, but not for PP2A A  or  
isoforms (Chen et al., 2008). 
Given the strong and most probably direct interaction between PP4c and PP4R1 or other 
PP4 regulatory subunits it is tempting to speculate that additional co-factors exist that, in 
analogy to various PP2A B subunits, modify PP4 core complexes and give rise to a wide 
collection of PP4 holoenzymes. 
 
 
Figure 6.3 | Schematic representation of distinct PP4 complexes and functions. The PP4 
catalytic subunit PP4c forms stable complexes with a number of distinct interaction partners, 
including PP4R1, PP4R2, PP4R3/, PP4R4, and alpha4. The interactions between PP4c and 
PP4R1, PP4R2, PP4R4, or alpha4 are likely to occur in a direct manner, whereas PP4R3 subunits 
depend on PP4R2 to associate with PP4c. The alpha subunit interacts with both PP4c and PP2Ac. 
All other PP4 regulatory subunits are specific for PP4c. The PP4c/PP4R2/PP4R3 module has been 
implicated in DNA damage repair and centrosome maturation. The PP4c/PP4R1 complex was 
previously shown to interact with HDAC3. Moreover, the present study identified PP4R1 as a direct 
interaction partner of IKK, connecting the PP4c/PP4R1 complex with the IKK complex (highlighted 
in red). The functions of other distinct PP4c complexes are largely unknown. 
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(ii) PP4c complexes and functions 
PP4c has been implicated in diverse cellular processes, including DNA damage 
checkpoint signaling, microtubule organization, spliceosome assembly and apoptosis 
regulation (reviewed in Cohen et al., 2005). The overall essential and non-redundant role 
of PP4c in ontogenesis and tissue development has been demonstrated by genetic 
studies using PP4c knock-out mice (Shui et al., 2007). Ablation of PP4c results in 
embryonic lethality of mice, and T cell-specific PP4c gene deletion causes abnormal 
thymic development and pre-TCR signaling (Shui et al., 2007). Pleiotropic functions of 
PP4c have been assigned to distinct PP4c-containing complexes with different 
compositions, subcellular localizations, substrate specificities, and activities (Fig. 6.3). 
Indeed, PP4c complexes are found throughout the cell, ranging from cytosolic to nuclear 
or centrosomal localizations (Brewis and Cohen, 1992; Brewis et al., 1993; Chen et al., 
2008; Cohen et al., 2005; Toyo-oka et al., 2008). The molecular functions of different 
PP4R subunits are largely elusive and have been best defined for ternary PP4c-PP4R2-
PP4R3 complexes that have been recently implicated in DNA damage repair (Chowdhury 
et al., 2008; Nakada et al., 2008). 
In support of the concept of modular PP4c activity the present study has uncovered a 
distinct PP4 complex, composed of PP4c and PP4R1, as a negative regulator of NF-B 
signaling in T lymphocytes (Fig. 6.2). PP4R1 and PP4c were shown to co-associate with 
the IKK complex in a stimulation-dependent manner (Fig. 5.11), and in preliminary 
experiments it could be shown that the PP4c co-association is largely abolished in 
PP4R1-silenced cells (data not shown). Therefore, it is concluded that PP4R1 acts as an 
adapter bridging the IKK complex and PP4c and directing PP4c catalytic activity to 
specifically mediate IKK dephosphorylation. Given the stimulation-dependent profile of the 
PP4R1-IKK interaction it is likely that auxiliary factors and/or posttranslational 
modifications are required to mediate IKK-PP4R1-PP4c complex formation and IKK 
dephosphorylation. Analysis of PP4R1-associated proteins by mass spectrometry might 
lead to the identification of additional basal or inducible interaction partners of PP4R1. 
However, it cannot be excluded that the PP4R1/PP4c module serves separate and IKK-
independent functions, depending on the molecular and subcellular context. Indeed, a 
recent report demonstrated the PP4c-PP4R1 complex to physically associate with histone 
deacetylase 3 (HDAC3) and to negatively regulate HDAC3 activity (Zhang et al., 2005). 
Although the physiological relevance of this interaction is elusive it may imply a role of 
PP4 in epigenetic regulation of gene transcription. 
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(iii) PP4C and its controversial role in regulating NF-B 
Previous studies have linked PP4c to positive regulation of NF-B activity. Based on a 
yeast-two-hybrid screening approach PP4c was identified as an interaction partner of      
c-Rel, and PP4c was shown to interact with recombinant c-Rel, RelA (p65), and p50 (Hu 
et al., 1998) and endogenous p65 (Yeh et al., 2004). Increased NF-B signaling upon 
PP4c overexpression was suggested to be dependent on PP4c-mediated 
dephosphorylation of inhibitory threonine residues within p65 (Hu et al., 1998; Yeh et al., 
2004). Moreover, knock-down of PP4c was shown to cause reduced basal and TNF-
induced NF-B activity (Li et al., 2006b). In addition, it has been suggested that PP4c is a 
positive regulator of HPK1 (Zhou et al., 2004b) which, in turn, acts as a Carma1/IKK-
activating kinase in T lymphocytes (Brenner et al., 2005; Brenner et al., 2009). 
In contrast to these results, the present study has identified the PP4R1/PP4c module as 
negative regulator of IKK activity. How can one explain these apparently controversial 
findings? It is important to note that on the basis of the experimental systems employed in 
this study single knock-down of PP4c by RNAi did not yield any significant NF-B 
phenotype, neither with respect to TCR nor with respect to TNFR1 signaling. Moreover 
and in contrast to other reports, overexpression of PP4c alone did not alter TCR-induced 
NF-B signaling in Jurkat cells (data not shown). Obviously, PP4c serves ambivalent    
NF-B signaling functions that are most likely determined by the co-action of different 
regulatory subunits. Moreover and as outlined above, PP4c plays important roles in a 
wide variety of cellular processes. It is reasonable to assume that pleiotropic and 
counteracting functions of PP4c mask and superimpose separate PP4c signaling roles 
and, therefore, complicate a functional analysis of PP4c. Analysis of IKK activity in the 
presence or absence of PP4c could omit downstream functions of PP4c and directly 
address its role in regulating IKK activity. Moreover, the analysis of T cell-specific PP4R1 
knock-out mice will certainly shed more light on the biological functions of the PP4R1-
PP4c complex in T cell activation and inflammation. 
 
6.2.3 Regulation of the regulator: How is PP4R1-associated phosphatase activity 
controlled?  
Based on in vitro phosphatase activity and IKK dephosphorylation assays using 
overexpressed proteins it could be demonstrated that (i) PP4R1 potentiates PP4c catalytic 
activity and (ii) that TCR stimulation results in a transient induction of PP4R1-associated 
phosphatase activity, peaking at around 25 minutes of stimulation (Fig. 5.14). 
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PP4R1-mediated modulation of PP4c activity may be due to structural changes within 
PP4c and allosteric regulation of phosphatase activity or to the PP4R1-dependent co-
recruitment of additional PP4c-activating factors. Indeed, distinct PP4c complexes have 
been described to exhibit differential phosphatase activities (Chen et al., 2008). In contrast 
to PP4R1, however, PP4R2/PP4R3 and PP4R4-containing complexes were reported to 
be less active than unbound PP4c subunits. 
Stimulation-dependent modulation of PP4c activity has been previously described for 
TNF-stimulated HEK293T cells (Zhou et al., 2002). The authors reported induction of 
PP4c activity by about 4-fold in response TNF treatment which was precisely paralleled 
by transient TNF-induced serine/threonine phosphorylation of PP4c. Similarly, PP2Ac 
has been shown to be subject to tyrosine and threonine phosphorylation (Chen et al., 
1994; Guo and Damuni, 1993), and IL-6 stimulation triggered PP2A phosphorylation and 
increased phosphatase activity (Kantrow et al., 2000). Regulation of PP4c phosphatase 
activity may involve different or additional reversible post-translational modifications. For 
instance, PP2A-type phosphatases have been described to undergo carboxy-methyl 
modifications at their C-termini, possibly modulating interactions with regulatory subunits 
(Bryant et al., 1999; Tolstykh et al., 2000). Further studies, including (phospho)-mass 
spectrometric analysis of PP4c/PP4R1 complexes in response to TCR or TNFR1 
stimulation as well as phosphatase assays using purified recombinant PP4R1 and PP4c 
proteins, are required to gain more insights into the mechanisms regulating PP4c/PP4R1 
phosphatase activity. 
 
6.2.4 Implications for IKK as a bifunctional signaling device 
PP4R1 was shown to specifically interact with IKK upon overexpression. In contrast, 
PP4R1 failed to interact with the structural IKK subunit NEMO and displayed only weak 
interaction with IKK. Moreover, in vitro translated PP4R1 associated with IKK as 
efficiently as with the catalytic subunit PP4c indicative of a direct protein-protein 
interaction (Fig. 5.11). 
Apart from its function in promoting NF-B activation, several lines of evidence suggest an 
inhibitory role of IKK in NF-B activation. For example, IKK-deficient mice exhibited 
exaggerated inflammatory responses, and IKK-deficient macrophages displayed higher 
kinase activity of IKK (Li et al., 2005). Interestingly, IKK-dependent repression of IKK 
activity was shown to be independent of IKK kinase activity, indicating a negative 
regulatory adapter function of IKK (Lawrence et al., 2005). In line with these data, 
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biochemical studies have demonstrated the presence of IKK/NEMO complexes activated 
by anti-CD3/CD28 antibodies in primary T cells (Khoshnan et al., 1999) and revealed the 
presence of an IKK-only complex lacking IKK (Mercurio et al., 1999). Although these 
data demonstrated IKK to be a bifunctional modulator of IKK activity and NF-B 
signaling the molecular basis for these observations remained elusive. 
The present study significantly contributes to a more precise understanding of the 
ambivalent signaling properties of IKK and suggests a molecular mechanism for its 
negative regulatory function in IKK signaling. Through specific and direct binding to 
PP4R1 IKK may serve as a PP4R1-specific adaptor bridging the IKK and PP4R1/PP4c 
complex to mediate IKK dephosphorylation and inactivation (Fig. 6.2). So far, the 
importance of the PP4R1/PP4c module in controlling IKK activity was revealed by knock-
down of PP4R1 in Jurkat cells which caused enhanced and sustained IKK 
phosphorylation and abrogated the co-recruitment of PP4c. Analogously, it will be 
necessary to specifically knock-down IKK in Jurkat T cells and primary T lymphocytes to 
directly investigate the effect of IKK deficiency on IKK activation and PP4R1/PP4c co-
association. 
 
 
6.3 PP4R1 and its potential role in lymphomas 
6.3.1 CTCL and oncogenic activation of NF-B in lymphomas 
CTCL is a clinically heterogeneous lymphoma entity among which the leukemic variant 
Sézary syndrome represents the most aggressive subtype (Diamandidou et al., 1996; Kim 
et al., 2005). A growing body of evidence has established a key role of NF-B in CTCL 
progression and survival. Recent reports demonstrated constitutive activation of the 
canonical NF-B pathway in the CTCL cell lines SeAx, MyLa, Hut78, and HH as well as in 
malignant peripheral blood T lymphocytes from patients with Sézary syndrome (so called 
Sézary cells) (Izban et al., 2000; Sors et al., 2006). Consistently, a specific NF-B target 
gene expression signature was observed for the CTCL lines SeAx, Hut78, and HH in 
comparison to Jurkat T cells (Fig. 16 A). 
Interestingly, constitutive activation of the NF-B pathway does not seem to be a 
paraneoplastic event, but is indispensable for the continued proliferation and survival of 
CTCL cells in vitro and in vivo. Inhibition of NF-B by IB overexpression or chemical 
compounds, such as an IKK activation inhibitor or proteasome inhibitors, selectively 
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induced apoptosis in CTCL cell lines and malignant Sézary cells, but not in non-malignant 
cells from Sézary patients or healthy donors (Kiessling et al., 2009; Sors et al., 2006; Sors 
et al., 2008). 
The dependence of CTCL cells on chronic NF-B signaling for survival reflects a general 
phenomenon of oncogenesis, known as oncogenic addiction. The term “oncogenic 
addiction” was introduced by Weinstein and conceptualizes the frequent observation that 
cancer cells are physiologically dependent on (“addicted to”) the sustained activity of a 
certain oncogene or an oncogenic signaling pathway (e.g. the NF-B pathway) for the 
maintenance of their transformed phenotype (Weinstein, 2002). Single oncogenic lesions 
are not sufficient to induce tumorigenesis and to bypass cell-intrinsic checkpoint 
mechanisms, but require the collaboration with other oncogenes or with loss of tumor 
suppressors for tumor initiation (oncogene collaboration). Single oncogene inactivation, in 
turn, is thought to lead to an imbalance between proapoptotic vs. antiapoptotic programs 
and to the restoration of physiological checkpoint mechanisms resulting in spontaneous 
apoptosis of tumor cells (Weinstein, 2002; Weinstein and Joe, 2008). 
Physiological addiction to NF-B signaling has also been reported for other lymphoid 
malignancies, such as ABC-DLBCL or Hodgkin lymphoma (reviewed in Staudt, 2010). In a 
subset of ABC-DLBCL cells a number of dominant active, oncogenic mutations for 
components of the BCR-induced NF-B pathway, such as CD79A, CD79B, Carma1, 
TRAF2, and TAK1 have been identified, causing constitutive, ligand-independent NF-B 
activity. In contrast to tumor initiation by direct oncogene activation, however, not every 
protein in a tumor-promoting pathway may be mutated or overexpressed although still 
being rate-limiting to oncogenic pathway activity. This phenomenon has been termed 
“non-oncogene addiction” (Luo et al., 2009b; Solimini et al., 2007). For instance, activating 
Carma1 mutations in a fraction of ABC-DLBCL cells have uncovered Carma as a bona 
fide NF-B oncogene (Lenz et al., 2008). By contrast, mutations of Bcl10 or CK1, two 
other crucial components of the CBM complex, have not been identified. Yet, targeting of 
Bcl10 or CK1 by RNAi caused cell death of ABC-DLBCL cells to a similar extent as 
downregulation of Carma1, revealing these signaling components as essential malignancy 
genes in ABC-DLBCL cells (Bidere et al., 2008; Ngo et al., 2006). 
A central role of NF-B-driven anti-apoptotic gene expression has also been reported for a 
number of non-lymphoid epithelial malignancies. Based on an RNAi screen to identify 
synthetic lethal partners of oncogenic K-Ras it was recently demonstrated that the non-
canonical NF-B-activating TANK-binding kinase 1 (TBK1) is selectively essential for the 
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survival of KRAS mutant tumors (Barbie et al., 2009). Moreover, mutant K-Ras 
overexpression was shown activate the canonical NF-B pathway (Meylan et al., 2009). A 
co-dependence between MAPK and NF-B signaling for tumor formation and 
maintenance was further demonstrated by a previous study that identified the IKK family 
member IKK as a breast cancer oncogene (Boehm et al., 2007). 
 
6.3.2 PP4R1: suppressor of NF-B and tumor suppressor? 
Conceptually, aberrant NF-B activity in tumor cells can result from mutated or amplified 
signaling activators with oncogenic activity (e.g. Carma1; see 6.3.1) and/or from 
mutational inactivation or deficiency of NF-B repressors. Indeed, recent studies provided 
evidence for a function of A20, a negative regulator of NF-B signaling, as a central tumor 
suppressor in a wide variety of NF-B-dependent B cell lymphomas. In ABC-DLBCL, 
MALT lymphoma, a large panel of additional non-Hodgkin lymphomas, Hodkin lymphoma, 
and primary mediastinal B cell lymphoma (PMBL) the A20 gene (TNFAIP3) was frequently 
inactivated by mutations and/or deletions affecting both TNFAIP3 alleles which is a 
hallmark of tumor suppressor genes (Hymowitz and Wertz, 2010). A20 deficiency 
correlated with increased NF-B-dependent gene expression, and reconstitution of A20-
deficient lymphomas with wild-type A20 suppressed cell growth and promoted apoptosis 
(Compagno et al., 2009; Honma et al., 2009; Kato et al., 2009; Schmitz et al., 2009). 
Moreover, KEAP1, an E3 ligase for IKK that inhibits the NF-B pathway, was recently 
shown to be frequently mutated or downregulated in several breast cancer cell lines and 
primary human breast cancer specimens (Lee et al., 2009). 
In contrast, the molecular aetiology underlying constitutive NF-B signaling in CTCL cells 
remains largely unknown. Although constitutive NF-B activation was demonstrated to be 
predominantly IKK-dependent (Sors et al., 2006; Sors et al., 2008), a contribution of the 
alternative pathway is also discussed (Zhang et al., 1994). However, molecular lesions 
that promote constitutive IKK signaling in CTCL have not been described yet. 
The present study revealed significant downregulation of PP4R1 expression in a fraction 
of CTCL cell lines and primary CTCL cells from Sézary patients (Fig. 5.15). Whereas 
SeAx and MyLa cell lines were PP4R1-sufficient, Hut78 displayed reduced PP4R1 protein 
levels, and HH cells completely lacked PP4R1 expression. PP4R1 deficiency correlated 
well with constitutive IKK activity in PP4R1-deficient CTCL cells. Forced re-expression of 
PP4R1 in HH cells reversed constitutive IKK activation and NF-B signaling, indicating 
that PP4R1 deficiency is sufficient and causative for IKK hyperactivation in these cells (Fig. 
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5.16). This is in accordance with the physiological role of PP4R1 in negative regulation of 
IKK phosphorylation and T cell activation and implies a role of PP4R1 in lymphoma 
survival. Indeed, reconstitution of PP4R1 expression sensitized Hut78 and most 
prominently PP4R1-deficient HH cells to cell death, whereas the survival of PP4R1-
sufficient SeAx and MyLa cells was not affected (Fig. 5.16 E). Collectively, these results 
provide genetic and functional evidence that PP4R1 is a suppressor of the NF-B 
pathway whose downregulation unleashes constitutive IKK activity and is required for the 
continued survival of a subset of CTCL cells. 
Whether PP4R1 – analogously to A20 – is a tumor suppressor or serves tumor 
suppressor-like functions remains to be addressed. Given its functional role in NF-B 
signaling and CTCL survival it is likely that loss of PP4R1 expression does not reflect a 
tumor intrinsic program, but represents a pathogenetic event that is essential for the 
initiation or propagation of a specific, NF-B-addicted malignant phenotype. To address 
this question, gene expression profile studies and mutational analyses of the PPP4R1 
locus using larger cohorts of CTCL or Sézary patients are required. Moreover, these 
genetic analyses have to be extended to examine whether deregulated PP4R1 expression 
is a CTCL-specific phenomenon or may also contribute to the pathogenesis of other types 
of lymphoid malignancies, such as ABC-DLBCL, Hodgkin lymphoma, and MM. So far, no 
defective PP4R1 expression in two tested ABC-DLBCL cell lines was detected (Fig. 5.15 
D), although the possibility of inactivating point mutations cannot be ruled out. Expression 
screening and PPP4R1 sequence analysis of a larger panel of available cell lines as well 
as of primary patient material are needed. Importantly, deregulation of PP4R1 expression 
is restricted to a subtype of CTCL cells and, therefore, most probably not the only 
molecular determinant of NF-B activation and malignancy in the Sézary Syndrome. It will 
be interesting to investigate whether Sézary cells display mutations and/or aberrant 
expression of other known regulators of NF-B (e.g. Carma1, A20) or distinct oncogenic 
pathways (e.g. the Ras pathway), and whether some of these aberrations cooperate with 
PP4R1 deficiency to promote constitutive NF-B signaling and lymphoma survival. 
 
6.3.3 PP4R1 deficiency in Sézary cells: implications for diagnosis and therapy 
In general, the pharmacological exploitation of mutations or deficiencies of tumor 
suppressors or tumor suppressor-like proteins is a challenging strategy because it is 
difficult – in contrast to drug-mediated targeting of oncogenes – to restore or mimic the 
function of a specific protein (Luo et al., 2009b). Nonetheless, the finding that PP4R1 is 
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downregulated in a subset of CTCL cells may have important implications for the 
molecular diagnosis, classification, and individualized therapy of Sézary tumors. (i) The 
analysis of PP4R1 expression or functional inactivation might be valuable to categorize 
CTCL cells in IKK-dependent vs. IKK-independent tumors. PP4R1-deficiency was shown 
to result in constitutive IKK activity. Therefore, PP4R1-deficient CTCL cells are likely to be 
more sensitive to specific IKK inhibitors, such as the NBP (May et al., 2000) or chemical 
IKK activation inhibitors (Kiessling et al., 2009) than PP4R1-sufficient cells. In these latter 
cells constitutive NF-B signaling may result from aberrations affecting signaling 
components that are either upstream or downstream (and thus independent) of IKK 
activity. (ii) It is not clear yet, how PP4R1 expression is downregulated. Since loss of 
PP4R1 seems to occur on a transcriptional level (Fig. 5.15 A-C) possible mechanisms 
may include promoter mutations or chromosomal aberrations and/or epigenetic alterations 
such as promoter methylation and histone deacetylation. For instance, loss of A20 
expression was shown to be in part due to chromosomal rearrangements and promoter 
methylations in MALT lymphomas (Chanudet et al., 2010). Treatment of Sézary patients 
with HDAC or DNA methyl-transferase inhibitors (Heider et al., 2009), in combination with 
conventional chemotherapeutics or NF-B inhibitors, such as IAP antagonists (Vucic and 
Fairbrother, 2007) or proteasome inhibitors (Baud and Karin, 2009; Dunleavy et al., 2009; 
Richardson et al., 2005) might be a promising approach to restore PP4R1 expression and 
to sensitize CTCL cells to apoptosis. 
 
 
6.4 Outlook 
The current study has identified the regulatory subunit PP4R1 as a central regulator of 
NF-B signaling and T cell activation, and has also provided evidence for PP4R1 as a 
suppressor of human lymphoma cell survival. These results significantly expanded our 
understanding of TCR-induced signal transduction and have provided novel insights into 
the mechanisms governing negative regulation of NF-B signaling. Further biochemical 
and functional analyses are required to precisely dissect how the PP4R1/PP4c complex 
interferes with IKK activation and how this phosphatase module itself is regulated by TCR 
signaling. Moreover, the analysis of PP4R1 knock-out mice will help to understand the 
physiological role of PP4R1 in T cell development, activation, and apoptosis as well as its 
function in other cellular compartments in vivo. Furthermore, it is tempting to speculate 
that PP4R1 controls and limits inflammatory responses, and therefore deregulated PP4R1 
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activity may be involved in the development of autoimmune disorders or chronic 
inflammatory diseases. The finding that loss of PP4R1 expression is causative for 
constitutive IKK/NF-B signaling and is required for survival of a fraction of CTCL cells 
implies a role of PP4R1 in the pathogenesis of T cell lymphomas. It will be necessary to 
investigate whether PP4R1 inactivation is a more general mechanism accompanying or 
promoting tumorigenesis and may contribute to other NF-B-driven haematological 
malignancies. The identification and molecular characterization of PP4R1 as a NF-B-
suppressing regulator might open up new strategies of anti-tumour therapy for a subgroup 
of NF-B-dependent lymphomas. 
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7.2 List of abbreviations 
°C Degree Celsius 
Aa Amino acid 
ABC-DLBCL Activated B cell-like DLBCL 
ADAP Adhesion- and degranulation-promoting adapter protein 
Ag Antigen(s) 
ANK Ankyrin repeat motif 
AP-1 Activating protein 1 
APC  Antigen presenting cell  
APS Ammonium persulfate 
ATL Adult T cell lymphoma/leukemia 
ATP  Adenosine triphosphate 
Bcl B cell lymphoma 
BCR B cell antigen receptor 
bp (kb) Base pair (kilo base pair) 
CARD Caspase recruitment domain 
Caspase Cysteine-aspartate specific protease 
CBM complex Carma1-Bcl10-MALT1 complex 
Cbp Csk-binding protein 
CD Cluster of differentiation 
CD95L CD95 ligand 
cDNA Complementary DNA 
CED Caspase-8 deficiency  
c-FLIP Cellular FLICE inhibitory protein 
c-IAP Cellular inhibitor of apoptosis 
CRAC Calcium release activated calcium channel 
Csk Cellular src kinase 
CTLC Cutaneous T cell lymphoma 
CYLD Cylindromatosis tumor suppressor  
d  Day 
DAG Diacylglycerol 
DC Dendritic cell 
DD Death domain 
DLBCL Diffuse large B cell lymphoma 
Dlgh1 Discs large homolog 1  
DMEM Dulbecco’s Modified Eagle Medium  
DMSO  Dimethyl sulfoxide 
DNA Desoxyribonucleic acid 
DTT  Dithiothreitol 
DUB Deubiquitinating enzyme 
ECL Enhanced chemiluminescence 
EDTA  Ethylenediaminetetraacetic acid 
EGFP Enhanced GFP 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
ERK Extracellular signal-regulated kinase 
EtOH Ethanol 
FACS  Fluorescence activated cell sorter 
FCS  Fetal calf serum  
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FHC Ferritin heavy chain 
Fig. Figure 
g Gramm 
Gads Grb2-related adaptor downstream of Shc 
GAP GTPase-activating protein 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase  
GCB-DLBCL Germinal center B cell-like DLBCL 
GEF Guanine-nucleotide-exchange factor  
GFP Green fluorescent protein 
Grb2 Growth factor receptor-bound protein 2 
GRP GDP release protein 
GRR Glycine rich region 
GUK Guanylat-Kinase-Domäne 
GUK Guanylate kinase  
h Hour 
HLH Helix-loop-helix  
HPK1 Haematopoietic progenitor kinase 1  
HPRT1 Hypoxanthine phosphoribosyl-transferase 1 
HRP Horseradish peroxidase 
HTLV-1 Human T-lymphotropic virus type I 
HTS High throughput screening 
IB Immunoblot(ting) 
IFN Interferon  
IgG Immunoglobulin 
IgGH Immunoglobulin heavy chain 
IgGL Immunoglobulin light chain 
IKK IB kinase 
IL  Interleukin  
IMDM  Iscove’s modified Eagles medium 
Iono Ionomycin 
IP Immunoprecipitation 
IP3 Inositol 3,4,5-trisphosphate 
IRES Internal ribosomal entry site 
ITAM Immunoreceptor tyrosine-based activation motif 
Itk IL-2 inducible Tec kinase 
IB Inhibitor of B proteins 
JNK/SAPK c-Jun N-terminal kinase/stress-activated protein kinase 
KBD Kinase binding domain 
KD Kinase domain  
kDa Kilo Dalton 
l Liter 
LAT Linker of activated T cells 
LZ Leucine zipper  
mAb  Monoclonal antibody  
MACS  Magnetic activated cell sorter  
MAGUK Membrane-associated guanylate kinase  
MALT1 Mucosa-associated lymphoid tissue lymphoma translocation protein 1
MAPK Mitogen-activated protein kinase 
MEF Murine embryonic fibroblast 
MEKK MAPK/ERK Kinase Kinase 
MeOH Methanol 
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MF Mycosis fungoides 
MFI Mean fluorescence intensity 
MHC  Major histocompatibility complex  
min Minute(s) 
MLK Mixed-lineage protein kinase 
MM Multiple myeloma 
mRNA  Messenger ribonucleic acid  
NBD Nemo-Binde-Domäne 
NBP NBD peptide 
Nck Non-catalytic region of tyrosine kinase  
NEMO NF-B essential modulator 
NES Nuclear export sequence  
NFAT  Nuclear factor of activated T cells  
NF-B  Nuclear factor-kappaB  
NIK NF-B-inducing kinase 
NK cells Natural killer cells 
NLS Nuclear translocation sequence  
p Peptide 
PAGE Polyacrylamide gel electrophoresis 
PAMP Pathogen-associated molecular pattern 
PBL Peripheral blood leukocyte 
PBS  Phosphate buffered saline  
PCR Polymerase chain reaction 
PDK1 3-Phosphoinositid-abhängige Kinase 1 
PHA Phytohemagglutinin 
PI3K Phosphoinositide-3 kinase 
PKC Protein kinase C 
PLC1 Phospholipase C1 
PMA Phorbol 12-myristate-13-acetate  
PP1c Protein phosphatase 1 catalytic subunit 
PP2A Protein phosphatase 2A 
PP2Ac Protein phosphatase 2A catalytic subunit 
PP4c Protein phosphatase 4 catalyticsubunit 
PP4R Protein phosphatase 4 regulatory subunit 
PPP Phosphoprotein phosphatase 
PRD PKC-regulated domain  
PRR Pattern recognition receptor 
PSK Protein serine/threonine kinase 
PSP Protein serine/threonine phosphatase 
PSP Protein serine/threonine phosphatases 
PTEN Phosphatase and tensin homolog 
PTK Protein tyrosine kinase 
PTP Protein tyrosine phosphatase 
PTPN Protein tyrosine phosphatase, non-receptor type 
PTPR Protein tyrosine phosphatase, receptor type 
pUb Poly-ubiquitin 
RHD Rel homology domain 
RIP1 Receptor-interacting protein 1 
RLU Relative light unit 
RNA Ribonucleic acid 
RNAi RNA interference 
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ROS Reactive oxygen species 
rpm Rotations per minute 
RT Room temperature 
RT-PCR Reverse transcription PCR 
SDS Sodium dodecyl sulfate 
Sec Second 
SFK Src family protein tyrosine kinase 
SH Src homology 
SHIP1 SH2 domain-containing inositol phosphatase 1 
SHP1 SH2 domain-containing phosphatase 1 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SLP76 SH2-domain-containing leukocyte protein of 76 kd 
SOCE Store-operated calcium entry 
SOS Son of sevenless 
Sts Suppressor of TCR signaling  
Syk Spleen tyrosine kinase 
TAD Transactivation domain 
TAK1 TGF-b-activated kinase 1  
T-ALL T cell acute lymphocytic leukaemia  
TCR  T cell antigen receptor  
TEMED N,N,N’,N’-Tetramethyl-ethylenediamine 
TNFR TNF receptor 
TNF-RSC TNFR signaling complex 
TNF Tumor necrosis factor  
TRADD TNFR1-associated death domain protein 
TRAF TNFR-associated factor  
Tris Tris-[hydroxymethyl]amino-methane 
Ub Ubiquitin 
UPL Universal probe library 
vs. versus 
wt Wild type 
ZAP-70  Zeta chain-associated kinase of 70 kDa 
ZF Zinc finger  
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Amino acid Three-letter code Single-letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
Tyrosine Tyr Y 
Valine Val V 
any aa  x 
 
Nucleobase Symbol 
Adenine A 
Cytosine C 
Guanine G 
Thymine T 
Uracil U 
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